Delaware
|
|
98-0178636
|
(State
or other jurisdiction of
|
|
(I.R.S.
Employer
|
incorporation
or organization)
|
|
Identification
No.)
|
|
|
|
33
Harbour Square, Suite 202, Toronto, Canada
|
|
M5J
2G2
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Title
of each class
|
|
Name
of each exchange on which registered
|
Common
Stock, $.001 par value per share
|
|
The
NASDAQ Stock Market LLC
|
Large
accelerated filer o
|
Accelerated
filer þ
|
|
Non-accelerated
filer o
(Do
not check if a smaller reporting company)
|
Smaller
reporting company o
|
|
|
Page
|
||
Forward-Looking
Statements
|
|
1
|
||
|
|
|
||
Part
I
|
|
|
|
|
Item
1.
|
|
Business.
|
|
2
|
Item
1A.
|
|
Risk
Factors.
|
|
23
|
Item
1B.
|
|
Unresolved
Staff Comments.
|
|
30
|
Item
2.
|
|
Properties.
|
|
30
|
Item
3.
|
|
Legal
Proceedings.
|
|
30
|
Item
4.
|
|
Submission
of Matters to a Vote of Security Holders.
|
|
31
|
|
|
|
|
|
Part
II
|
|
|
|
|
Item
5.
|
|
Market
For Registrant’s Common Equity, Related Stockholder Matters and Issuer
Purchases of Equity Securities.
|
|
32
|
Item
6.
|
|
Selected
Financial Data.
|
|
34
|
Item
7.
|
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations.
|
|
35
|
Item
7A.
|
|
Quantitative
and Qualitative Disclosures About Market Risk
|
|
49
|
Item
8.
|
|
Financial
Statements and Supplementary Data.
|
|
50
|
Item
9.
|
|
Changes
in and Disagreements With Accountants on Accounting and Financial
Disclosure.
|
|
94
|
Item
9A.
|
|
Controls
and Procedures.
|
|
94
|
Item
9B.
|
|
Other
Information.
|
|
95
|
|
|
|
|
|
Part
III
|
|
|
|
|
Item
10.
|
|
Directors,
Executive Officers and Corporate Governance.
|
|
95
|
Item
11.
|
|
Executive
Compensation.
|
|
95
|
Item
12.
|
|
Security
Ownership of Certain Beneficial Owners and Management and Related
Stockholder Matters.
|
|
96
|
Item
13.
|
|
Certain
Relationships and Related Transactions, and Director
Independence.
|
|
96
|
Item
14.
|
|
Principal
Accountant Fees and Services.
|
|
96
|
|
|
|
|
|
Part
IV
|
|
|
|
|
Item
15.
|
|
Exhibits
and Financial Statement Schedules.
|
|
96
|
|
|
|
|
|
Signatures
|
|
|
|
98
|
|
·
|
our
expectations concerning product candidates for our
technologies;
|
|
|
|
|
·
|
our
expectations concerning existing or potential development and license
agreements for third-party collaborations and joint
ventures;
|
|
|
|
|
·
|
our
expectations of when different phases of clinical activity may commence
and conclude;
|
|
|
|
|
·
|
our
expectations of when regulatory submissions may be filed or when
regulatory approvals may be received; and
|
|
|
|
|
·
|
our
expectations of when commercial sales of our products may commence
and
when actual revenue from the product sales may be
received.
|
|
·
|
the
inherent uncertainties of product development based on our new and
as yet
not fully proven technologies;
|
|
|
|
|
·
|
the
risks and uncertainties regarding the actual effect on humans of
seemingly
safe and efficacious formulations and treatments when tested
clinically;
|
|
|
|
|
·
|
the
inherent uncertainties associated with clinical trials of product
candidates;
|
|
|
|
|
·
|
the
inherent uncertainties associated with the process of obtaining regulatory
approval to market product candidates;
|
|
|
|
|
·
|
the
inherent uncertainties associated with commercialization of products
that
have received regulatory approval; and
|
·
|
our
ability to obtain the necessary financing to fund our
operations.
|
·
|
Conducting
and completing Phase III clinical trials of Generex Oral-lyn™ in the
United States and Canada, Europe and certain countries in Eastern
Europe
including Russia, Ukraine, Bulgaria and Romania;
|
·
|
Commercializing
Generex Oral-lyn™ in Ecuador and India, the two countries where we have
obtained regulatory approval for its commercial marketing and sale,
by
undertaking additional commercial manufacturing runs of Oral-lyn™ at
PharmaBrand, S.A.’s facilities in Quito, Ecuador later in calendar year
2008 and expanding such production facilities to meet the anticipated
demand for the product in India and other jurisdictions where governmental
approvals are pending and pursuing post-approval clinical studies
and
marketing efforts in India.
|
·
|
Establishing
strategic relationships worldwide for product development and distribution
and working with our multinational licensed distributors in the Middle
East and throughout Eastern Europe, Africa and Asia to obtain regulatory
approval for the registration, importation, marketing, distribution
and
sale of Generex Oral-lyn™ in those countries.
|
·
|
Conducting
and completing Phase II clinical trials of Antigen’s synthetic peptide
vaccines designed to stimulate a potent and specific immune response
against tumors expressing the HER-2/neu oncogene for patients with
HER-2/neu positive breast cancer, a Phase I prostate cancer trial
and a
Phase I trial in patients with breast or ovarian cancer;
and
|
·
|
Conducting
and completing a Phase I clinical trial of Antigen’s synthetic peptide
vaccines against avian influenza.
|
·
|
quality
test/studies;
|
|
|
·
|
pre-clinical
tests /studies;
|
|
|
·
|
submission
to the FDA of Investigational New Drug Applications (“INDs”) and/or
Amendments for each planned human clinical trial;
|
|
|
·
|
FDA
acceptance of INDs, which permit human clinical trials to
commence;
|
|
|
·
|
commencement
and completion of numerous human clinical trials to establish the
safety
and efficacy of the subject drug;
|
|
|
·
|
submission
of a New Drug Application to the FDA; and
|
|
|
·
|
FDA
approval of the New Drug Application, including approval of all product
labeling
|
· |
Primary
and Secondary Pharmacodynamics
|
· |
Safety
Pharmacology
|
· |
Other
Pharmacodynamics
|
· |
Single
and Multiple Dose Kinetics
|
· |
Tissue
Distribution
|
· |
Metabolism
|
· |
PK
Drug Interactions
|
· |
Other
PK studies
|
· |
Single
and Multiple Dose Toxicity
|
· |
Genotoxicity
|
· |
Carcinogenicity
|
· |
Reproduction
Toxicity
|
· |
Other
Toxicity
|
·
|
We
obtained regulatory approval to begin clinical trials of our oral
insulin
formulation in Canada in November 1998. In April 2003, we received
approval of an Oral-lyn™ Phase II-B clinical trial protocol in
Canada. In September 2006 Health Canada approved our Clinical Trial
Application in respect of our proposed Generex Oral-lyn™ protocol for
late-stage trials; we expect to use the data collected from these
trials
in the New Drug Submission that will be prepared concurrently with
the
progression of the late-stage trials.
|
·
|
In
May 2005, we received approval from the Ecuadorian Ministry of Public
Health for the commercial marketing and sale of Generex Oral- lyn™ for
treatment of Type 1 and Type 2 diabetes.
|
·
|
In
November 2007, we obtained approval for the importation and commercial
marketing and sale in India of Generex Oral-lyn™ from the Central Drugs
Standard Control Organization (CDSCO), Directorate General of Health
Services, Government of India, which is responsible for authorizing
marketing approval of all new pharmaceutical products in
India.
|
·
|
We
obtained regulatory approval in Canada to begin clinical trials of
our
buccal morphine product in March 2002 and our fentanyl product in
October
2002.
|
·
|
Applications
were filed and approvals obtained for Phase I prostate cancer using
AE37
in Athens, Greece from the Hellenic Organization of Drugs. The Ministry
of
Health in Lebanon gave approval for Phase I trial of our experimental
H5N1
prophylactic vaccine in Beirut, Lebanon following submission of an
application.
|
·
|
Leosons
General Trading Company/Generex MENA Office - 15 Middle Eastern
countries;
|
·
|
Shreya
Life Sciences Pvt. Ltd. - India, Pakistan, Bangladesh, Nepal, Bhutan,
Sri
Lanka, and Myanmar;
|
·
|
Adcock
Ingram Limited and Adcock Ingram Healthcare (Pty) Ltd. - South Africa,
Lesotho, Swaziland, Botswana, Namibia, Mozambique and
Zimbabwe;
|
·
|
E&V
Alca Distribution Corp. - Albania, Montenegro, and the Kosovo;
|
·
|
Medrey
S.A.L. (formerly MedGen Corp.) and Benta S.A.L. –
Lebanon;
|
·
|
SciGen,
Ltd. - China, Hong Kong, Indonesia, Malaysia, the Philippines, Singapore,
Thailand and Vietnam; and
|
· |
Dong
Sung Pharm. Co. Ltd. – South
Korea.
|
· |
Rite
Aid,
|
· |
Butler
Drug Store,
|
· |
Rexall
PharmaPlus,
|
· |
Fruth
Pharmacy,
|
· |
Loblaws
Companies Ltd.,
|
· |
Hy-Vee
Inc.,
|
· |
Kerr
Drug Inc.,
|
· |
Kinney
Drug, Inc.,
|
· |
Medicine
Shop,
|
· |
Meijer,
|
· |
ShopKo,
|
· |
Weiss
Markets Inc.,
|
· |
Aurora
Pharmacy, and
|
· |
Shoppers
Drug Mart.
|
·
|
Pfizer
announced in October 2007 the discontinuation of development and
marketing
activities relating to Exubera®, the inhaled insulin product developed by
Nektar Therapeutics. Exubera® was the first inhaled insulin formulation to
receive FDA approval. In April 2008, Pfizer and Nektar Therapeutics
announced that clinical trials of Exubera demonstrated increased
lung
cancer rates in certain patient. We are not aware of any product
currently
in Pfizer’s pipeline that directly competes with
Oral-lyn™.
|
·
|
Nektar
Therapeutics and Pfizer terminated their collaborative development
and
licensing agreement for Exubera® and Nektar’s next-generation inhaled
insulin product in November 2007. In April 2008, Nektar announced
that it
had ceased all negotiations with potential partners for Exubera® and the
next-general inhaled insulin product as a result of new data analysis
from
ongoing clinical trials conducted by Pfizer which indicated an increased
risk of lung cancer in certain patients. We are not aware of any
product
candidates under development by Nektar that compete directly with
Oral-lyn™.
|
·
|
Alkermes,
Inc. and Eli Lilly and Company entered into a licensing agreement
in 2001
for the development of an AIR® inhaled insulin system based upon Alkermes’
AIR® pulmonary drug delivery system for large molecule drugs to the lungs
with a dry power formulation. In March 2008, Eli Lilly announced
its
termination of development work relating to this product.
|
·
|
MannKind
Corporation’s product candidates include Technosphere® insulin, comprised
of MannKind’s dry power formulation and proprietary MedTone® inhaler.
Phase III clinical trials are underway in the U.S., Europe and Latin
America.
|
·
|
CPEX
Pharmaceuticals, Inc.’s proprietary permeation enhancer, CPE-215®,
provides skin, mouth, nose and eye membrane absorption of a variety
of
pharmaceuticals. CPEX has applied this technology to Nasulin™, through
which insulin is absorbed via nasal mucosa. In 2007, Nasulin™ commenced
Phase III clinical trials which CPEX expects to conclude in mid-2010.
Bentley Pharmaceuticals spun off its drug delivery business as CPEX
prior
to Bentley’s merger with Teva Pharmaceuticals Industries, Ltd.
|
·
|
Abbott
Laboratories, which offers a broad array of diabetes products, acquired
Kos Pharmaceuticals in late 2006. Prior to the acquisition, Kos had
conducted Phase II clinical trails for its metered dose inhaler for
aerosol liquid insulin.
|
·
|
Emisphere
Technologies, Inc. has an active oral insulin program focused on
developing GLP-1 analogs. GLP-1 may potentially be absorbed through
the GI
tract in tablet form.
|
·
|
Novo
Nordisk A/S, one of the two leading manufacturers of insulin in the
world,
announced in May 2008 the termination of clinical testing of the
pulmonary
delivery system for inhaled insulin, the AERx® insulin Diabetes Management
System (AERx iDMS), initially developed by Aradigm Corporation. The
product was in Phase III clinical trials at the time of Novo Nordisk’s
announcement.
|
·
|
Nastech
Pharmaceutical Company Inc. is conducting a Phase II clinical trial
in
Europe to evaluate its insulin nasal spray in Type 2 diabetics.
|
·
|
Cephalon,
Inc. received FDA approval in September 2006 for FENTORA™ and launched the
product in the United States shortly thereafter. FENTORA™ is a fentanyl
buccal tablet that is placed between the patient’s upper cheek and gum and
is indicated for the management of breakthrough pain in patients
with
cancer who are already receiving and are tolerant to opioid therapy
for
their underlying persistent cancer pain. Cephalon anticipates submitting
a
NDA to the FDA in late 2007 to expand the labeled indications for
FENTORA™
to include non-cancer breakthrough pain in opioid-tolerant patients.
Other
competing products commonly prescribed to treat persistent pain are
Ortho-McNeil’s DURAGESIC® and Purdue Pharmaceuticals’ OXYCONTIN® and
MS-CONTIN®.
|
·
|
Nastech
Pharmaceuticals is developing an intranasal formulation of morphine
that
is in Phase II clinical trials.
..
|
·
|
Advaxis,
Inc. uses a proprietary technique to bioengineer Listeria bacteria
to
create a specific antigen that can stimulate an immune response after
recognition by the recipient’s immune system. Advaxis’ most advanced
product candidate is Lovaxin C, which is used to treat head and neck
cancer and human papillomavirus (HPV)-derived cervical cancer. Advaxis
may
begin Phase II clinical trials for Lovaxin C in 2008 and has prostate
and
breast cancer vaccines in preclinical
phases.
|
·
|
Micromet,
Inc. uses two platform technologies to treat cancers, autoimmune
diseases
and inflammation: (i) the creation of Single-Chain Antibodies (SCAs)
through the use of the antigen-binding region of a full-sized antibody,
held together by a linker; and (ii) BiTE® technology which utilizes the
body’s CTLs to attack tumor cells. Micromet has completed Phase I clinical
trials for its most developed product candidate, adecatumumab (MT201),
for
treatment of metastatic breast cancer.
|
·
|
Sanofi
Pasteur Inc., the vaccine division of sanofi-aventis and one of the
largest vaccines companies in the world, has product candidates including
inoculations against 20 varieties of infectious diseases. It received
FDA
approval for an H5N1 avian influenza vaccine in April 2007.
|
·
|
Dendreon
Corporation’s product portfolio includes therapeutic vaccines, monoclonal
antibodies and small molecules. Its most advanced product candidate
now in
Phase III clinical trials is Provenge® (sipuleucel-T), an investigational
autologous (patient-specific) active cellular immunotherapy (ACI)
for the
treatment of prostate cancer. Dendreon is expected to release interim
survival data compiled from the Phase III trials in late 2008. Dendreon
has completed Phase I clinical trials in of Lapuleucel-T in patients
with
breast, ovarian and colorectal tumors. Lapuleucel-T targets HER/2-positive
cancers.
|
·
|
Cell
Genesys, Inc. currently has two clinical stage product platforms:
(i)
off-the-shelf GVAX™ cancer immunotherapies for prostate cancer (Phase
III), pancreatic cancer (Phase II) and leukemia (Phase II), and (2)
oncolytic virus therapies for bladder cancer (Phase I) and other
tumors.
The GVAX™ cancer treatments are composed of tumor cells that are
genetically modified to secrete an immune-stimulating cytokine and
are
irradiated for safety. Cell Genesys and Takeda Pharmaceutical Co.
have
entered into an exclusive licensing agreement for GVAX. Cell Genesys
has
formed a partnership with Novartis AG for development of the oncolytic
virus therapies.
|
·
|
Pharmexa-Epimmune,
Inc., the U.S. subsidiary of Pharmexa A/S, has in its product pipeline
a
peptide vaccine, GV1001, which is in Phase III clinical trials for
pancreatic cancer and Phase II clinical trials for liver and non-small
cell lung cancer and two vaccines against HER/2-positive breast cancer
in
Phase I and Phase II clinical trials. Pharmexa-Epimmune has received
significant NIH funding for vaccines against malaria and HIV, some
of
which are currently in Phase I testing.
|
·
|
Cel-Sci
Corporation has developed the Ligand Epitope Antigen Presentation
System
(L.E.A.P.S.) delivery technology. In April 2006, Cel-Sci filed a
provisional U.S. patent application covering CEL-1000, the lead product
developed from the L.E.A.P.S. technology, for the prevention/treatment
of
bird flu and/or as an adjuvant to be included in a bird flu vaccine.
|
Name
|
|
Age
|
|
Position
Held with Generex
|
|
|
|
|
|
Anna
E. Gluskin
|
|
57
|
|
Chairman,
President, Chief Executive Officer and Director
|
|
|
|
|
|
Rose
C. Perri
|
|
41
|
|
Chief
Operating Officer, Chief Financial Officer, Treasurer, Secretary
and
Director
|
|
|
|
|
|
Mark
Fletcher, Esquire
|
|
42
|
|
Executive
Vice President and General Counsel
|
Gerald
Bernstein, M.D.
|
75
|
Vice
President, Medical Affairs
|
||
|
|
|
|
|
John
P. Barratt
|
|
64
|
|
Director
|
Brian
T. McGee
|
|
47
|
|
Director
|
|
|
|
|
|
Nola
E. Masterson
|
|
61
|
|
Director
|
|
·
|
to
proceed with the development of our buccal insulin
product;
|
|
·
|
to
finance the research and development of new products based on our
buccal
delivery and immunomedicine technologies, including clinical testing
relating to new products;
|
|
·
|
to
finance the research and development activities of our subsidiary
Antigen
with respect to other potential technologies;
|
|
|
|
|
·
|
to
commercially launch and market developed products;
|
|
·
|
to
develop or acquire other technologies or other lines of
business;
|
|
·
|
to
establish and expand our manufacturing capabilities;
|
|
·
|
to
finance general and administrative activities that are not related
to
specific products under development; and
|
|
·
|
to
otherwise carry on business.
|
·
|
The
financial institution will offer to purchase the auction rate securities
of large and institutional investors, presumably such as Generex,
in a buy
back that will begin no later than June 10, 2009 and conclude by
June 30,
2009; and
|
·
|
Until
the financial institution actually provides for the liquidation of
the
auction rate securities, the financial institution will provide customers
no net loans that will remain outstanding until the auction rate
securities are repurchased.
|
|
·
|
acceptance
of the formulation or treatment by health care professionals and
diabetic
patients;
|
|
·
|
the
availability, effectiveness and relative cost of alternative diabetes
or
immunomedicine treatments that may be developed by competitors;
and
|
|
·
|
the
availability of third-party (i.e., insurer and governmental agency)
reimbursements.
|
|
·
|
announcements
of research activities and technology innovations or new products
by us or
our competitors;
|
|
·
|
changes
in market valuation of companies in our industry
generally;
|
|
·
|
variations
in operating results;
|
|
·
|
changes
in governmental regulations;
|
|
·
|
developments
in patent and other proprietary rights;
|
|
·
|
public
concern as to the safety of drugs or treatments developed by us or
others;
|
|
·
|
results
of clinical trials of our products or our competitors' products;
and
|
|
·
|
regulatory
action or inaction on our products or our competitors'
products.
|
|
·
|
elected
all five nominees to the Board of Directors (Proposal
1);
|
|
·
|
approved
the potential issuance of shares of our common stock upon the conversion
of convertible notes, upon payment of principal and interest due
on the
convertible notes and upon the exercise of warrants at a conversion
or
exercise price (as the case may be) less than the market price on
March
31, 2008, which convertible notes and warrants were issued in a private
placement financing for the purpose of complying with a Securities
Purchase Agreement, dated March 31, 2008, among Generex and the investors
in the private placement, and the rules governing the NASDAQ Capital
Market (Proposal 2); and
|
|
·
|
ratified
the appointment of Danziger Hochman Partners LLP as our independent
public
accountants for the fiscal year ending July 31, 2008 (Proposal
3).
|
Election
of nominees to Board of Directors for terms expiring May 27,
2009
|
Votes
For
|
Votes
Against
|
Abstentions
|
|||||||
Anna
E. Gluskin
|
69.114%
|
|
0.000%
|
|
2.384%
|
|
||||
76,465,120
|
0
|
2,637,878
|
||||||||
John
P. Barratt
|
69.240%
|
|
0.000%
|
|
2.258%
|
|
||||
76,604,807
|
0
|
2,498,191
|
||||||||
Brian
T. McGee
|
69.259%
|
|
0.000%
|
|
2.240%
|
|
||||
76,625,038
|
0
|
2,477,960
|
||||||||
Nola
E. Masterson
|
69.199%
|
|
0.000%
|
|
2.299%
|
|
||||
76,559,095
|
0
|
2,543,903
|
||||||||
Rose
C. Perri
|
69.171%
|
|
0.000%
|
|
2.327%
|
|
||||
76,528,029
|
0
|
2,574,969
|
Proposal
|
Votes
For
|
Votes
Against
|
Abstention
|
Broker
Non-Votes
|
|||||||||
Proposal
2
|
63.796%
70,581,523
|
6.753%
7,471,127
|
0.949%
1,050,347
|
1
|
|||||||||
Ratification
of Danziger Hochman Partners LLP
|
69.276%
76,643,761
|
1.135%
1,255,761
|
1.088%
1,203,474
|
2
|
|||||||||
Item
5.
|
Market
For Registrant’s Common Equity, Related Stockholder Matters and
Issuer Purchases of Equity
Securities.
|
|
Bid
Prices
|
||||||
|
High
|
Low
|
|||||
Fiscal
2007
|
|
|
|||||
First
Quarter
|
$
|
2.70
|
1.25
|
||||
Second
Quarter
|
$
|
2.32
|
1.53
|
||||
Third
Quarter
|
$
|
1.97
|
1.60
|
||||
Fourth
Quarter
|
$
|
2.14
|
1.26
|
||||
Fiscal
2008
|
|||||||
First
Quarter
|
$
|
1.70
|
1.41
|
||||
Second
Quarter
|
$
|
1.95
|
1.27
|
||||
Third
Quarter
|
$
|
1.45
|
0.81
|
||||
Fourth
Quarter
|
$
|
1.19
|
0.74
|
In
thousands
|
2008
|
2007
|
2006
|
2005
|
2004
|
|||||||||||
|
|
|
|
|
||||||||||||
Operating
Results:
|
||||||||||||||||
Revenue
|
$
|
125
|
$
|
180
|
$
|
175
|
$
|
392
|
$
|
627
|
||||||
Net
Loss
|
(36,229
|
)
|
(23,505
|
)
|
(67,967
|
)
|
(24,002
|
)
|
(18,363
|
)
|
||||||
Net
Loss Available to Common Stockholders
|
(36,229
|
)
|
(23,505
|
)
|
(67,967
|
)
|
(24,002
|
)
|
(19,173
|
)
|
||||||
Cash
Dividends per share
|
—
|
—
|
—
|
—
|
—
|
|||||||||||
Loss
per Common Share:
|
||||||||||||||||
Basic
and Diluted Net Loss Per Common Share
|
(.33
|
)
|
(.22
|
)
|
(.90
|
)
|
(.66
|
)
|
(.64
|
)
|
||||||
Financial
Positions:
|
||||||||||||||||
Total
Assets
|
$
|
38,148
|
$
|
46,404
|
$
|
64,105
|
$
|
13,466
|
$
|
19,012
|
||||||
Long-Term
Debt
|
$
|
3,187
|
$
|
3,144
|
$
|
3,036
|
$
|
3,288
|
$
|
2,225
|
||||||
Convertible
Debentures
|
$
|
4,719
|
$
|
—
|
$
|
161
|
$
|
1,315
|
$
|
—
|
||||||
Series
A, Preferred Stock
|
$
|
—
|
$
|
—
|
$
|
—
|
$
|
—
|
$
|
14,310
|
||||||
Stockholder's
Equity
|
$
|
22,647
|
$
|
36,071
|
$
|
55,464
|
$
|
6,127
|
$
|
530
|
(i)
|
the
product of (A) the sum of the principal amount to be redeemed together
with accrued and unpaid interest and unpaid late charges with respect
to
such principal amount and (B) 135%,
and
|
(ii) |
the
product of
|
(X)
|
the
principal amount of the Notes to be prepaid, plus all other accrued
and
unpaid interest thereof, divided by the conversion price on in effect
at
such time as the holder delivers an Event of Default redemption notice
and
|
(Y)
|
the
product of (1) the 135% and (2) the greater of (I) the closing sale
price
of our common stock on the date immediately preceding such Event
of
Default, (II) the closing sale price of our common stock on the date
immediately after such Event of Default and (III) the closing sale
price
of the common stock on the date the holder delivers the Event of
Default
redemption notice.
|
(i)
|
Series
A and A-1 Warrants, which are exercisable for a period of 7 years
into an
aggregate of 75% of the number of shares of our common stock initially
issuable upon conversion of the Notes, with the Series A Warrants
being
exercisable into 5,257,729 shares immediately upon issuance and the
Series
A-1 warrants being exercisable into 7,541,857 shares beginning October
1,
2008;
|
|
(ii)
|
Series
B Warrants, which are exercisable beginning October 1, 2008 into
100% of
the shares of our common stock initially issuable upon conversion
of the
Notes (initially 17,066,166 shares) and remaining exercisable for
a period
of 18 months after a registration statement covering the shares of
common
stock issuable upon conversion or exercise of the Notes and Warrants
is
declared effective by the SEC; and
|
|
(iii)
|
Series
C Warrants, which are exercisable for a period of 7 years beginning
October 1, 2008, but only to the extent that the Series B Warrant
are
exercised and only in the same percentage that the Series B Warrants
are
exercised, up to a maximum percentage of 75% of the number of shares
of
our common stock initially issuable upon conversion of the Notes
(initially a maximum of 12,799,580 shares).
|
Date Issued
|
Aggregate
No. of
Shares Unexercised
|
Exercise
Price*
|
Exercise Date
|
Expiration Date
|
|||||||||
March
31, 2008
|
12,697,024
|
$
|
1.10
|
March 31, 2008
|
March
31, 2015
|
||||||||
|
|||||||||||||
March
31, 2008
|
5,257,729
|
$
|
1.21
|
March
31, 2008
|
March
31, 2015
|
||||||||
|
|||||||||||||
March
31, 2008
|
20,341,437
|
$
|
1.21
|
October 1, 2008
|
October 1, 2015
|
||||||||
|
|||||||||||||
March
31, 2008
|
17,066,117
|
$
|
1.21
|
October
1, 2008
|
October
1, 2009
|
·
|
22,527,275
shares of our common stock issuable upon conversion of, and as interest
payments on, the Notes (120%);
|
·
|
6,309,275
shares of common stock issuable upon exercise of the Series A Warrants
issued to the holders of the Notes;
and
|
·
|
1,355,117
shares of common stock issuable upon exercise of some of the Series
A-1
Warrants.
|
·
|
the
registration statement for the resale of all of the shares of common
stock
underlying the Notes and the Warrants was not effective at least
thirty
days prior to the installment notice date of August 1, 2008;
and
|
·
|
we
failed to comply with the minimum bid price requirement of Marketplace
Rule 4310(c)(4) of The Nasdaq Stock
Market.
|
·
|
On
the August 1st
installment date, we paid the accrued and unpaid interest in
cash.
|
·
|
We
paid the balance of the August 1st installment amount in shares of
our
common stock as follows:
|
·
|
50%
of the shares were issued at the same time and in the same manner
as the
shares issued in payment of the September 1, 2008 installment amount;
and
|
·
|
50%
of the shares were issued at the same time and in the same manner
as the
shares issued in payment of the October 1, 2008 installment
amount.
|
·
|
The
shares issued in respect of the August 1st installment amount were
calculated using the lower of:
|
· |
the
then applicable conversion price,
|
·
|
the
price computed as 90% of the arithmetic average of the volume weighted
average price (“VWAP”) of the common stock on each of the twenty
consecutive trading days immediately preceding August 1, 2008
and
|
·
|
the
price computed as 90% of the arithmetic average of the VWAP of the
common
stock on each of the twenty consecutive trading days immediately
preceding
the delivery or deemed delivery of our installment notice with respect
to
the installment amount due on September 1, 2008 or October 1, 2008,
as
applicable.
|
· |
the
timing and amount of expense incurred to complete our clinical trials;
|
·
|
the
costs and timing of the regulatory process as we seek approval of
our
products in development;
|
·
|
the
advancement of our products in development;
|
·
|
our
ability to generate new relationships with industry partners throughout
the world that will provide us with regulatory assistance and long-term
commercialization opportunities;
|
·
|
the
timing, receipt and amount of sales, if any, from Generex Oral-lyn™ in
India and Ecuador;
|
·
|
the
timing, receipt and amount of sales, if any, from our over-the-counter
products;
|
·
|
the
cost of manufacturing (paid to third parties) of our licensed products,
and the cost of marketing and sales activities of those products;
|
·
|
the
costs of prosecuting, maintaining, and enforcing patent claims, if
any
claims are made;
|
·
|
our
ability to maintain existing collaborative relationships and establish
new
relationships as we advance our products in development; and
|
·
|
the
receptivity of the financial market to biopharmaceutical companies.
|
Payments Due by Period
|
||||||||||||||||
Contractual Obligations
|
Total
|
Less than 1
Year
|
1-3 years
|
3-5 years
|
More
than
5 years
|
|||||||||||
Long-Term
Debt Obligations
|
3,472,448
|
1,990,432
|
1,482,016
|
|||||||||||||
Convertible
Debt Obligations
|
22,191,866
|
18,005,576
|
4,186,290
|
|||||||||||||
Capital
Lease Obligations
|
||||||||||||||||
Operating
Lease Obligations
|
493,975
|
153,030
|
230,581
|
109,587
|
777
|
|||||||||||
Purchase
Obligations
|
||||||||||||||||
Other
Long-Term Liabilities Reflected on the Registrant's
Balance Sheet under GAAP
|
||||||||||||||||
Total
|
$
|
26,158,289
|
$
|
20,149,038
|
$
|
5,898,887
|
$
|
109,587
|
$
|
777
|
Loan Amount
|
Interest Rate
per Annum
|
||||
446,115
|
6.82
|
%
|
|||
276,602
|
6.82
|
%
|
|||
676,485
|
7.60
|
%
|
|||
390,800
|
8.50
|
%
|
|||
209,530
|
10
|
%
|
|||
1,187,716
|
6.07
|
%
|
|||
3,187,248
|
Total
|
|
Page
|
|
|
Reports
of Independent Registered Public Accounting Firms
|
51
|
|
|
Consolidated
Balance Sheets July 31, 2008 and 2007
|
55
|
|
|
Consolidated
Statements of Operations For the Years Ended July 31, 2008, 2007
and 2006
and Cumulative From Inception to July 31, 2008
|
56
|
|
|
Consolidated
Statements of Changes in Stockholders’ Equity For the Period November 2,
1995 (Date of Inception) to July 31, 2008
|
57
|
|
|
Consolidated
Statements of Cash Flows For the Years Ended July 31, 2008, 2007
and 2006
and Cumulative From Inception to July 31, 2008
|
70
|
|
|
Notes
to Consolidated Financial Statements
|
71
|
July
31,
|
|||||||
2008
|
2007
|
||||||
ASSETS
|
|||||||
Current
Assets:
|
|||||||
Cash
and cash equivalents
|
$
|
17,237,510
|
$
|
21,026,067
|
|||
Short-term
investments
|
8,852,214
|
14,011,738
|
|||||
Accounts
receivable
|
81,784
|
58,264
|
|||||
Inventory
|
1,465,222
|
123,931
|
|||||
Other
current assets
|
380,927
|
469,210
|
|||||
Deferred
debt issuance costs
|
506,608
|
—
|
|||||
Total
Current Assets
|
28,524,265
|
35,689,210
|
|||||
Deferred
Debt Issuance Costs
|
211,086
|
—
|
|||||
Property
and Equipment, Net
|
1,744,974
|
2,137,027
|
|||||
Assets
Held for Investment, Net
|
3,713,317
|
3,693,183
|
|||||
Patents,
Net
|
3,954,241
|
4,884,984
|
|||||
TOTAL
ASSETS
|
$
|
38,147,883
|
$
|
46,404,404
|
|||
LIABILITIES
AND STOCKHOLDERS’ EQUITY
|
|||||||
Current
Liabilities:
|
|||||||
Accounts
payable and accrued expenses
|
$
|
7,469,710
|
$
|
7,156,709
|
|||
Deferred
revenue and rebate liability
|
125,598
|
33,314
|
|||||
Current
maturities of long-term debt
|
1,832,684
|
84,503
|
|||||
Convertible
debentures, net of debt discount of $15,931,480 and $-0-at July 31,
2008
and 2007, respectively
|
4,718,520
|
—
|
|||||
Total
Current Liabilities
|
14,146,512
|
7,274,526
|
|||||
Long-Term
Debt, Net
|
1,354,564
|
3,059,286
|
|||||
Commitments
and Contingencies
|
|||||||
Stockholders’
Equity:
|
|||||||
Special
Voting Rights Preferred Stock, $.001 par value; authorized 1,000
shares at
July 31, 2008 and 2007; -0- shares issued and outstanding at July
31, 2008
and 2007
|
—
|
—
|
|||||
Common
stock, $.001 par value; authorized 500,000,000 shares at July 31,
2008 and
2007; 111,992,603 and 109,616,518 shares issued and outstanding at
July
31, 2008 and 2007, respectively
|
111,992
|
109,616
|
|||||
Additional
paid-in capital
|
269,849,581
|
247,079,439
|
|||||
Deficit
accumulated during the development stage
|
(248,229,261
|
)
|
(212,000,270
|
)
|
|||
Accumulated
other comprehensive income
|
914,495
|
881,807
|
|||||
Total
Stockholders’ Equity
|
22,646,807
|
36,070,592
|
|||||
TOTAL
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
$
|
38,147,883
|
$
|
46,404,404
|
Cumulative From
|
|||||||||||||
November 2, 1995
|
|||||||||||||
(Date of Inception)
|
|||||||||||||
For the Years Ended July 31,
|
to July 31,
|
||||||||||||
2008
|
2007
|
2006
|
2008
|
||||||||||
Revenues
|
$
|
128,039
|
$
|
182,429
|
$
|
175,000
|
$
|
2,504,764
|
|||||
Sales
discounts
|
(3,148
|
)
|
(2,231
|
)
|
—
|
(5,379
|
)
|
||||||
Net
Revenue
|
124,891
|
180,198
|
175,000
|
2,499,385
|
|||||||||
Cost
of Goods Sold
|
52,025
|
61,623
|
—
|
113,648
|
|||||||||
Operating
Expenses:
|
|||||||||||||
Research
and development
|
16,359,030
|
11,983,626
|
6,554,393
|
89,815,494
|
|||||||||
Research
and development - related party
|
—
|
—
|
—
|
220,218
|
|||||||||
Selling
and marketing
|
1,562,258
|
693,309
|
56,028
|
2,311,595
|
|||||||||
General
and administrative
|
15,597,048
|
12,317,742
|
12,270,562
|
105,636,466
|
|||||||||
General
and administrative - related party
|
—
|
—
|
—
|
314,328
|
|||||||||
Total
Operating Expenses
|
33,518,336
|
24,994,677
|
18,880,983
|
198,298,101
|
|||||||||
Operating
Loss
|
(33,445,470
|
)
|
(24,876,102
|
)
|
(18,705,983
|
)
|
(195,912,364
|
)
|
|||||
Other
Income (Expense):
|
|||||||||||||
Miscellaneous
income (expense)
|
65
|
—
|
500
|
196,258
|
|||||||||
Income
from rental operations, net
|
330,533
|
277,474
|
236,521
|
1,251,461
|
|||||||||
Interest
income
|
1,166,439
|
2,180,380
|
767,598
|
7,508,897
|
|||||||||
Interest
expense
|
(4,280,558
|
)
|
(849,548
|
)
|
(37,715,275
|
)
|
(47,882,573
|
)
|
|||||
Loss
on extinguishment of debt
|
—
|
(237,162
|
)
|
(12,550,565
|
)
|
(14,134,068
|
)
|
||||||
Net
Loss Before Undernoted
|
(36,228,991
|
)
|
(23,504,958
|
)
|
(67,967,204
|
)
|
(248,972,389
|
)
|
|||||
Minority
Interest Share of Loss
|
—
|
—
|
—
|
3,038,185
|
|||||||||
Net
Loss
|
(36,228,991
|
)
|
(23,504,958
|
)
|
(67,967,204
|
)
|
(245,934,204
|
)
|
|||||
Preferred
Stock Dividend
|
—
|
—
|
—
|
2,295,057
|
|||||||||
Net
Loss Available to Common Shareholders
|
$
|
(36,228,991
|
)
|
$
|
(23,504,958
|
)
|
$
|
(67,967,204
|
)
|
$
|
(248,229,261
|
)
|
|
Basic
and Diluted Net Loss Per Common Share
|
$
|
(.33
|
)
|
$
|
(.22
|
)
|
$
|
(.90
|
)
|
||||
Weighted
Average Number of Shares of Common Stock Outstanding
|
110,991,192
|
108,416,023
|
75,416,234
|
Deficit
|
||||||||||||||||||||||||||||||||||
SVR
|
Notes
|
Accumulated
|
Accumulated
|
|||||||||||||||||||||||||||||||
Preferred
|
Common
|
Treasury
|
Additional
|
Receivable -
|
During the
|
Other
|
Total
|
|||||||||||||||||||||||||||
Stock
|
Stock
|
Stock
|
Paid-In
|
Common
|
Development
|
Comprehensive
|
Stockholders’
|
|||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Stock
|
Stage
|
Income (Loss)
|
Equity
|
||||||||||||||||||||||||
Balance November 2, 1995
|
||||||||||||||||||||||||||||||||||
(Inception)
|
-
|
$
|
-
|
-
|
$
|
-
|
-
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
-
|
|||||||||||||||
Issuance of common stock for cash,
|
||||||||||||||||||||||||||||||||||
February
1996, $.0254
|
-
|
-
|
321,429
|
321
|
-
|
-
|
7,838
|
-
|
-
|
-
|
8,159
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
February
1996, $.0510
|
-
|
-
|
35,142
|
35
|
-
|
-
|
1,757
|
-
|
-
|
-
|
1,792
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
February
1996, $.5099
|
-
|
-
|
216,428
|
216
|
-
|
-
|
110,142
|
-
|
-
|
-
|
110,358
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
March
1996, $10.2428
|
-
|
-
|
2,500
|
3
|
-
|
-
|
25,604
|
-
|
-
|
-
|
25,607
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
April
1996, $.0516
|
-
|
-
|
489,850
|
490
|
-
|
-
|
24,773
|
-
|
-
|
-
|
25,263
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
May
1996, $.0512
|
-
|
-
|
115,571
|
116
|
-
|
-
|
5,796
|
-
|
-
|
-
|
5,912
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
May
1996, $.5115
|
-
|
-
|
428,072
|
428
|
-
|
-
|
218,534
|
-
|
-
|
-
|
218,962
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
May
1996, $10.2302
|
-
|
-
|
129,818
|
130
|
-
|
-
|
1,327,934
|
-
|
-
|
1,328,064
|
||||||||||||||||||||||||
Issuance
of common stock for cash,
|
-
|
|||||||||||||||||||||||||||||||||
July
1996, $.0051
|
-
|
-
|
2,606,528
|
2,606
|
-
|
-
|
10,777
|
-
|
-
|
13,383
|
||||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
July
1996, $.0255
|
-
|
-
|
142,857
|
143
|
-
|
-
|
3,494
|
-
|
-
|
-
|
3,637
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
July
1996, $.0513
|
-
|
-
|
35,714
|
36
|
-
|
-
|
1,797
|
-
|
-
|
-
|
1,833
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
July
1996, $10.1847
|
-
|
-
|
63,855
|
64
|
-
|
-
|
650,282
|
-
|
-
|
-
|
650,346
|
|||||||||||||||||||||||
Costs related to issuance of common
|
||||||||||||||||||||||||||||||||||
stock
|
-
|
-
|
-
|
-
|
-
|
-
|
(10,252
|
)
|
-
|
-
|
-
|
(10,252
|
)
|
|||||||||||||||||||||
Founders Shares transferred for services
|
||||||||||||||||||||||||||||||||||
rendered
|
-
|
-
|
-
|
-
|
-
|
-
|
330,025
|
-
|
-
|
-
|
330,025
|
|||||||||||||||||||||||
Comprehensive
Income (Loss):
|
||||||||||||||||||||||||||||||||||
Net
loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(693,448
|
)
|
-
|
(693,448
|
)
|
|||||||||||||||||||||
Other comprehensive income (loss)
|
||||||||||||||||||||||||||||||||||
Currency translation adjustment
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(4,017
|
)
|
(4,017
|
)
|
|||||||||||||||||||||
Total Comprehensive Income (Loss)
|
(693,448
|
)
|
(4,017
|
)
|
(697,465
|
)
|
||||||||||||||||||||||||||||
Balance,
July 31, 1996
|
-
|
$
|
-
|
4,587,764
|
$
|
4,588
|
-
|
$
|
-
|
$
|
2,708,501
|
$
|
-
|
$
|
(693,448
|
)
|
$
|
(4,017
|
)
|
$
|
2,015,624
|
Deficit
|
||||||||||||||||||||||||||||||||||
SVR
|
Notes
|
Accumulated
|
Accumulated
|
|||||||||||||||||||||||||||||||
Preferred
|
Common
|
Treasury
|
Additional
|
Receivable -
|
During the
|
Other
|
Total
|
|||||||||||||||||||||||||||
Stock
|
Stock
|
Stock
|
Paid-In
|
Common
|
Development
|
Comprehensive
|
Stockholders’
|
|||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Stock
|
Stage
|
Income (Loss)
|
Equity
|
||||||||||||||||||||||||
Balance,
August 1, 1996
|
-
|
$
|
-
|
4,587,764
|
$
|
4,588
|
-
|
$
|
-
|
$
|
2,708,501
|
$
|
-
|
$
|
(693,448
|
)
|
$
|
(4,017
|
)
|
$
|
2,015,624
|
|||||||||||||
Issuance of common stock for cash,
|
||||||||||||||||||||||||||||||||||
September
1996, $.0509
|
-
|
-
|
2,143
|
2
|
-
|
-
|
107
|
-
|
-
|
-
|
109
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
December
1996, $10.2421
|
-
|
-
|
1,429
|
1
|
-
|
-
|
14,635
|
-
|
-
|
-
|
14,636
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
January
1997, $.0518
|
-
|
-
|
1,466
|
1
|
-
|
-
|
75
|
-
|
-
|
-
|
76
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
March
1997, $10.0833
|
-
|
-
|
12
|
-
|
-
|
-
|
121
|
-
|
-
|
-
|
121
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
May
1997, $.0512
|
-
|
-
|
4,233
|
4
|
-
|
-
|
213
|
-
|
-
|
-
|
217
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
May
1997, $.5060
|
-
|
-
|
4,285,714
|
4,286
|
-
|
-
|
2,164,127
|
-
|
-
|
-
|
2,168,413
|
|||||||||||||||||||||||
Costs
related to issuance of common
|
||||||||||||||||||||||||||||||||||
stock,
May 1997
|
-
|
-
|
-
|
-
|
-
|
-
|
(108,421
|
)
|
-
|
-
|
-
|
(108,421
|
)
|
|||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
May
1997, $10.1194
|
-
|
-
|
18,214
|
18
|
-
|
-
|
184,297
|
-
|
-
|
-
|
184,315
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
June
1997, $.0504
|
-
|
-
|
10,714
|
11
|
-
|
-
|
529
|
-
|
-
|
-
|
540
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
June
1997, $.5047
|
-
|
-
|
32,143
|
32
|
-
|
-
|
16,190
|
-
|
-
|
-
|
16,222
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
June
1997, $8.9810
|
-
|
-
|
29,579
|
30
|
-
|
-
|
265,618
|
-
|
-
|
-
|
265,648
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
June
1997, $10.0978
|
-
|
-
|
714
|
1
|
-
|
-
|
7,209
|
-
|
-
|
-
|
7,210
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
July
1997, $10.1214
|
-
|
-
|
25,993
|
26
|
-
|
-
|
263,060
|
-
|
-
|
-
|
263,086
|
|||||||||||||||||||||||
Costs related to issuance of common
|
||||||||||||||||||||||||||||||||||
stock
|
-
|
-
|
-
|
-
|
-
|
-
|
(26,960
|
)
|
-
|
-
|
-
|
(26,960
|
)
|
|||||||||||||||||||||
Founders
Shares transferred for services
|
||||||||||||||||||||||||||||||||||
rendered
|
-
|
-
|
-
|
-
|
-
|
-
|
23,481
|
-
|
-
|
-
|
23,481
|
|||||||||||||||||||||||
Comprehensive
Income (Loss):
|
||||||||||||||||||||||||||||||||||
Net
loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(1,379,024
|
)
|
-
|
(1,379,024
|
)
|
|||||||||||||||||||||
Other comprehensive income (loss)
|
||||||||||||||||||||||||||||||||||
Currency translation adjustment
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
3,543
|
3,543
|
|||||||||||||||||||||||
Total Comprehensive Income (Loss)
|
(1,379,024
|
)
|
3,543
|
(1,375,481
|
)
|
|||||||||||||||||||||||||||||
Balance,
July 31, 1997
|
-
|
$
|
-
|
9,000,118
|
$
|
9,000
|
-
|
$
|
-
|
$
|
5,512,782
|
$
|
-
|
$
|
(2,072,472
|
)
|
$
|
(474
|
)
|
$
|
3,448,836
|
Deficit
|
||||||||||||||||||||||||||||||||||
SVR
|
Notes
|
Accumulated
|
Accumulated
|
|||||||||||||||||||||||||||||||
Preferred
|
Common
|
Treasury
|
Additional
|
Receivable -
|
During the
|
Other
|
Total
|
|||||||||||||||||||||||||||
Stock
|
Stock
|
Stock
|
Paid-In
|
Common
|
Development
|
Comprehensive
|
Stockholders’
|
|||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Stock
|
Stage
|
Income (Loss)
|
Equity
|
||||||||||||||||||||||||
Balance,
August 1, 1997
|
-
|
$
|
-
|
9,000,118
|
$
|
9,000
|
-
|
$
|
-
|
$
|
5,512,782
|
$
|
-
|
$
|
(2,072,472
|
)
|
$
|
(474
|
)
|
$
|
3,448,836
|
|||||||||||||
Issuance of warrants in exchange for
|
||||||||||||||||||||||||||||||||||
services
rendered, October 1997, $.50
|
-
|
-
|
-
|
-
|
-
|
-
|
234,000
|
-
|
-
|
-
|
234,000
|
|||||||||||||||||||||||
Issuance
of common stock in exchange
|
||||||||||||||||||||||||||||||||||
for
services rendered, December 1997, $0.05
|
-
|
-
|
234,000
|
234
|
-
|
-
|
10,698
|
-
|
-
|
-
|
10,932
|
|||||||||||||||||||||||
Issuance
of SVR Preferred Stock in exchange
|
||||||||||||||||||||||||||||||||||
for
services rendered, January 1998, $.001
|
1,000
|
1
|
-
|
-
|
-
|
-
|
99
|
-
|
-
|
-
|
100
|
|||||||||||||||||||||||
Shares
issued pursuant to the January 9, 1998
|
||||||||||||||||||||||||||||||||||
reverse
merger between GBC-Delaware, Inc.and Generex Biotechnology Corporation
|
-
|
-
|
1,105,000
|
1,105
|
-
|
-
|
(1,105
|
)
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||
Issuance
of common stock for cash, March
|
||||||||||||||||||||||||||||||||||
1998,
$2.50
|
-
|
-
|
70,753
|
71
|
-
|
-
|
176,812
|
-
|
-
|
-
|
176,883
|
|||||||||||||||||||||||
Issuance
of common stock for cash, April
|
||||||||||||||||||||||||||||||||||
1998,
$2.50
|
-
|
-
|
60,000
|
60
|
-
|
-
|
149,940
|
-
|
-
|
-
|
150,000
|
|||||||||||||||||||||||
Issuance
of common stock in exchange
|
||||||||||||||||||||||||||||||||||
for
services rendered, April 1998, $2.50
|
-
|
-
|
38,172
|
38
|
-
|
-
|
95,392
|
-
|
-
|
-
|
95,430
|
|||||||||||||||||||||||
Issuance
of common stock for cash, May
|
||||||||||||||||||||||||||||||||||
1998,
$2.50
|
-
|
-
|
756,500
|
757
|
-
|
-
|
1,890,493
|
-
|
-
|
-
|
1,891,250
|
|||||||||||||||||||||||
Issuance
of common stock in exchange
|
||||||||||||||||||||||||||||||||||
for
services rendered, May 1998, $2.50
|
-
|
-
|
162,000
|
162
|
-
|
-
|
404,838
|
-
|
-
|
-
|
405,000
|
|||||||||||||||||||||||
Issuance
of warrants in exchange for
|
||||||||||||||||||||||||||||||||||
services
rendered, May 1998, $.60
|
-
|
-
|
-
|
-
|
-
|
-
|
300,000
|
-
|
-
|
-
|
300,000
|
|||||||||||||||||||||||
Issuance
of common stock for cash, June
|
||||||||||||||||||||||||||||||||||
1998,
$2.50
|
-
|
-
|
286,000
|
286
|
-
|
-
|
714,714
|
-
|
-
|
-
|
715,000
|
|||||||||||||||||||||||
Exercise
of warrants for cash, June
|
||||||||||||||||||||||||||||||||||
1998,
$0.0667
|
-
|
-
|
234,000
|
234
|
-
|
-
|
15,374
|
-
|
-
|
-
|
15,608
|
|||||||||||||||||||||||
Issuance
of common stock in exchange
|
||||||||||||||||||||||||||||||||||
for
services rendered, June 1998, $2.50
|
-
|
-
|
24,729
|
24
|
-
|
-
|
61,799
|
-
|
-
|
-
|
61,823
|
|||||||||||||||||||||||
Comprehensive Income (Loss):
|
||||||||||||||||||||||||||||||||||
Net
loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(4,663,604
|
)
|
-
|
(4,663,604
|
)
|
|||||||||||||||||||||
Other comprehensive income (loss)
|
||||||||||||||||||||||||||||||||||
Currency translation adjustment
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(198,959
|
)
|
(198,959
|
)
|
|||||||||||||||||||||
Total Comprehensive Income (Loss)
|
(4,663,604
|
)
|
(198,959
|
)
|
4,862,563
|
|||||||||||||||||||||||||||||
Balance,
July 31, 1998
|
1,000
|
$
|
1
|
11,971,272
|
$
|
11,971
|
-
|
$
|
-
|
$
|
9,565,836
|
$
|
-
|
$
|
(6,736,076
|
)
|
$
|
(199,433
|
)
|
$
|
2,642,299
|
Deficit
|
||||||||||||||||||||||||||||||||||
SVR
|
Notes
|
Accumulated
|
Accumulated
|
|||||||||||||||||||||||||||||||
Preferred
|
Common
|
Treasury
|
Additional
|
Receivable
-
|
During
the
|
Other
|
Total
|
|||||||||||||||||||||||||||
Stock
|
Stock
|
Stock
|
Paid-In
|
Common
|
Development
|
Comprehensive
|
Stockholders’
|
|||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Stock
|
Stage
|
Income
(Loss)
|
Equity
|
||||||||||||||||||||||||
Balance,
August 1, 1998
|
1,000
|
$
|
1
|
11,971,272
|
$
|
11,971
|
-
|
$
|
-
|
$
|
9,565,836
|
$
|
-
|
$
|
(6,736,076
|
)
|
$
|
(199,433
|
)
|
$
|
2,642,299
|
|||||||||||||
Issuance of common stock for cash, August
|
||||||||||||||||||||||||||||||||||
1998,
$3.00
|
-
|
-
|
100,000
|
100
|
-
|
-
|
299,900
|
-
|
-
|
-
|
300,000
|
|||||||||||||||||||||||
Issuance
of common stock for cash, August
|
||||||||||||||||||||||||||||||||||
1998,
$3.50
|
-
|
-
|
19,482
|
19
|
-
|
-
|
68,168
|
-
|
-
|
-
|
68,187
|
|||||||||||||||||||||||
Redemption
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
September
1998, $7.75
|
-
|
-
|
(15,357
|
)
|
(15
|
)
|
-
|
-
|
(119,051
|
)
|
-
|
-
|
-
|
(119,066
|
)
|
|||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
September
- October 1998, $3.00
|
-
|
-
|
220,297
|
220
|
-
|
-
|
660,671
|
-
|
-
|
-
|
660,891
|
|||||||||||||||||||||||
Issuance
of common stock for cash, August -
|
||||||||||||||||||||||||||||||||||
October
1998, $4.10
|
-
|
-
|
210,818
|
211
|
-
|
-
|
864,142
|
-
|
-
|
-
|
864,353
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for
|
||||||||||||||||||||||||||||||||||
services
rendered, August - October 1998, $2.50
|
-
|
-
|
21,439
|
21
|
-
|
-
|
53,577
|
-
|
-
|
-
|
53,598
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for
|
||||||||||||||||||||||||||||||||||
services
rendered, August - October 1998, $4.10
|
-
|
-
|
18,065
|
18
|
-
|
-
|
74,048
|
-
|
-
|
-
|
74,066
|
|||||||||||||||||||||||
Issuance
of common stock in exchange
|
||||||||||||||||||||||||||||||||||
for
services rendered, September 1998, $4.10
|
-
|
-
|
180,000
|
180
|
-
|
-
|
737,820
|
-
|
-
|
-
|
738,000
|
|||||||||||||||||||||||
Issuance
of warrants in exchange for
|
||||||||||||||||||||||||||||||||||
services
rendered, October 1998, $.26
|
-
|
-
|
-
|
-
|
-
|
-
|
2,064
|
-
|
-
|
-
|
2,064
|
|||||||||||||||||||||||
Issuance
of stock options in exchange for
|
||||||||||||||||||||||||||||||||||
services
rendered, November 1998, $1.85
|
-
|
-
|
-
|
-
|
-
|
-
|
92,500
|
-
|
-
|
-
|
92,500
|
|||||||||||||||||||||||
Issuance
of warrants in exchange for
|
||||||||||||||||||||||||||||||||||
services
rendered, November 1998, $1.64
|
-
|
-
|
-
|
-
|
-
|
-
|
246,000
|
-
|
-
|
-
|
246,000
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
November
1998 - January 1999, $3.50
|
-
|
-
|
180,000
|
180
|
-
|
-
|
629,820
|
-
|
-
|
-
|
630,000
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
November
1998 - January 1999, $4.00
|
-
|
-
|
275,000
|
275
|
-
|
-
|
1,099,725
|
-
|
-
|
-
|
1,100,000
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
November
1998 - January 1999, $4.10
|
-
|
-
|
96,852
|
97
|
-
|
-
|
397,003
|
-
|
-
|
-
|
397,100
|
|||||||||||||||||||||||
Issuance
of common stock in exchange
|
||||||||||||||||||||||||||||||||||
for
services rendered, November 1998 -
|
||||||||||||||||||||||||||||||||||
January
1999, $4.10
|
-
|
-
|
28,718
|
29
|
-
|
-
|
117,715
|
-
|
-
|
-
|
117,744
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
November
1998 - January 1999, $5.00
|
-
|
-
|
20,000
|
20
|
-
|
-
|
99,980
|
-
|
-
|
-
|
100,000
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
November
1998 - January 1999, $5.50
|
-
|
-
|
15,000
|
15
|
-
|
-
|
82,485
|
-
|
-
|
-
|
82,500
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for
|
||||||||||||||||||||||||||||||||||
services
rendered, January 1999, $5.00
|
-
|
-
|
392
|
-
|
-
|
-
|
1,960
|
-
|
-
|
-
|
1,960
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
February
1999, $5.00
|
-
|
-
|
6,000
|
6
|
-
|
-
|
29,994
|
-
|
-
|
-
|
30,000
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for
|
||||||||||||||||||||||||||||||||||
services
rendered, February 1999, $6.00
|
-
|
-
|
5,000
|
5
|
-
|
-
|
29,995
|
-
|
-
|
-
|
30,000
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
March
1999, $6.00
|
-
|
-
|
11,000
|
11
|
-
|
-
|
65,989
|
-
|
-
|
-
|
66,000
|
|||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
April
1999, $5.50
|
-
|
-
|
363,637
|
364
|
-
|
-
|
1,999,640
|
-
|
-
|
-
|
2,000,004
|
|||||||||||||||||||||||
Issuance
of warrants in exchange for
|
||||||||||||||||||||||||||||||||||
services
rendered, April 1999, $3.21
|
-
|
-
|
-
|
-
|
-
|
-
|
160,500
|
-
|
-
|
-
|
160,500
|
|||||||||||||||||||||||
Issuance
of warrants in exchange for
|
||||||||||||||||||||||||||||||||||
services
rendered, April 1999, $3.17
|
-
|
-
|
-
|
-
|
-
|
-
|
317,000
|
-
|
-
|
-
|
317,000
|
|||||||||||||||||||||||
Issuance
of warrants in exchange for
|
||||||||||||||||||||||||||||||||||
services
rendered, April 1999, $2.89
|
-
|
-
|
-
|
-
|
-
|
-
|
144,500
|
-
|
-
|
-
|
144,500
|
|||||||||||||||||||||||
Issuance
of warrants in exchange for
|
||||||||||||||||||||||||||||||||||
services
rendered, April 1999, $3.27
|
-
|
-
|
-
|
-
|
184,310
|
-
|
-
|
-
|
184,310
|
|||||||||||||||||||||||||
Stock
adjustment
|
-
|
-
|
714
|
1
|
-
|
-
|
(1
|
)
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
May
1999, $5.50
|
-
|
-
|
272,728
|
273
|
-
|
-
|
1,499,731
|
-
|
-
|
-
|
1,500,004
|
|||||||||||||||||||||||
Issuance of common stock in exchange for
|
||||||||||||||||||||||||||||||||||
services
rendered, May - June 1999, $5.50
|
-
|
-
|
60,874
|
61
|
-
|
-
|
334,746
|
-
|
334,807
|
|||||||||||||||||||||||||
Exercise of warrants for cash, June 1999, $5.50
|
-
|
-
|
388,375
|
389
|
-
|
1,941,484
|
-
|
-
|
-
|
1,941,873
|
||||||||||||||||||||||||
Exercise
of warrants in exchange for note
|
||||||||||||||||||||||||||||||||||
receivable,
June 1999, $5.00
|
-
|
-
|
94,776
|
95
|
-
|
-
|
473,787
|
(473,882
|
)
|
-
|
-
|
-
|
||||||||||||||||||||||
Exercise
of warrants in exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
June 1999, $5.00
|
-
|
-
|
13,396
|
13
|
-
|
-
|
66,967
|
-
|
-
|
-
|
66,980
|
|||||||||||||||||||||||
Reduction of note receivable in exchange for
|
||||||||||||||||||||||||||||||||||
services
rendered
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
38,979
|
-
|
-
|
38,979
|
|||||||||||||||||||||||
Shares
tendered in conjunction with warrant
|
||||||||||||||||||||||||||||||||||
exercise,
June 1999, $7.8125
|
-
|
-
|
(323,920
|
)
|
(324
|
)
|
-
|
-
|
(2,530,301
|
)
|
-
|
-
|
-
|
(2,530,625
|
)
|
|||||||||||||||||||
Exercise
of warrants for shares tendered,
|
||||||||||||||||||||||||||||||||||
June
1999, $5.00
|
-
|
-
|
506,125
|
506
|
-
|
-
|
2,530,119
|
-
|
-
|
-
|
2,530,625
|
|||||||||||||||||||||||
Cost
of warrants redeemed for cash
|
-
|
-
|
-
|
-
|
-
|
(3,769
|
)
|
-
|
-
|
-
|
(3,769
|
)
|
||||||||||||||||||||||
Cost related to warrant redemption, June 1999
|
-
|
-
|
-
|
-
|
-
|
-
|
(135,431
|
)
|
-
|
-
|
-
|
(135,431
|
)
|
|||||||||||||||||||||
Costs
related to issuance of common stock
|
-
|
-
|
-
|
-
|
-
|
-
|
(1,179,895
|
)
|
-
|
-
|
-
|
(1,179,895
|
)
|
|||||||||||||||||||||
Comprehensive
Income (Loss):
|
||||||||||||||||||||||||||||||||||
Net
Loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(6,239,602
|
)
|
-
|
(6,239,602
|
)
|
|||||||||||||||||||||
Other
comprehensive income (loss):
|
||||||||||||||||||||||||||||||||||
Currency
translation adjustment
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1,393
|
1,393
|
|||||||||||||||||||||||
Total
Comprehensive Income (Loss)
|
(6,239,602
|
)
|
1,393
|
(6,238,209
|
)
|
|||||||||||||||||||||||||||||
Balance,
July 31, 1999
|
1,000
|
$
|
1
|
14,740,683
|
$
|
14,741
|
-
|
$
|
-
|
$
|
20,903,728
|
$
|
(434,903
|
)
|
$
|
(12,975,678
|
)
|
$
|
(198,040
|
)
|
$
|
7,309,849
|
Deficit
|
||||||||||||||||||||||||||||||||||
SVR
|
Notes
|
Accumulated
|
Accumulated
|
|||||||||||||||||||||||||||||||
Preferred
|
Common
|
Treasury
|
Additional
|
Receivable
-
|
During
the
|
Other
|
Total
|
|||||||||||||||||||||||||||
Stock
|
Stock
|
Stock
|
Paid-In
|
Common
|
Development
|
Comprehensive
|
Stockholders’
|
|||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Stock
|
Stage
|
Income
(Loss)
|
Equity
|
||||||||||||||||||||||||
Balance,
August 1, 1999
|
1,000
|
$
|
1
|
14,740,683
|
$
|
14,741
|
-
|
$
|
-
|
$
|
20,903,728
|
$
|
(434,903
|
)
|
$
|
(12,975,678
|
)
|
$
|
(198,040
|
)
|
$
|
7,309,849
|
||||||||||||
Adjustment for exercise of warrants recorded
|
||||||||||||||||||||||||||||||||||
June
1999, $5.00
|
-
|
-
|
(2,300
|
)
|
(2
|
)
|
-
|
-
|
2
|
-
|
-
|
-
|
-
|
|||||||||||||||||||||
Issuance
of common stock for cash,
|
||||||||||||||||||||||||||||||||||
September
1999, $6.00
|
-
|
-
|
2,500
|
2
|
-
|
-
|
14,998
|
-
|
-
|
-
|
15,000
|
|||||||||||||||||||||||
Issuance
of common stock for cash pursuant to
|
||||||||||||||||||||||||||||||||||
private
placement, January 2000, $4.25
|
-
|
-
|
470,590
|
471
|
-
|
-
|
1,999,537
|
-
|
-
|
-
|
2,000,008
|
|||||||||||||||||||||||
Financing costs associated with private placement,
|
||||||||||||||||||||||||||||||||||
January,
2000
|
-
|
-
|
-
|
-
|
-
|
-
|
(220,192
|
)
|
-
|
-
|
-
|
(220,192
|
)
|
|||||||||||||||||||||
Issuance
of stock in exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
January 2000, $5.00
|
-
|
-
|
8,100
|
8
|
-
|
-
|
40,492
|
-
|
-
|
-
|
40,500
|
|||||||||||||||||||||||
Granting
of stock options for services
|
||||||||||||||||||||||||||||||||||
rendered,
January 2000
|
-
|
-
|
-
|
-
|
-
|
-
|
568,850
|
-
|
-
|
-
|
568,850
|
|||||||||||||||||||||||
Granting
of warrants for services rendered,
|
||||||||||||||||||||||||||||||||||
January
2000
|
-
|
-
|
-
|
-
|
-
|
-
|
355,500
|
-
|
-
|
-
|
355,500
|
|||||||||||||||||||||||
Exercise of warrants for cash, February 2000, $5.50
|
-
|
-
|
2,000
|
2
|
-
|
-
|
10,998
|
-
|
-
|
-
|
11,000
|
|||||||||||||||||||||||
Exercise
of warrants for cash, March 2000, $5.50
|
-
|
-
|
29,091
|
29
|
-
|
-
|
159,972
|
-
|
-
|
-
|
160,001
|
|||||||||||||||||||||||
Exercise
of warrants for cash, March 2000, $6.00
|
-
|
-
|
2,000
|
2
|
-
|
-
|
11,998
|
-
|
-
|
-
|
12,000
|
|||||||||||||||||||||||
Exercise
of warrants for cash, March 2000, $7.50
|
-
|
-
|
8,000
|
8
|
-
|
-
|
59,992
|
-
|
-
|
-
|
60,000
|
|||||||||||||||||||||||
Issuance
of common stock for cash pursuant to
|
||||||||||||||||||||||||||||||||||
private
placement, June 2000, $6.00
|
-
|
-
|
1,041,669
|
1,042
|
-
|
-
|
6,248,972
|
-
|
-
|
-
|
6,250,014
|
|||||||||||||||||||||||
Financing
costs associated with private
|
||||||||||||||||||||||||||||||||||
placement,
June 2000
|
-
|
-
|
-
|
-
|
-
|
-
|
(385,607
|
)
|
-
|
-
|
-
|
(385,607
|
)
|
|||||||||||||||||||||
Issuance
of common stock for services,
|
||||||||||||||||||||||||||||||||||
June
2000, $6.00
|
-
|
-
|
4,300
|
4
|
-
|
-
|
25,796
|
-
|
-
|
-
|
25,800
|
|||||||||||||||||||||||
Exercise of warrants for cash, July 2000, $6.00
|
-
|
-
|
3,000
|
3
|
-
|
-
|
17,997
|
-
|
-
|
-
|
18,000
|
|||||||||||||||||||||||
Exercise
of warrants for cash, July 2000, $7.50
|
-
|
-
|
16,700
|
17
|
-
|
-
|
125,233
|
-
|
-
|
-
|
125,250
|
|||||||||||||||||||||||
Granting
of stock options for services
|
||||||||||||||||||||||||||||||||||
rendered,
July 2000
|
-
|
-
|
-
|
-
|
-
|
-
|
496,800
|
-
|
-
|
-
|
496,800
|
|||||||||||||||||||||||
Reduction
of note receivable in exchange for
|
||||||||||||||||||||||||||||||||||
services
rendered
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
384,903
|
-
|
-
|
384,903
|
|||||||||||||||||||||||
Accrued
interest on note receivable
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(4,118
|
)
|
-
|
-
|
(4,118
|
)
|
|||||||||||||||||||||
Comprehensive
Income (Loss):
|
||||||||||||||||||||||||||||||||||
Net
Loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(8,841,047
|
)
|
-
|
(8,841,047
|
)
|
|||||||||||||||||||||
Other
comprehensive income (loss):
|
||||||||||||||||||||||||||||||||||
Currency
translation adjustment
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
32,514
|
32,514
|
|||||||||||||||||||||||
Total
Comprehensive Income (Loss)
|
(8,841,047
|
)
|
32,514
|
(8,808,533
|
)
|
|||||||||||||||||||||||||||||
Balance,
July 31, 2000
|
1,000
|
$
|
1
|
16,326,333
|
$
|
16,327
|
-
|
$
|
-
|
$
|
30,435,066
|
$
|
(54,118
|
)
|
$
|
(21,816,725
|
)
|
$
|
(165,526
|
)
|
$
|
8,415,025
|
Deficit
|
||||||||||||||||||||||||||||||||||
SVR
|
Notes
|
Accumulated
|
Accumulated
|
|||||||||||||||||||||||||||||||
Preferred
|
Common
|
Treasury
|
Additional
|
Receivable
-
|
During
the
|
Other
|
Total
|
|||||||||||||||||||||||||||
Stock
|
Stock
|
Stock
|
Paid-In
|
Common
|
Development
|
Comprehensive
|
Stockholders’
|
|||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Stock
|
Stage
|
Income
(Loss)
|
Equity
|
||||||||||||||||||||||||
Balance,
August 1, 2000
|
1,000
|
$
|
1
|
16,326,333
|
$
|
16,327
|
-
|
$
|
-
|
$
|
30,435,066
|
$
|
(54,118
|
)
|
$
|
(21,816,725
|
)
|
$
|
(165,526
|
)
|
$
|
8,415,025
|
||||||||||||
Exercise of warrants for cash, August 2000, $6.00
|
-
|
-
|
2,000
|
2
|
-
|
-
|
11,998
|
-
|
-
|
-
|
12,000
|
|||||||||||||||||||||||
Issuance
of common stock for services rendered
|
||||||||||||||||||||||||||||||||||
August
2000
|
-
|
-
|
35,000
|
35
|
-
|
-
|
411,215
|
-
|
-
|
-
|
411,250
|
|||||||||||||||||||||||
Issuance
of warrants in exchange for equity line
|
||||||||||||||||||||||||||||||||||
agreement,
August 2000
|
-
|
-
|
-
|
-
|
-
|
-
|
3,406,196
|
-
|
-
|
-
|
3,406,196
|
|||||||||||||||||||||||
Exercise
of warrants for cash, August 2000, $7.50
|
-
|
-
|
30,300
|
30
|
-
|
-
|
227,220
|
-
|
-
|
-
|
227,250
|
|||||||||||||||||||||||
Exercise
of warrants for cash, August 2000, $8.6625
|
-
|
-
|
30,000
|
30
|
-
|
-
|
259,845
|
-
|
-
|
-
|
259,875
|
|||||||||||||||||||||||
Cashless
exercise of warrants, August 2000
|
-
|
-
|
8,600
|
9
|
-
|
-
|
(9
|
)
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||
Exercise
of warrants for cash, August 2000, $10.00
|
-
|
-
|
10,000
|
10
|
-
|
-
|
99,990
|
-
|
-
|
-
|
100,000
|
|||||||||||||||||||||||
Exercise of warrants for cash, September 2000, $8.6625
|
-
|
-
|
63,335
|
63
|
-
|
-
|
548,576
|
-
|
-
|
-
|
548,639
|
|||||||||||||||||||||||
Exercise
of warrants for cash, September 2000, $5.50
|
-
|
-
|
16,182
|
16
|
-
|
-
|
88,986
|
-
|
-
|
-
|
89,002
|
|||||||||||||||||||||||
Exercise
of warrants for cash, September 2000, $6.00
|
-
|
-
|
53,087
|
53
|
-
|
-
|
318,470
|
-
|
-
|
-
|
318,523
|
|||||||||||||||||||||||
Exercise
of warrants for cash, September 2000, $10.00
|
-
|
-
|
9,584
|
10
|
-
|
-
|
95,830
|
-
|
-
|
-
|
95,840
|
|||||||||||||||||||||||
Exercise
of warrants for cash, September 2000, $7.50
|
-
|
-
|
32,416
|
32
|
-
|
-
|
243,088
|
-
|
-
|
-
|
243,120
|
|||||||||||||||||||||||
Issuance
of common stock for cash pursuant to
|
||||||||||||||||||||||||||||||||||
private
placement, October 2000, $11.00
|
-
|
-
|
2,151,093
|
2,151
|
-
|
-
|
23,659,872
|
-
|
-
|
-
|
23,662,023
|
|||||||||||||||||||||||
Exercise
of warrants for cash, Oct. 2000, $6.00
|
-
|
-
|
1,000
|
1
|
-
|
-
|
5,999
|
-
|
-
|
-
|
6,000
|
|||||||||||||||||||||||
Financing
costs associated with private placement,
|
||||||||||||||||||||||||||||||||||
October
2000
|
-
|
-
|
-
|
-
|
-
|
-
|
(1,956,340
|
)
|
-
|
-
|
-
|
(1,956,340
|
)
|
|||||||||||||||||||||
Exercise
of warrants for cash, November - December
|
||||||||||||||||||||||||||||||||||
2000,
$4.25
|
-
|
-
|
23,528
|
23
|
-
|
-
|
99,971
|
-
|
-
|
-
|
99,994
|
|||||||||||||||||||||||
Cashless
exercise of warrants, December 2000
|
-
|
-
|
3,118
|
3
|
-
|
-
|
(3
|
)
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||
Exercise
of warrants for cash, November - December
|
||||||||||||||||||||||||||||||||||
2000,
$6.00
|
-
|
-
|
22,913
|
23
|
-
|
-
|
137,455
|
-
|
-
|
-
|
137,478
|
|||||||||||||||||||||||
Exercise
of warrants for cash, December 2000, $7.00
|
-
|
-
|
8,823
|
9
|
-
|
-
|
61,752
|
-
|
-
|
-
|
61,761
|
|||||||||||||||||||||||
Issuance
of common stock as employee
|
||||||||||||||||||||||||||||||||||
compensation,
December 2000
|
-
|
-
|
8,650
|
8
|
-
|
-
|
100,548
|
-
|
-
|
-
|
100,556
|
|||||||||||||||||||||||
Exercise
of warrants for cash, January 2001, $6.00
|
-
|
-
|
3,000
|
3
|
-
|
-
|
17,997
|
-
|
-
|
-
|
18,000
|
|||||||||||||||||||||||
Issuance
of common stock for cash pursuant to
|
||||||||||||||||||||||||||||||||||
private
placement, January 2001, $14.53
|
-
|
-
|
344,116
|
344
|
-
|
-
|
4,999,656
|
-
|
-
|
-
|
5,000,000
|
|||||||||||||||||||||||
Financing
costs associated with private placement,
|
||||||||||||||||||||||||||||||||||
January
2001
|
-
|
-
|
-
|
-
|
-
|
-
|
(200,000
|
)
|
-
|
-
|
-
|
(200,000
|
)
|
|||||||||||||||||||||
Issuance
of common stock pursuant to litigation
|
||||||||||||||||||||||||||||||||||
settlement,
January 2001
|
-
|
-
|
2,832
|
2
|
-
|
-
|
21,096
|
-
|
-
|
-
|
21,098
|
|||||||||||||||||||||||
Granting
of stock options in exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
January 2001
|
-
|
-
|
-
|
-
|
-
|
-
|
745,000
|
-
|
-
|
-
|
745,000
|
|||||||||||||||||||||||
Granting
of stock options in exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
February 2001
|
-
|
-
|
-
|
-
|
-
|
-
|
129,600
|
-
|
-
|
-
|
129,600
|
|||||||||||||||||||||||
Exercise
of stock options for cash,
|
||||||||||||||||||||||||||||||||||
February
2001, $5.00
|
-
|
-
|
50,000
|
50
|
-
|
-
|
249,950
|
-
|
-
|
-
|
250,000
|
|||||||||||||||||||||||
Exercise
of warrants for cash, March 2001, $6.00
|
-
|
-
|
500
|
1
|
-
|
-
|
2,999
|
-
|
-
|
-
|
3,000
|
|||||||||||||||||||||||
Exercise
of stock options in exchange for note
|
||||||||||||||||||||||||||||||||||
receivable,
March 2001
|
-
|
-
|
50,000
|
50
|
-
|
-
|
249,950
|
(250,000
|
)
|
-
|
-
|
-
|
||||||||||||||||||||||
Issuance
of common stock in exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
March 2001, $5.50
|
-
|
-
|
8,000
|
8
|
-
|
-
|
43,992
|
-
|
-
|
-
|
44,000
|
|||||||||||||||||||||||
Granting
of stock options in exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
May 2001
|
-
|
-
|
-
|
-
|
-
|
-
|
592,300
|
-
|
-
|
-
|
592,300
|
|||||||||||||||||||||||
Exercise of stock options for cash, June 2001, $5.00
|
-
|
-
|
75,000
|
75
|
-
|
-
|
374,925
|
-
|
-
|
-
|
375,000
|
|||||||||||||||||||||||
Exercise
of stock options for cash, June 2001, $5.50
|
-
|
-
|
12,500
|
12
|
-
|
-
|
68,738
|
-
|
-
|
-
|
68,750
|
|||||||||||||||||||||||
Exercise
of warrants for cash, June 2001, $6.00
|
-
|
-
|
4,000
|
4
|
-
|
-
|
23,996
|
-
|
-
|
-
|
24,000
|
|||||||||||||||||||||||
Exercise
of stock options for cash, July 2001, $5.00
|
-
|
-
|
7,500
|
8
|
-
|
-
|
37,492
|
-
|
-
|
-
|
37,500
|
|||||||||||||||||||||||
Exercise
of stock options for cash, July 2001, $5.50
|
-
|
-
|
2,500
|
3
|
-
|
-
|
13,747
|
-
|
-
|
-
|
13,750
|
|||||||||||||||||||||||
Exercise
of warrants for cash, July 2001, $6.00
|
-
|
-
|
2,000
|
2
|
-
|
-
|
11,998
|
-
|
-
|
-
|
12,000
|
|||||||||||||||||||||||
Issuance
of common stock for cash pursuant to
|
||||||||||||||||||||||||||||||||||
private
placement, July 2001, $9.25
|
-
|
-
|
1,254,053
|
1,254
|
-
|
-
|
11,598,736
|
-
|
-
|
-
|
11,599,990
|
|||||||||||||||||||||||
Financing
costs associated with private placement,
|
||||||||||||||||||||||||||||||||||
July
2001
|
-
|
-
|
-
|
-
|
-
|
-
|
(768,599
|
)
|
-
|
-
|
-
|
(768,599
|
)
|
|||||||||||||||||||||
Shares
issued in exchange for services rendered,
|
||||||||||||||||||||||||||||||||||
July
2001, $9.25
|
-
|
-
|
23,784
|
24
|
-
|
-
|
219,978
|
-
|
-
|
-
|
220,002
|
|||||||||||||||||||||||
Shares
issued for Anti-Dilution Provisions, July 2001
|
-
|
-
|
5,779
|
6
|
-
|
-
|
53,450
|
-
|
-
|
-
|
53,456
|
|||||||||||||||||||||||
Issuance
of warrants in exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
July 2001
|
-
|
-
|
-
|
-
|
-
|
-
|
19,134
|
-
|
-
|
-
|
19,134
|
|||||||||||||||||||||||
Accrued
interest on note receivable
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(10,182
|
)
|
-
|
-
|
(10,182
|
)
|
|||||||||||||||||||||
Comprehensive
Income (Loss):
|
||||||||||||||||||||||||||||||||||
Net
Loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(27,097,210
|
)
|
-
|
(27,097,210
|
)
|
|||||||||||||||||||||
Other
comprehensive income (loss):
|
||||||||||||||||||||||||||||||||||
Currency
translation adjustment
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(81,341
|
)
|
(81,341
|
)
|
|||||||||||||||||||||
Total
Comprehensive Income (Loss)
|
(27,097,210
|
)
|
(81,341
|
)
|
(27,178,551
|
)
|
||||||||||||||||||||||||||||
Balance
at July 31, 2001
|
1,000
|
$
|
1
|
20,681,526
|
$
|
20,681
|
-
|
$
|
-
|
$
|
76,761,860
|
$
|
(314,300
|
)
|
$
|
(48,913,935
|
)
|
$
|
(246,867
|
)
|
$
|
27,307,440
|
Deficit
|
||||||||||||||||||||||||||||||||||
SVR
|
Notes
|
Accumulated
|
Accumulated
|
|||||||||||||||||||||||||||||||
Preferred
|
Common
|
Treasury
|
Additional
|
Receivable
-
|
During
the
|
Other
|
Total
|
|||||||||||||||||||||||||||
Stock
|
Stock
|
Stock
|
Paid-In
|
Common
|
Development
|
Comprehensive
|
Stockholders’
|
|||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Stock
|
Stage
|
Income
(Loss)
|
Equity
|
||||||||||||||||||||||||
Balance,
August 1, 2001
|
1,000
|
$
|
1
|
20,681,526
|
$
|
20,681
|
-
|
$
|
-
|
$
|
76,761,860
|
$
|
(314,300
|
)
|
$
|
(48,913,935
|
)
|
$
|
(246,867
|
)
|
$
|
27,307,440
|
||||||||||||
Exercise of stock options for cash,
|
||||||||||||||||||||||||||||||||||
August
2001, $5.50
|
-
|
-
|
5,000
|
5
|
-
|
-
|
27,495
|
-
|
-
|
-
|
27,500
|
|||||||||||||||||||||||
Purchase
of Treasury Stock for cash
|
||||||||||||||||||||||||||||||||||
October
2001, $3.915
|
-
|
-
|
-
|
-
|
(10,000
|
)
|
(39,150
|
)
|
-
|
-
|
-
|
-
|
(39,150
|
)
|
||||||||||||||||||||
Issuance
of stock options in exchange for
|
||||||||||||||||||||||||||||||||||
services
rendered, December 2001
|
-
|
-
|
-
|
-
|
-
|
-
|
25,000
|
-
|
-
|
-
|
25,000
|
|||||||||||||||||||||||
Issuance
of common stock as employee
|
||||||||||||||||||||||||||||||||||
compensation,
January 2002
|
-
|
-
|
10,800
|
11
|
-
|
-
|
71,161
|
-
|
-
|
-
|
71,172
|
|||||||||||||||||||||||
Preferred
stock dividend paid January 2002
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(720,900
|
)
|
-
|
(720,900
|
)
|
|||||||||||||||||||||
Purchase
of Treasury Stock for cash
|
||||||||||||||||||||||||||||||||||
February
2002, $4.693
|
-
|
-
|
-
|
-
|
(31,400
|
)
|
(147,346
|
)
|
-
|
-
|
-
|
-
|
(147,346
|
)
|
||||||||||||||||||||
Issuance of warrants in exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
March 2002
|
-
|
-
|
-
|
-
|
-
|
-
|
202,328
|
-
|
-
|
-
|
202,328
|
|||||||||||||||||||||||
Purchase
of Treasury Stock for cash
|
||||||||||||||||||||||||||||||||||
March
2002, $4.911
|
-
|
-
|
-
|
-
|
(7,700
|
)
|
(37,816
|
)
|
-
|
-
|
-
|
-
|
(37,816
|
)
|
||||||||||||||||||||
Purchase
of Treasury Stock for cash
|
||||||||||||||||||||||||||||||||||
April
2002, $4.025
|
-
|
-
|
-
|
-
|
(12,800
|
)
|
(54,516
|
)
|
-
|
-
|
-
|
-
|
(54,516
|
)
|
||||||||||||||||||||
Issuance
of stock options in exchange for
|
||||||||||||||||||||||||||||||||||
services
rendered, June 2002
|
-
|
-
|
-
|
-
|
-
|
-
|
132,387
|
-
|
-
|
-
|
132,387
|
|||||||||||||||||||||||
Purchase
of Treasury Stock for cash
|
-
|
|||||||||||||||||||||||||||||||||
July
2002, $4.025
|
-
|
-
|
-
|
-
|
(34,600
|
)
|
(116,703
|
)
|
-
|
-
|
-
|
-
|
(116,703
|
)
|
||||||||||||||||||||
Accrued
interest on note receivable
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(22,585
|
)
|
-
|
-
|
(22,585
|
)
|
|||||||||||||||||||||
Comprehensive
Income (Loss):
|
||||||||||||||||||||||||||||||||||
Net
Loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(13,693,034
|
)
|
-
|
(13,693,034
|
)
|
|||||||||||||||||||||
Other
comprehensive income (loss):
|
||||||||||||||||||||||||||||||||||
Currency
translation adjustment
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(71,185
|
)
|
(71,185
|
)
|
|||||||||||||||||||||
Total
Comprehensive Income (Loss)
|
(13,693,034
|
)
|
(71,185
|
)
|
(13,764,219
|
)
|
||||||||||||||||||||||||||||
Balance
at July 31, 2002
|
1,000
|
$
|
1
|
20,697,326
|
$
|
20,697
|
(96,500
|
)
|
$
|
(395,531
|
)
|
$
|
77,220,231
|
$
|
(336,885
|
)
|
$
|
(63,327,869
|
)
|
$
|
(318,052
|
)
|
$
|
12,862,592
|
Deficit
|
||||||||||||||||||||||||||||||||||
SVR
|
Notes
|
Accumulated
|
Accumulated
|
|||||||||||||||||||||||||||||||
Preferred
|
Common
|
Treasury
|
Additional
|
Receivable -
|
During the
|
Other
|
Total
|
|||||||||||||||||||||||||||
Stock
|
Stock
|
Stock
|
Paid-In
|
Common
|
Development
|
Comprehensive
|
Stockholders’
|
|||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Stock
|
Stage
|
Income (Loss)
|
Equity
|
||||||||||||||||||||||||
Balance,
August 1, 2002
|
1,000
|
$
|
1
|
20,697,326
|
$
|
20,697
|
(96,500
|
)
|
$
|
(395,531
|
)
|
$
|
77,220,231
|
$
|
(336,885
|
)
|
$
|
(63,327,869
|
)
|
$
|
(318,052
|
)
|
$
|
12,862,592
|
||||||||||
Receipt of restricted shares of common stock as
|
||||||||||||||||||||||||||||||||||
settlement for executive loan, September 2002, $1.90
|
-
|
-
|
-
|
-
|
(592,716
|
)
|
(1,126,157
|
)
|
-
|
-
|
-
|
-
|
(1,126,157
|
)
|
||||||||||||||||||||
Purchase
of Treasury Stock for cash
|
||||||||||||||||||||||||||||||||||
October
2002, $1.5574
|
-
|
-
|
-
|
-
|
(40,000
|
)
|
(62,294
|
)
|
-
|
-
|
-
|
-
|
(62,294
|
)
|
||||||||||||||||||||
Issuance
of warrants in exchange for the services
|
||||||||||||||||||||||||||||||||||
rendered,
November 2002, $2.50
|
-
|
-
|
-
|
-
|
-
|
-
|
988,550
|
-
|
-
|
-
|
988,550
|
|||||||||||||||||||||||
Issuance of stock options in exchange for services
|
||||||||||||||||||||||||||||||||||
receivable,
November 2002, $2.10
|
-
|
-
|
-
|
-
|
-
|
-
|
171,360
|
-
|
-
|
-
|
171,360
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
November 2002, $2.10
|
-
|
-
|
30,000
|
30
|
-
|
-
|
62,970
|
-
|
-
|
-
|
63,000
|
|||||||||||||||||||||||
Issuance
of common stock as employee
|
||||||||||||||||||||||||||||||||||
compensation, January
2003, $2.10
|
-
|
-
|
9,750
|
10
|
-
|
-
|
20,465
|
-
|
-
|
-
|
20,475
|
|||||||||||||||||||||||
Purchase
of Treasury Stock for cash
|
||||||||||||||||||||||||||||||||||
December
2002, $2.0034
|
-
|
-
|
-
|
-
|
(13,000
|
)
|
(26,044
|
)
|
-
|
-
|
-
|
-
|
(26,044
|
)
|
||||||||||||||||||||
Preferred
stock dividend paid January 2003
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(764,154
|
)
|
-
|
(764,154
|
)
|
|||||||||||||||||||||
Issuance of common stock in exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
March 2003, $1.00
|
-
|
-
|
70,000
|
70
|
-
|
-
|
69,930
|
-
|
-
|
-
|
70,000
|
|||||||||||||||||||||||
Issuance
of common stock for cash pursuant to
|
||||||||||||||||||||||||||||||||||
private
placement, May 2003, $1.15
|
-
|
-
|
2,926,301
|
2,926
|
-
|
-
|
3,362,324
|
-
|
-
|
-
|
3,365,250
|
|||||||||||||||||||||||
Financing
costs associated with private placement,
|
||||||||||||||||||||||||||||||||||
May
2003
|
-
|
-
|
-
|
-
|
-
|
-
|
(235,568
|
)
|
-
|
-
|
-
|
(235,568
|
)
|
|||||||||||||||||||||
Exercise
of warrants for cash, May 2003, $1.50
|
-
|
-
|
35,000
|
35
|
-
|
-
|
52,465
|
-
|
-
|
-
|
52,500
|
|||||||||||||||||||||||
Issuance
of common stock for cash pursuant to
|
||||||||||||||||||||||||||||||||||
private
placement, June 2003, $1.50
|
-
|
-
|
666,667
|
667
|
-
|
-
|
999,333
|
-
|
-
|
-
|
1,000,000
|
|||||||||||||||||||||||
Issuance
of common stock as employee
|
||||||||||||||||||||||||||||||||||
compensation, June
2003, $2.00
|
-
|
-
|
100
|
-
|
-
|
-
|
200
|
-
|
-
|
-
|
200
|
|||||||||||||||||||||||
Exercise
of warrants for cash, June 2003, $1.50
|
-
|
-
|
1,496,001
|
1,496
|
-
|
-
|
2,242,506
|
-
|
-
|
-
|
2,244,002
|
|||||||||||||||||||||||
Cashless
exercise of warrants, June 2003
|
-
|
-
|
16,379
|
16
|
-
|
-
|
(16
|
)
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||
Exercise
of stock options for cash, June 2003, $1.59
|
-
|
-
|
70,000
|
70
|
-
|
-
|
111,230
|
-
|
-
|
-
|
111,300
|
|||||||||||||||||||||||
Accrued
interest on note receivable
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(23,113
|
)
|
-
|
-
|
(23,113
|
)
|
|||||||||||||||||||||
Comprehensive
Income (Loss):
|
||||||||||||||||||||||||||||||||||
Net
Loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(13,261,764
|
)
|
-
|
(13,261,764
|
)
|
|||||||||||||||||||||
Other
comprehensive income (loss)
|
||||||||||||||||||||||||||||||||||
Currency
translation adjustment
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
406,830
|
406,830
|
|||||||||||||||||||||||
Total
Comprehensive Income (Loss)
|
(13,261,764
|
)
|
406,830
|
(12,854,934
|
)
|
|||||||||||||||||||||||||||||
Balance
at July 31, 2003
|
1,000
|
$
|
1
|
26,017,524
|
$
|
26,017
|
(742,216
|
)
|
$
|
(1,610,026
|
)
|
$
|
85,065,980
|
$
|
(359,998
|
)
|
$
|
(77,353,787
|
)
|
$
|
88,778
|
$
|
5,856,965
|
Deficit
|
||||||||||||||||||||||||||||||||||
SVR
|
Notes
|
Accumulated
|
Accumulated
|
|||||||||||||||||||||||||||||||
Preferred
|
Common
|
Treasury
|
Additional
|
Receivable
-
|
During
the
|
Other
|
Total
|
|||||||||||||||||||||||||||
Stock
|
Stock
|
Stock
|
Paid-In
|
Common
|
Development
|
Comprehensive
|
Stockholders’
|
|||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Stock
|
Stage
|
Income
(Loss)
|
Equity
|
||||||||||||||||||||||||
Balance,
August 1, 2003
|
1,000
|
$
|
1
|
26,017,524
|
$
|
26,017
|
(742,216
|
)
|
$
|
(1,610,026
|
)
|
$
|
85,065,980
|
$
|
(359,998
|
)
|
$
|
(77,353,787
|
)
|
$
|
88,778
|
$
|
5,856,965
|
|||||||||||
Shares
issued pursuant to acquisition of Antigen
|
||||||||||||||||||||||||||||||||||
Express
Inc., August 2003
|
-
|
-
|
2,779,974
|
2,780
|
-
|
-
|
4,639,777
|
-
|
-
|
-
|
4,642,557
|
|||||||||||||||||||||||
Cost
of stock options to be assumed in conjunction
|
||||||||||||||||||||||||||||||||||
with
merger
|
-
|
-
|
-
|
-
|
-
|
-
|
154,852
|
-
|
-
|
-
|
154,852
|
|||||||||||||||||||||||
Exercise
of stock options for cash, September 2003,
|
||||||||||||||||||||||||||||||||||
$1.59
|
-
|
-
|
10,000
|
10
|
-
|
-
|
15,890
|
-
|
-
|
-
|
15,900
|
|||||||||||||||||||||||
Exercise of stock options for cash, October 2003, $2.10
|
-
|
-
|
14,900
|
15
|
-
|
-
|
31,275
|
-
|
-
|
-
|
31,290
|
|||||||||||||||||||||||
Exercise
of stock options for cash, October 2003, $1.59
|
-
|
-
|
10,000
|
10
|
-
|
-
|
15,890
|
-
|
-
|
-
|
15,900
|
|||||||||||||||||||||||
Exercise
of stock options for cash, October 2003, $0.30
|
-
|
-
|
65,000
|
65
|
-
|
-
|
19,435
|
-
|
-
|
-
|
19,500
|
|||||||||||||||||||||||
Exercise
of stock options for cash, October 2003, $0.55
|
-
|
-
|
40,000
|
40
|
-
|
-
|
21,960
|
-
|
-
|
-
|
22,000
|
|||||||||||||||||||||||
Issuance
of common stock In exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
October 2003, $1.98
|
-
|
-
|
150,000
|
150
|
-
|
-
|
296,850
|
-
|
-
|
-
|
297,000
|
|||||||||||||||||||||||
Issuance
of common stock In exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
October 2003, $1.84
|
-
|
-
|
337,500
|
338
|
-
|
-
|
620,662
|
-
|
-
|
-
|
621,000
|
|||||||||||||||||||||||
Issuance
of warrants in exchange for the services
|
||||||||||||||||||||||||||||||||||
rendered
October 2003 (at $1.35)
|
-
|
-
|
-
|
-
|
-
|
-
|
27,000
|
-
|
-
|
-
|
27,000
|
|||||||||||||||||||||||
Exercise
of stock options for cash, November 2003,
|
||||||||||||||||||||||||||||||||||
$2.10
|
-
|
-
|
10,500
|
10
|
-
|
-
|
22,040
|
-
|
-
|
-
|
22,050
|
|||||||||||||||||||||||
Redemption of Treasury Stock, November 2003, $2.17
|
-
|
-
|
(742,216
|
)
|
(742
|
)
|
742,216
|
1,610,026
|
(1,609,284
|
)
|
-
|
-
|
-
|
-
|
||||||||||||||||||||
Granting
of stock options in exchange for services,
|
||||||||||||||||||||||||||||||||||
November
2003 (at $1.71)
|
-
|
-
|
-
|
-
|
-
|
-
|
151,433
|
-
|
-
|
-
|
151,433
|
|||||||||||||||||||||||
Issuance
of common stock for cash pursuant to
|
||||||||||||||||||||||||||||||||||
private
placement, Jan 2004, $1.47
|
-
|
-
|
1,700,680
|
1,701
|
-
|
-
|
2,498,299
|
-
|
-
|
-
|
2,500,000
|
|||||||||||||||||||||||
Issuance
of common stock for cash pursuant to
|
||||||||||||||||||||||||||||||||||
private
placement, Jan 2004, $1.80
|
-
|
-
|
55,556
|
56
|
-
|
-
|
99,944
|
-
|
-
|
-
|
100,000
|
|||||||||||||||||||||||
Issuance
of common stock for cash pursuant to
|
||||||||||||||||||||||||||||||||||
private
placement, Jan 2004, $1.75
|
-
|
-
|
228,572
|
229
|
-
|
-
|
399,771
|
-
|
-
|
-
|
400,000
|
|||||||||||||||||||||||
Financing
costs associated with private placement,
|
||||||||||||||||||||||||||||||||||
January
2004
|
-
|
-
|
-
|
-
|
-
|
-
|
(68,012
|
)
|
-
|
-
|
-
|
(68,012
|
)
|
|||||||||||||||||||||
Preferred
Stock Dividend paid in January
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(810,003
|
)
|
-
|
(810,003
|
)
|
|||||||||||||||||||||
Issuance
of common stock for cash pursuant to
|
||||||||||||||||||||||||||||||||||
private
placement, Feb 2004, $1.60
|
-
|
-
|
93,750
|
94
|
-
|
-
|
149,906
|
-
|
-
|
-
|
150,000
|
|||||||||||||||||||||||
Issuance
of common stock for cash pursuant to
|
||||||||||||||||||||||||||||||||||
private
placement, Feb 2004, $1.66
|
-
|
-
|
68,675
|
69
|
-
|
-
|
113,932
|
-
|
-
|
-
|
114,001
|
|||||||||||||||||||||||
Issuance
of common stock for cash pursuant to
|
||||||||||||||||||||||||||||||||||
private
placement, Feb 2004, $1.50
|
-
|
-
|
666,667
|
667
|
-
|
-
|
999,334
|
-
|
-
|
-
|
1,000,001
|
|||||||||||||||||||||||
Issuance
of common stock as employee
|
||||||||||||||||||||||||||||||||||
compensation,
Feb 2004, $1.48
|
-
|
-
|
8,850
|
8
|
-
|
-
|
13,089
|
-
|
-
|
-
|
13,097
|
|||||||||||||||||||||||
Issuance of common stock In exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
Feb 2004, $1.48
|
-
|
-
|
175,000
|
175
|
-
|
-
|
258,825
|
-
|
-
|
-
|
259,000
|
|||||||||||||||||||||||
Issuance
of common stock In exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
Feb 2004, $1.51
|
-
|
-
|
112,500
|
113
|
-
|
-
|
169,762
|
-
|
-
|
-
|
169,875
|
|||||||||||||||||||||||
Issuance
of common stock for cash pursuant to
|
||||||||||||||||||||||||||||||||||
private
placement, July 2004, $1.22
|
-
|
-
|
2,459,016
|
2,459
|
-
|
-
|
2,997,541
|
-
|
-
|
-
|
3,000,000
|
|||||||||||||||||||||||
Financing
costs associated with private placement,
|
||||||||||||||||||||||||||||||||||
July
2004
|
-
|
-
|
-
|
-
|
-
|
-
|
(41,250
|
)
|
-
|
-
|
-
|
(41,250
|
)
|
|||||||||||||||||||||
Variable accounting non-cash compensation expense
|
-
|
-
|
-
|
-
|
-
|
-
|
45,390
|
-
|
-
|
-
|
45,390
|
|||||||||||||||||||||||
Accrued
interest on note receivable
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(24,805
|
)
|
-
|
-
|
(24,805
|
)
|
|||||||||||||||||||||
Comprehensive
Income (Loss):
|
||||||||||||||||||||||||||||||||||
Net
Loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(18,362,583
|
)
|
-
|
(18,362,583
|
)
|
|||||||||||||||||||||
Other
comprehensive income (loss)
|
||||||||||||||||||||||||||||||||||
Currency
translation adjustment
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
207,593
|
207,593
|
|||||||||||||||||||||||
Total
Comprehensive Income (Loss)
|
(18,362,583
|
)
|
207,593
|
(18,154,990
|
)
|
|||||||||||||||||||||||||||||
Balance
at July 31, 2004
|
1,000
|
$
|
1
|
34,262,448
|
$
|
34,264
|
-
|
$
|
-
|
$
|
97,110,291
|
$
|
(384,803
|
)
|
$
|
(96,526,373
|
)
|
$
|
296,371
|
$
|
529,751
|
Deficit
|
||||||||||||||||||||||||||||||||||
SVR
|
Notes
|
Accumulated
|
Accumulated
|
|||||||||||||||||||||||||||||||
Preferred
|
Common
|
Treasury
|
Additional
|
Receivable
-
|
During
the
|
Other
|
Total
|
|||||||||||||||||||||||||||
Stock
|
Stock
|
Stock
|
Paid-In
|
Common
|
Development
|
Comprehensive
|
Stockholders’
|
|||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Stock
|
Stage
|
Income
(Loss)
|
Equity
|
||||||||||||||||||||||||
Balance,
August 1, 2004
|
1,000
|
$
|
1
|
34,262,448
|
$
|
34,264
|
-
|
$
|
-
|
$
|
97,110,291
|
$
|
(384,803
|
)
|
$
|
(96,526,373
|
)
|
$
|
296,371
|
$
|
529,751
|
|||||||||||||
Issuance of common stock In exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
Aug 2004, $1.09
|
-
|
-
|
620,000
|
620
|
-
|
-
|
675,180
|
-
|
-
|
-
|
675,800
|
|||||||||||||||||||||||
Issuance
of warrants in exchange for services
|
||||||||||||||||||||||||||||||||||
rendered
Aug 2004, $1.08
|
-
|
-
|
-
|
-
|
-
|
-
|
415,000
|
-
|
-
|
-
|
415,000
|
|||||||||||||||||||||||
Granting
of stock options in exchange for services,
|
||||||||||||||||||||||||||||||||||
Oct
2004, $0.94
|
-
|
-
|
-
|
-
|
-
|
-
|
75,600
|
-
|
-
|
-
|
75,600
|
|||||||||||||||||||||||
Cancellation
of common stock for non-performance of
|
||||||||||||||||||||||||||||||||||
services,
Oct 2004, $0.94
|
-
|
-
|
(75,000
|
)
|
(75
|
)
|
-
|
-
|
(137,925
|
)
|
-
|
-
|
-
|
(138,000
|
)
|
|||||||||||||||||||
Issuance
of warrants in conjunction with financing,
|
||||||||||||||||||||||||||||||||||
Nov
2004, $0.91
|
-
|
-
|
-
|
-
|
-
|
-
|
89,900
|
-
|
-
|
-
|
89,900
|
|||||||||||||||||||||||
Issuance
of warrants in conjunction with convertible
|
||||||||||||||||||||||||||||||||||
debentures,
$4,000,000, Nov 2004 $0.91
|
-
|
-
|
-
|
-
|
-
|
-
|
1,722,222
|
-
|
-
|
-
|
1,722,222
|
|||||||||||||||||||||||
Value
of beneficial conversion feature on convertible
|
||||||||||||||||||||||||||||||||||
debentures,
$4,000,000, Nov 2004 $0.91
|
-
|
-
|
-
|
-
|
-
|
-
|
1,722,222
|
-
|
-
|
-
|
1,722,222
|
|||||||||||||||||||||||
Issuance
of common stock In exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
Dec 2004, $0.71
|
-
|
-
|
48,000
|
48
|
-
|
-
|
34,032
|
-
|
-
|
-
|
34,080
|
|||||||||||||||||||||||
Conversion
of Series A Preferred Stock, Dec 2004
|
||||||||||||||||||||||||||||||||||
$25.77
|
-
|
-
|
534,085
|
534
|
-
|
-
|
14,309,523
|
-
|
-
|
-
|
14,310,057
|
|||||||||||||||||||||||
Issuance
of common stock In exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
Jan 2005, $0.85
|
-
|
-
|
18,000
|
18
|
-
|
-
|
15,282
|
-
|
-
|
-
|
15,300
|
|||||||||||||||||||||||
Issuance
of common stock In exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
Jan 2005, $0.75
|
-
|
-
|
40,000
|
40
|
-
|
-
|
29,960
|
-
|
-
|
-
|
30,000
|
|||||||||||||||||||||||
Issuance
of common stock In exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
Feb 2005, $0.69
|
-
|
-
|
18,000
|
18
|
-
|
-
|
12,402
|
-
|
-
|
-
|
12,420
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of principal
|
||||||||||||||||||||||||||||||||||
and
interest due, $4,000,000, Feb 2005
|
-
|
-
|
250,910
|
251
|
-
|
-
|
181,262
|
-
|
-
|
-
|
181,513
|
|||||||||||||||||||||||
Issuance
of common stock In exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
Feb 2005, $0.68
|
-
|
-
|
50,000
|
50
|
-
|
-
|
33,950
|
-
|
-
|
-
|
34,000
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of principal
|
||||||||||||||||||||||||||||||||||
and
interest due, $4,000,000, Mar 2005
|
-
|
-
|
265,228
|
265
|
-
|
-
|
162,197
|
-
|
-
|
-
|
162,462
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of principal
|
||||||||||||||||||||||||||||||||||
and
interest due, $4,000,000, Apr 2005
|
-
|
-
|
314,732
|
315
|
-
|
-
|
162,275
|
-
|
-
|
-
|
162,590
|
|||||||||||||||||||||||
Issuance of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$143,500
of $4,000,000 debenture, Apr 2005
|
-
|
-
|
175,316
|
175
|
-
|
-
|
143,584
|
-
|
-
|
-
|
143,759
|
|||||||||||||||||||||||
Issuance
of common stock as employee
|
||||||||||||||||||||||||||||||||||
compensation,
Apr 2005, $0.56
|
-
|
-
|
8,800
|
9
|
-
|
-
|
4,919
|
-
|
-
|
-
|
4,928
|
|||||||||||||||||||||||
Issuance
of warrants in conjunction with convertible
|
||||||||||||||||||||||||||||||||||
debentures,
$500,000, Apr 2005, $0.82
|
-
|
-
|
-
|
-
|
-
|
-
|
245,521
|
-
|
-
|
-
|
245,521
|
|||||||||||||||||||||||
Value
of beneficial conversion feature on convertible
|
||||||||||||||||||||||||||||||||||
debentures,
$500,000, Apr 2005, $0.82
|
-
|
-
|
-
|
-
|
-
|
-
|
86,984
|
-
|
-
|
-
|
86,984
|
|||||||||||||||||||||||
Issuance
of warrants in conjunction with convertible
|
||||||||||||||||||||||||||||||||||
debentures,
$100,000, Apr 2005, $0.82
|
-
|
-
|
-
|
-
|
-
|
-
|
49,104
|
-
|
-
|
-
|
49,104
|
|||||||||||||||||||||||
Value
of beneficial conversion feature on convertible
|
||||||||||||||||||||||||||||||||||
debentures,
$100,000, Apr 2005, $0.82
|
-
|
-
|
-
|
-
|
-
|
-
|
17,397
|
-
|
-
|
-
|
17,397
|
|||||||||||||||||||||||
Issuance
of warrants in exchange for services
|
||||||||||||||||||||||||||||||||||
rendered
Apr 2005, $0.82
|
-
|
-
|
-
|
-
|
-
|
-
|
40,000
|
-
|
-
|
-
|
40,000
|
|||||||||||||||||||||||
Issuance
of common stock In exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
Apr 2005, $0.82
|
-
|
-
|
350,000
|
350
|
-
|
-
|
286,650
|
-
|
-
|
-
|
287,000
|
|||||||||||||||||||||||
Issuance
of common stock in satisfaction of
|
||||||||||||||||||||||||||||||||||
accounts
payable, Apr 2005, $0.82
|
-
|
-
|
950,927
|
951
|
-
|
-
|
778,809
|
-
|
-
|
-
|
779,760
|
|||||||||||||||||||||||
Granting
of stock options in exchange for outstanding
|
||||||||||||||||||||||||||||||||||
liabilities,
Apr 2005, $0.001
|
-
|
-
|
-
|
-
|
-
|
-
|
1,332,052
|
-
|
-
|
-
|
1,332,052
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of principal
|
||||||||||||||||||||||||||||||||||
and
interest due, $4,000,000, May 2005
|
-
|
-
|
482,071
|
482
|
-
|
-
|
321,877
|
-
|
-
|
-
|
322,359
|
|||||||||||||||||||||||
Issuance of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$300,000
of $4,000,000 debenture, May 2005
|
-
|
-
|
365,914
|
366
|
-
|
-
|
299,683
|
-
|
-
|
-
|
300,049
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$244,000
of $4,000,000 debenture, May 2005
|
-
|
-
|
297,659
|
298
|
-
|
-
|
243,783
|
-
|
-
|
-
|
244,081
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$410,000
of $4,000,000 debenture, May 2005
|
-
|
-
|
500,000
|
500
|
-
|
-
|
409,500
|
-
|
-
|
-
|
410,000
|
|||||||||||||||||||||||
Issuance
of warrants in conjunction with 1st extension of due
|
||||||||||||||||||||||||||||||||||
date of $600,000 convertible debentures, May 2005, $0.82
|
-
|
-
|
-
|
-
|
-
|
-
|
717,073
|
-
|
-
|
-
|
717,073
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of principal
|
||||||||||||||||||||||||||||||||||
and
interest due, $4,000,000, June 2005
|
-
|
-
|
311,307
|
311
|
-
|
-
|
244,644
|
-
|
-
|
-
|
244,955
|
|||||||||||||||||||||||
Issuance
of common stock in conjunction with financing,
|
||||||||||||||||||||||||||||||||||
$2,000,000,
June 2005, $0.82
|
-
|
-
|
170,732
|
171
|
-
|
-
|
139,829
|
-
|
-
|
-
|
140,000
|
|||||||||||||||||||||||
Issuance
of warrants in conjunction with financing, $2,000,000,
|
||||||||||||||||||||||||||||||||||
June
2005, $0.82
|
-
|
-
|
-
|
-
|
-
|
-
|
20,300
|
-
|
-
|
-
|
20,300
|
|||||||||||||||||||||||
Issuance of warrants in conjunction with convertible debentures,
|
||||||||||||||||||||||||||||||||||
$2,000,000,
June 2005, $0.82
|
-
|
-
|
-
|
-
|
-
|
-
|
828,571
|
-
|
-
|
-
|
828,571
|
|||||||||||||||||||||||
Value
of beneficial conversion feature on convertible
|
||||||||||||||||||||||||||||||||||
debentures,
$2,000,000, June 2005, $0.82
|
-
|
-
|
-
|
-
|
-
|
-
|
1,171,429
|
-
|
-
|
-
|
1,171,429
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$100,000
of $2,000,000 debenture, June 2005
|
-
|
-
|
166,667
|
167
|
-
|
-
|
99,833
|
-
|
-
|
-
|
100,000
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$190,000
of $2,000,000 debenture, June 2005
|
-
|
-
|
316,927
|
317
|
-
|
-
|
189,839
|
-
|
-
|
-
|
190,156
|
|||||||||||||||||||||||
Issuance
of common stock In exchange for services
|
||||||||||||||||||||||||||||||||||
rendered,
June 2005, $0.60
|
-
|
-
|
63,207
|
63
|
-
|
-
|
37,861
|
-
|
-
|
-
|
37,924
|
|||||||||||||||||||||||
Issuance
of common stock in satisfaction of
|
||||||||||||||||||||||||||||||||||
accounts
payable, June 2005, $0.82
|
-
|
-
|
90,319
|
90
|
-
|
-
|
73,971
|
-
|
-
|
-
|
74,061
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$17,000
of $2,000,000 debenture, July 2005
|
-
|
-
|
28,398
|
28
|
-
|
-
|
17,011
|
-
|
-
|
-
|
17,039
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$75,000
of $2,000,000 debenture, July 2005
|
-
|
-
|
125,000
|
125
|
-
|
-
|
75,035
|
-
|
-
|
-
|
75,160
|
|||||||||||||||||||||||
Issuance of warrants in conjunction with 2nd extension of due
|
||||||||||||||||||||||||||||||||||
date of $600,000 convertible debentures, July 2005, $0.82
|
-
|
-
|
-
|
-
|
-
|
-
|
629,268
|
-
|
-
|
-
|
629,268
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of principal
|
||||||||||||||||||||||||||||||||||
and
interest due, $4,000,000, July 2005
|
-
|
-
|
364,123
|
364
|
-
|
-
|
237,586
|
-
|
-
|
-
|
237,950
|
|||||||||||||||||||||||
Issuance
of common stock in satisfaction of
|
||||||||||||||||||||||||||||||||||
accounts
payable, July 2005, $0.82
|
-
|
-
|
820,128
|
820
|
-
|
-
|
671,685
|
-
|
-
|
-
|
672,505
|
|||||||||||||||||||||||
Granting
of stock options in exchange for services,
|
||||||||||||||||||||||||||||||||||
July
2004, $0.63
|
-
|
-
|
-
|
-
|
-
|
-
|
17,155
|
-
|
-
|
-
|
17,155
|
|||||||||||||||||||||||
Accrued
interest on note receivable
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(6,300
|
)
|
-
|
-
|
(6,300
|
)
|
|||||||||||||||||||||
Write-off
of uncollectible notes receivable - common
|
||||||||||||||||||||||||||||||||||
stock
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
391,103
|
-
|
-
|
391,103
|
|||||||||||||||||||||||
Variable
accounting non-cash compensation expense
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||||||||||
Comprehensive
Income (Loss):
|
||||||||||||||||||||||||||||||||||
Net
Loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(24,001,735
|
)
|
-
|
(24,001,735
|
)
|
|||||||||||||||||||||
Other
comprehensive income (loss)
|
||||||||||||||||||||||||||||||||||
Currency
translation adjustment
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
272,478
|
272,478
|
|||||||||||||||||||||||
Total
Comprehensive Income (Loss)
|
(24,001,735
|
)
|
272,478
|
(23,729,257
|
)
|
|||||||||||||||||||||||||||||
Balance
at July 31, 2005
|
1,000
|
$
|
1
|
41,933,898
|
$
|
41,935
|
-
|
$
|
-
|
$
|
126,044,326
|
$
|
-
|
$
|
(120,528,108
|
)
|
$
|
568,849
|
$
|
6,127,003
|
Deficit
|
||||||||||||||||||||||||||||||||||
SVR
|
Notes
|
Accumulated
|
Accumulated
|
|||||||||||||||||||||||||||||||
Preferred
|
Common
|
Treasury
|
Additional
|
Receivable
-
|
During
the
|
Other
|
Total
|
|||||||||||||||||||||||||||
Stock
|
Stock
|
Stock
|
Paid-In
|
Common
|
Development
|
Comprehensive
|
Stockholders’
|
|||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Stock
|
Stage
|
Income
(Loss)
|
Equity
|
||||||||||||||||||||||||
Balance,
August 1, 2005
|
1,000
|
$
|
1
|
41,933,898
|
$
|
41,935
|
-
|
$
|
-
|
$
|
126,044,326
|
$
|
-
|
$
|
(120,528,108
|
)
|
$
|
568,849
|
$
|
6,127,003
|
||||||||||||||
Issuance of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization payments due, $4,000,000, August 2005
|
-
|
-
|
429,041
|
429
|
-
|
-
|
282,738
|
-
|
-
|
-
|
283,167
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services
|
||||||||||||||||||||||||||||||||||
rendered
August 2005 (at $0.61)
|
-
|
-
|
19,500
|
19
|
-
|
-
|
11,877
|
-
|
-
|
-
|
11,896
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services
|
||||||||||||||||||||||||||||||||||
rendered
August 2005 (at $0.59)
|
-
|
-
|
246,429
|
246
|
-
|
-
|
145,147
|
-
|
-
|
-
|
145,393
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization payments due, $4,000,000, September 2005
|
-
|
-
|
388,730
|
389
|
-
|
-
|
267,835
|
-
|
-
|
-
|
268,224
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, $2,000,000, September 2005
|
-
|
-
|
322,373
|
322
|
-
|
-
|
222,115
|
-
|
-
|
-
|
222,437
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$504,538
of $2,000,000 debenture, September 2005
|
-
|
-
|
841,309
|
841
|
-
|
-
|
503,945
|
-
|
-
|
-
|
504,786
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$286,538
of $2,000,000 debenture, September 2005
|
-
|
-
|
477,962
|
478
|
-
|
-
|
286,299
|
-
|
-
|
-
|
286,777
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$457,200
of 2nd $2,000,000 debenture, September 2005
|
-
|
-
|
762,000
|
762
|
-
|
-
|
456,739
|
-
|
-
|
-
|
457,501
|
|||||||||||||||||||||||
Issuance
of common stock in satisfaction of accounts
|
||||||||||||||||||||||||||||||||||
payable,
September 2005, $0.81
|
-
|
-
|
162,933
|
163
|
-
|
-
|
113,442
|
-
|
-
|
-
|
113,605
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$211,538
of $2,000,000 debenture, September 2005
|
-
|
-
|
353,665
|
354
|
-
|
-
|
211,845
|
-
|
-
|
-
|
212,199
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$150,000
of 2nd $2,000,000 debenture, September 2005
|
-
|
-
|
250,000
|
250
|
-
|
-
|
149,750
|
-
|
-
|
-
|
150,000
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$457,317
of 2nd $2,000,000 debenture, September 2005
|
-
|
-
|
762,195
|
762
|
-
|
-
|
458,209
|
-
|
-
|
-
|
458,971
|
|||||||||||||||||||||||
Issuance
of common stock in conjunction with financing,
|
||||||||||||||||||||||||||||||||||
2nd
$2,000,000, September 2005, $0.82
|
-
|
-
|
170,732
|
171
|
-
|
-
|
139,829
|
-
|
-
|
-
|
140,000
|
|||||||||||||||||||||||
Issuance
of warrants in conjunction with financing,
|
||||||||||||||||||||||||||||||||||
2nd
$2,000,000, September 2005, $0.82
|
-
|
-
|
-
|
-
|
-
|
-
|
30,600
|
-
|
-
|
-
|
30,600
|
|||||||||||||||||||||||
Issuance
of warrants in conjunction with convertible debentures,
|
||||||||||||||||||||||||||||||||||
2nd
$2,000,000, September 2005 (at $0.82)
|
-
|
-
|
-
|
-
|
-
|
-
|
785,185
|
-
|
-
|
-
|
785,185
|
|||||||||||||||||||||||
Value
of Beneficial Conversion Feature on Convertible
|
||||||||||||||||||||||||||||||||||
Debentures,
2nd $2,000,000, September 2005 (at $0.82)
|
-
|
-
|
-
|
-
|
-
|
-
|
1,185,185
|
-
|
-
|
-
|
1,185,185
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, $4,000,000, October 2005
|
-
|
-
|
243,836
|
244
|
-
|
-
|
163,126
|
-
|
-
|
-
|
163,370
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, $2,000,000, October 2005
|
-
|
-
|
67,949
|
68
|
-
|
-
|
45,458
|
-
|
-
|
-
|
45,526
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$307,317
of 2nd $2,000,000 debenture, October 2005
|
-
|
-
|
512,195
|
512
|
-
|
-
|
306,805
|
-
|
-
|
-
|
307,317
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$300,000
of $2,000,000 debenture, October 2005
|
-
|
-
|
501,397
|
501
|
-
|
-
|
300,337
|
-
|
-
|
-
|
300,838
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$500,000
of $500,000 debenture, October 2005
|
-
|
-
|
644,003
|
644
|
-
|
-
|
527,438
|
-
|
-
|
-
|
528,082
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$113,077
of $2,000,000 debenture, October 2005
|
-
|
-
|
189,019
|
189
|
-
|
-
|
113,222
|
-
|
-
|
-
|
113,411
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$297,692
of $4,000,000 debenture, October 2005
|
-
|
-
|
364,113
|
364
|
-
|
-
|
298,209
|
-
|
-
|
-
|
298,573
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, October 2005, $0.82
|
-
|
-
|
8,404,876
|
8,405
|
-
|
-
|
6,883,593
|
-
|
-
|
-
|
6,891,998
|
|||||||||||||||||||||||
Exercise
of stock options for cash, October 2005, $0.63
|
-
|
-
|
101,500
|
101
|
-
|
-
|
63,844
|
-
|
-
|
-
|
63,945
|
|||||||||||||||||||||||
Exercise
of stock options for cash, October 2005, $0.94
|
-
|
-
|
40,000
|
40
|
-
|
-
|
37,560
|
-
|
-
|
-
|
37,600
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$100,000
of $100,000 debenture, October 2005
|
-
|
-
|
128,834
|
129
|
-
|
-
|
105,515
|
-
|
-
|
-
|
105,644
|
|||||||||||||||||||||||
Issuance of warrants in conjunction with financing, $500,000,
|
||||||||||||||||||||||||||||||||||
October
2005, $0.82
|
-
|
-
|
-
|
-
|
-
|
-
|
14,250
|
-
|
-
|
-
|
14,250
|
|||||||||||||||||||||||
Issuance
of warrants in conjunction with convertible
|
||||||||||||||||||||||||||||||||||
debentures,
$500,000, October 2005, $0.82
|
-
|
-
|
-
|
-
|
-
|
-
|
270,950
|
-
|
-
|
-
|
270,950
|
|||||||||||||||||||||||
Issuance
of warrants as exercise inducement Oct 2005, $1.20
|
-
|
-
|
-
|
-
|
-
|
-
|
573,146
|
-
|
-
|
-
|
573,146
|
|||||||||||||||||||||||
Issuance
of warrants as exercise inducement Oct 2005, $1.25
|
-
|
-
|
-
|
-
|
-
|
-
|
2,501,390
|
-
|
-
|
-
|
2,501,390
|
|||||||||||||||||||||||
Value
of Beneficial Conversion Feature on Convertible
|
||||||||||||||||||||||||||||||||||
Debentures,
$500,000, October 2005 (at $0.82)
|
-
|
-
|
-
|
-
|
-
|
-
|
229,050
|
-
|
-
|
-
|
229,050
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, $4,000,000, Nov 2005, $1.17
|
-
|
-
|
108,006
|
108
|
-
|
-
|
126,259
|
-
|
-
|
-
|
126,367
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, $2,000,000, Nov 2005, $1.17
|
-
|
-
|
16,753
|
17
|
-
|
-
|
19,584
|
-
|
-
|
-
|
19,601
|
|||||||||||||||||||||||
Exercise
of stock options for cash, November 2005, $0.94
|
-
|
-
|
100,000
|
100
|
-
|
-
|
93,900
|
-
|
-
|
-
|
94,000
|
|||||||||||||||||||||||
Exercise
of stock options for cash, November 2005, $0.63
|
-
|
-
|
1,500
|
2
|
-
|
-
|
944
|
-
|
-
|
-
|
946
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, November 2005, $0.82
|
-
|
-
|
3,058,536
|
3,058
|
-
|
-
|
2,504,942
|
-
|
-
|
-
|
2,508,000
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services
|
||||||||||||||||||||||||||||||||||
rendered
November 2005, $0.97
|
-
|
-
|
64,287
|
64
|
-
|
-
|
62,294
|
-
|
-
|
-
|
62,358
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$42,800
of 2nd $2,000,000 debenture, Nov 2005, $1.23
|
-
|
-
|
72,058
|
72
|
-
|
-
|
88,559
|
-
|
-
|
-
|
88,631
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services
|
||||||||||||||||||||||||||||||||||
rendered
August 2005, $0.97
|
-
|
-
|
19,500
|
19
|
-
|
-
|
18,897
|
-
|
-
|
-
|
18,916
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$230,769
of $4,000,000 debenture, November 2005,$0.97
|
-
|
-
|
282,721
|
283
|
-
|
-
|
273,957
|
-
|
-
|
-
|
274,240
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, $2,000,000, Dec 2005, $0.98
|
-
|
-
|
212,750
|
213
|
-
|
-
|
208,282
|
-
|
-
|
-
|
208,495
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$1,451,000
of $3,500,000 debenture, Dec 2005, $0.93
|
-
|
-
|
1,770,223
|
1,770
|
-
|
-
|
1,644,537
|
-
|
-
|
-
|
1,646,307
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$4,221
of 2nd $2,000,000 debenture, Dec 2005, $0.85
|
-
|
-
|
7,042
|
7
|
-
|
-
|
5,979
|
-
|
-
|
-
|
5,986
|
|||||||||||||||||||||||
Issuance
of common stock in conjunction with financing,
|
||||||||||||||||||||||||||||||||||
$3,500,000,
December 2005, $0.95
|
-
|
-
|
224,000
|
224
|
-
|
-
|
212,576
|
-
|
-
|
-
|
212,800
|
|||||||||||||||||||||||
Issuance
of warrants in conjunction with financing, $3,500,000,
|
||||||||||||||||||||||||||||||||||
December
2005, $0.82
|
-
|
-
|
-
|
-
|
-
|
-
|
76,650
|
-
|
-
|
-
|
76,650
|
|||||||||||||||||||||||
Issuance
of warrants in conjunction with convertible
|
||||||||||||||||||||||||||||||||||
debentures,
$3,500,000, December 2005, $0.82
|
-
|
-
|
-
|
-
|
-
|
-
|
1,648,387
|
-
|
-
|
-
|
1,648,387
|
|||||||||||||||||||||||
Value
of Beneficial Conversion Feature on Convertible
|
||||||||||||||||||||||||||||||||||
Debentures,
$3,500,000, December 2005,$0.82
|
-
|
-
|
-
|
-
|
-
|
-
|
1,851,613
|
-
|
-
|
-
|
1,851,613
|
|||||||||||||||||||||||
Issuance
of warrants as exercise inducement Dec 2005, $1.25
|
-
|
-
|
-
|
-
|
-
|
-
|
1,115,853
|
-
|
-
|
-
|
1,115,853
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$82,000
of $3,500,000 debenture, December 2005, $0.84
|
-
|
-
|
100,000
|
100
|
-
|
-
|
83,900
|
-
|
-
|
-
|
84,000
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, 2nd $2,000,000, Jan 2006, $0.81
|
-
|
-
|
75,149
|
75
|
-
|
-
|
60,796
|
-
|
-
|
-
|
60,871
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, $500,000, Jan 2006, $0.81
|
-
|
-
|
53,612
|
54
|
-
|
-
|
43,372
|
-
|
-
|
-
|
43,426
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$617,000
of $3,500,000 debenture, January 2005, $0.94
|
-
|
-
|
757,630
|
758
|
-
|
-
|
711,415
|
-
|
-
|
-
|
712,173
|
|||||||||||||||||||||||
Issuance
of common stock in conjunction with financing,
|
||||||||||||||||||||||||||||||||||
$4,000,000,
January 2006, $1.00
|
-
|
-
|
266,667
|
267
|
-
|
-
|
266,400
|
-
|
-
|
-
|
266,667
|
|||||||||||||||||||||||
Issuance of warrants in conjunction with financing, $4,000,000,
|
||||||||||||||||||||||||||||||||||
January
2006, $1.05
|
-
|
-
|
-
|
-
|
-
|
-
|
88,800
|
-
|
-
|
-
|
88,800
|
|||||||||||||||||||||||
Issuance
of warrants in conjunction with convertible
|
||||||||||||||||||||||||||||||||||
debentures,
4,000,000, January 2006, $1.05
|
-
|
-
|
-
|
-
|
-
|
-
|
1,653,631
|
-
|
-
|
-
|
1,653,631
|
|||||||||||||||||||||||
Value
of Beneficial Conversion Feature on Convertible
|
||||||||||||||||||||||||||||||||||
Debentures,
4,000,000, January 2006, $1.05
|
-
|
-
|
-
|
-
|
-
|
-
|
1,463,155
|
-
|
-
|
-
|
1,463,155
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, January 2006, $0.82
|
-
|
-
|
7,317,072
|
7,317
|
-
|
-
|
5,992,682
|
-
|
-
|
-
|
5,999,999
|
|||||||||||||||||||||||
Issuance
of warrants as exercise inducement Jan 2006, $1.60
|
-
|
-
|
-
|
-
|
-
|
-
|
3,109,756
|
-
|
-
|
-
|
3,109,756
|
|||||||||||||||||||||||
Exercise
of stock options for cash, January 2006, $0.63
|
-
|
-
|
10,000
|
10
|
-
|
-
|
6,290
|
-
|
-
|
-
|
6,300
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$850,000
of $3,500,000 debenture, January 2006, $1.06
|
-
|
-
|
1,045,779
|
1,046
|
-
|
-
|
1,107,480
|
-
|
-
|
-
|
1,108,526
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, $500,000, Feb 2006, $1.23
|
-
|
-
|
49,812
|
50
|
-
|
-
|
61,219
|
-
|
-
|
-
|
61,269
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, $2,000,000, Feb 2006, $1.23
|
-
|
-
|
67,746
|
68
|
-
|
-
|
83,260
|
-
|
-
|
-
|
83,328
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation,
|
||||||||||||||||||||||||||||||||||
December
2005, $0.90
|
-
|
-
|
140,115
|
140
|
-
|
-
|
125,964
|
-
|
-
|
-
|
126,104
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, February 2006, $0.82
|
-
|
-
|
303,902
|
304
|
-
|
-
|
248,896
|
-
|
-
|
-
|
249,200
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services
|
||||||||||||||||||||||||||||||||||
rendered
February 2006, $1.53
|
-
|
-
|
50,000
|
50
|
-
|
-
|
76,450
|
-
|
-
|
-
|
76,500
|
|||||||||||||||||||||||
Exercise
of stock options for cash, February 2006, $0.94
|
-
|
-
|
80,000
|
80
|
-
|
-
|
75,120
|
-
|
-
|
-
|
75,200
|
|||||||||||||||||||||||
Exercise
of stock options for cash, February 2006, $1.59
|
-
|
-
|
80,000
|
80
|
-
|
-
|
127,120
|
-
|
-
|
-
|
127,200
|
|||||||||||||||||||||||
Exercise
of stock options for cash, February 2006, $1.38
|
-
|
-
|
20,000
|
20
|
-
|
-
|
27,580
|
-
|
-
|
-
|
27,600
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, February 2006, $1.05
|
-
|
-
|
3,809,524
|
3,810
|
-
|
-
|
3,996,191
|
-
|
-
|
-
|
4,000,001
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, February 2006, $1.20
|
-
|
-
|
909,756
|
910
|
-
|
-
|
1,090,797
|
-
|
-
|
-
|
1,091,707
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, February 2006, $1.25
|
-
|
-
|
4,578,048
|
4,578
|
-
|
-
|
5,717,982
|
-
|
-
|
-
|
5,722,560
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, February 2006, $1.72
|
-
|
-
|
34,782
|
35
|
-
|
-
|
59,790
|
-
|
-
|
-
|
59,825
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$950,000
of Jan $4,000,000 debenture, Feb 2006, $2.38
|
-
|
-
|
904,762
|
905
|
-
|
-
|
2,152,429
|
-
|
-
|
-
|
2,153,334
|
|||||||||||||||||||||||
Issuance
of warrants in conjunction with convertible
|
||||||||||||||||||||||||||||||||||
debentures,
4,000,000, February 2006, $1.05
|
-
|
-
|
-
|
-
|
-
|
-
|
2,374,507
|
-
|
-
|
-
|
2,374,507
|
|||||||||||||||||||||||
Value
of Beneficial Conversion Feature on Convertible
|
||||||||||||||||||||||||||||||||||
Debentures,
4,000,000, February 2006, $1.05
|
-
|
-
|
-
|
-
|
-
|
-
|
1,625,493
|
-
|
-
|
-
|
1,625,493
|
|||||||||||||||||||||||
Issuance
of warrants as exercise inducement Feb 2006, $3.00
|
-
|
-
|
-
|
-
|
-
|
-
|
8,294,141
|
-
|
-
|
-
|
8,294,141
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$1,550,000
of Jan $4,000,000 debenture, Mar 2006, $2.21
|
-
|
-
|
1,485,349
|
1,485
|
-
|
-
|
3,281,136
|
-
|
-
|
-
|
3,282,621
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, March 2006, $1.72
|
-
|
-
|
347,913
|
348
|
-
|
-
|
598,062
|
-
|
-
|
-
|
598,410
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, $2,000,000, Mar 2006, $2.31
|
-
|
-
|
67,094
|
67
|
-
|
-
|
154,920
|
-
|
-
|
-
|
154,987
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, $500,000, March 2006, $2.31
|
-
|
-
|
49,312
|
49
|
-
|
-
|
113,861
|
-
|
-
|
-
|
113,910
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, $3,500,000, Mar 2006, $2.31
|
-
|
-
|
55,644
|
56
|
-
|
-
|
128,482
|
-
|
-
|
-
|
128,538
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services
|
||||||||||||||||||||||||||||||||||
rendered
March 2006, $2.31
|
-
|
-
|
50,000
|
50
|
-
|
-
|
115,450
|
-
|
-
|
-
|
115,500
|
|||||||||||||||||||||||
Exercise
of stock options for cash, March 2006, $0.94
|
-
|
-
|
300,222
|
300
|
-
|
-
|
281,909
|
-
|
-
|
-
|
282,209
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$2,350,000
of Feb $4,000,000 debenture, Mar 2006, $2.31
|
-
|
-
|
1,880,000
|
1,880
|
-
|
-
|
4,340,920
|
-
|
-
|
-
|
4,342,800
|
|||||||||||||||||||||||
Exercise
of stock options for cash, March 2006, $1.47
|
-
|
-
|
274,500
|
274
|
-
|
-
|
403,241
|
-
|
-
|
-
|
403,515
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, March 2006, $1.25
|
-
|
-
|
1,600,000
|
1,600
|
-
|
-
|
1,998,400
|
-
|
-
|
-
|
2,000,000
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, March 2006, $0.91
|
-
|
-
|
60,000
|
60
|
-
|
-
|
54,540
|
-
|
-
|
-
|
54,600
|
|||||||||||||||||||||||
Exercise
of stock options for cash, March 2006, $1.59
|
-
|
-
|
263,700
|
264
|
-
|
-
|
419,019
|
-
|
-
|
-
|
419,283
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$500,000
of Feb $4,000,000 debenture, Mar 2006, $2.20
|
-
|
-
|
400,592
|
401
|
-
|
-
|
880,902
|
-
|
-
|
-
|
881,303
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, March 2006, $0.82
|
-
|
-
|
48,000
|
48
|
-
|
-
|
39,312
|
-
|
-
|
-
|
39,360
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, March 2006, $1.05
|
-
|
-
|
46,000
|
46
|
-
|
-
|
48,254
|
-
|
-
|
-
|
48,300
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$200,000
of Jan $4,000,000 debenture, March 2006, $2.31
|
-
|
-
|
192,136
|
192
|
-
|
-
|
443,642
|
-
|
-
|
-
|
443,834
|
|||||||||||||||||||||||
Exercise
of stock options for cash, March 2006, $1.71
|
-
|
-
|
180,000
|
180
|
-
|
-
|
307,620
|
-
|
-
|
-
|
307,800
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$384,615
of $500,000 debenture, March 2006, $3.33
|
-
|
-
|
470,450
|
470
|
-
|
-
|
1,566,129
|
-
|
-
|
-
|
1,566,599
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, March 2006, $1.68
|
-
|
-
|
1,639,344
|
1,639
|
-
|
-
|
2,752,459
|
-
|
-
|
-
|
2,754,098
|
|||||||||||||||||||||||
Cashless
exercise of stock warrants, March 2006, $2.50
|
-
|
-
|
8,179
|
8
|
-
|
-
|
(8
|
)
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||
Exercise
of stock warrants for cash, March 2006, $1.25
|
-
|
-
|
68,000
|
68
|
-
|
-
|
84,932
|
-
|
-
|
-
|
85,000
|
|||||||||||||||||||||||
Exercise
of stock options for cash, March 2006, $2.10
|
-
|
-
|
175,000
|
175
|
-
|
-
|
367,325
|
-
|
-
|
-
|
367,500
|
|||||||||||||||||||||||
Exercise
of stock options for cash, March 2006, $1.10
|
-
|
-
|
150,000
|
150
|
-
|
-
|
164,850
|
-
|
-
|
-
|
165,000
|
|||||||||||||||||||||||
Exercise
of stock options for cash, March 2006, $1.52
|
-
|
-
|
150,000
|
150
|
-
|
-
|
227,850
|
-
|
-
|
-
|
228,000
|
|||||||||||||||||||||||
Exercise
of stock options for cash, March 2006, $2.19
|
-
|
-
|
150,000
|
150
|
-
|
-
|
328,350
|
-
|
-
|
-
|
328,500
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, March 2006, $2.15
|
-
|
-
|
2,000
|
2
|
-
|
-
|
4,298
|
-
|
-
|
-
|
4,300
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, March 2006, $1.88
|
-
|
-
|
31,000
|
31
|
-
|
-
|
58,249
|
-
|
-
|
-
|
58,280
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, March 2006, $2.02
|
-
|
-
|
23,438
|
23
|
-
|
-
|
47,322
|
-
|
-
|
-
|
47,345
|
|||||||||||||||||||||||
Exercise
of stock options for cash, March 2006, $0.63
|
-
|
-
|
120,750
|
121
|
-
|
-
|
75,952
|
-
|
-
|
-
|
76,073
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, March 2006, $1.86
|
-
|
-
|
170,068
|
170
|
-
|
-
|
316,156
|
-
|
-
|
-
|
316,326
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services
|
||||||||||||||||||||||||||||||||||
rendered
March 2006, $2.96
|
-
|
-
|
25,000
|
25
|
-
|
-
|
73,975
|
-
|
-
|
-
|
74,000
|
|||||||||||||||||||||||
Issuance
of common stock in satisfaction of accounts
|
||||||||||||||||||||||||||||||||||
payable
March 2006, $3.20
|
-
|
-
|
2,390
|
2
|
-
|
-
|
7,646
|
-
|
-
|
-
|
7,648
|
|||||||||||||||||||||||
Issuance
of warrants as exercise inducement Mar 2006, $3.00
|
-
|
-
|
-
|
-
|
-
|
-
|
1,293,953
|
-
|
-
|
-
|
1,293,953
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, $2,000,000, April 2006, $2.70
|
-
|
-
|
67,083
|
67
|
-
|
-
|
181,057
|
-
|
-
|
-
|
181,124
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, $3,500,000, April 2006, $2.70
|
-
|
-
|
49,812
|
50
|
-
|
-
|
134,443
|
-
|
-
|
-
|
134,493
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization payments due, Jan $4,000,000, Apr 2006, $2.70
|
-
|
-
|
167,144
|
167
|
-
|
-
|
451,122
|
-
|
-
|
-
|
451,289
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, April 2006, $1.88
|
-
|
-
|
29,000
|
29
|
-
|
-
|
54,491
|
-
|
-
|
-
|
54,520
|
|||||||||||||||||||||||
Exercise
of stock options for cash, April 2006, $1.47
|
-
|
-
|
95,500
|
95
|
-
|
-
|
140,290
|
-
|
-
|
-
|
140,385
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$307,692
of 2nd $2,000,000 debenture, April 2006, $2.63
|
-
|
-
|
513,158
|
513
|
-
|
-
|
1,349,092
|
-
|
-
|
-
|
1,349,605
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$423,077
of $3,500,000 debenture, April 2005, $2.63
|
-
|
-
|
516,291
|
516
|
-
|
-
|
1,357,329
|
-
|
-
|
-
|
1,357,845
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of
|
||||||||||||||||||||||||||||||||||
$923,077
of Jan $4,000,000 debenture, April 2006, $2.63
|
-
|
-
|
879,699
|
880
|
-
|
-
|
2,312,729
|
-
|
-
|
-
|
2,313,609
|
|||||||||||||||||||||||
Exercise
of stock options for cash, April 2006, $0.94
|
-
|
-
|
25,000
|
25
|
-
|
-
|
23,475
|
-
|
-
|
-
|
23,500
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, April 2006, $0.82
|
-
|
-
|
132,000
|
132
|
-
|
-
|
108,108
|
-
|
-
|
-
|
108,240
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, April 2006, $0.91
|
-
|
-
|
60,000
|
60
|
-
|
-
|
54,540
|
-
|
-
|
-
|
54,600
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, April 2006, $1.05
|
-
|
-
|
69,000
|
69
|
-
|
-
|
72,381
|
-
|
-
|
-
|
72,450
|
|||||||||||||||||||||||
Issuance
of common stock in satisfaction of deposit
|
||||||||||||||||||||||||||||||||||
April
2006, $1.25
|
-
|
-
|
204,465
|
204
|
-
|
-
|
255,377
|
-
|
-
|
-
|
255,581
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services
|
||||||||||||||||||||||||||||||||||
rendered
April 2006, $2.67
|
-
|
-
|
38,400
|
38
|
-
|
-
|
102,490
|
-
|
-
|
-
|
102,528
|
|||||||||||||||||||||||
Issuance
of warrants in exchange for the services rendered
|
||||||||||||||||||||||||||||||||||
April
2006, $2.66
|
-
|
-
|
-
|
-
|
-
|
-
|
137,200
|
-
|
-
|
-
|
137,200
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, Jan $4,000,000, May 2006, $3.10
|
-
|
-
|
74,322
|
74
|
-
|
-
|
230,324
|
-
|
-
|
-
|
230,398
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, Feb $4,000,000, May 2006, $3.10
|
-
|
-
|
172,713
|
173
|
-
|
-
|
535,238
|
-
|
-
|
-
|
535,411
|
|||||||||||||||||||||||
Exercise
of stock options for cash, May 2006, $2.10
|
-
|
-
|
25,000
|
25
|
-
|
-
|
52,475
|
-
|
-
|
-
|
52,500
|
|||||||||||||||||||||||
Exercise
of stock options for cash, May 2006, $1.47
|
-
|
-
|
10,000
|
10
|
-
|
-
|
14,690
|
-
|
-
|
-
|
14,700
|
|||||||||||||||||||||||
Issuance
of warrants in exchange for the services rendered
|
||||||||||||||||||||||||||||||||||
May
2006, $1.91
|
-
|
-
|
-
|
-
|
-
|
-
|
35,250
|
-
|
-
|
-
|
35,250
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation
|
||||||||||||||||||||||||||||||||||
May
2006, $1.88
|
-
|
-
|
755,000
|
755
|
-
|
-
|
1,418,645
|
-
|
-
|
-
|
1,419,400
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services
|
||||||||||||||||||||||||||||||||||
rendered
May 2006, $1.85
|
-
|
-
|
3,784
|
4
|
-
|
-
|
6,997
|
-
|
-
|
-
|
7,001
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services
|
||||||||||||||||||||||||||||||||||
rendered
May 2006, $1.88
|
-
|
-
|
38,000
|
38
|
-
|
-
|
71,402
|
-
|
-
|
-
|
71,440
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, Jan $4,000,000, Jun 2006, $1.96
|
-
|
-
|
73,979
|
74
|
-
|
-
|
144,925
|
-
|
-
|
-
|
144,999
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, Feb $4,000,000, Jun 2006, $1.96
|
-
|
-
|
83,911
|
84
|
-
|
-
|
164,382
|
-
|
-
|
-
|
164,466
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, June 2006, $1.25
|
-
|
-
|
1,327,880
|
1,328
|
-
|
-
|
1,658,522
|
-
|
-
|
-
|
1,659,850
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, June 2006, $1.60
|
-
|
-
|
3,036,310
|
3,036
|
-
|
-
|
4,855,060
|
-
|
-
|
-
|
4,858,096
|
|||||||||||||||||||||||
Issuance
of warrants as exercise inducement June 2006, $2.35
|
-
|
-
|
-
|
-
|
-
|
-
|
4,549,670
|
-
|
-
|
-
|
4,549,670
|
|||||||||||||||||||||||
Issuance
of common stock for cash pursuant to private
|
||||||||||||||||||||||||||||||||||
placement,
June 2006, $2.05
|
-
|
-
|
3,414,636
|
3,415
|
-
|
-
|
6,996,589
|
-
|
-
|
-
|
7,000,004
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services
|
||||||||||||||||||||||||||||||||||
rendered
June 2006, $1.85
|
-
|
-
|
3,784
|
4
|
-
|
-
|
6,997
|
-
|
-
|
-
|
7,001
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization
payments due, Jan $4,000,000, July 2006, $1.75
|
-
|
-
|
66,264
|
66
|
-
|
-
|
115,896
|
-
|
-
|
-
|
115,962
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly
|
||||||||||||||||||||||||||||||||||
amortization payments due, Feb $4,000,000, July 2006, $1.75
|
-
|
-
|
64,923
|
65
|
-
|
-
|
113,550
|
-
|
-
|
-
|
113,615
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services
|
||||||||||||||||||||||||||||||||||
rendered
July 2006, $1.40
|
-
|
-
|
5,000
|
5
|
-
|
-
|
6,995
|
-
|
-
|
-
|
7,000
|
|||||||||||||||||||||||
Comprehensive
Income (Loss):
|
||||||||||||||||||||||||||||||||||
Net
Loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(67,967,204
|
)
|
-
|
(67,967,204
|
)
|
|||||||||||||||||||||
Other
comprehensive income (loss)
|
||||||||||||||||||||||||||||||||||
Currency
translation adjustment
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
185,232
|
185,232
|
|||||||||||||||||||||||
Total
Comprehensive Income (Loss)
|
(67,967,204
|
)
|
185,232
|
(67,781,972
|
)
|
|||||||||||||||||||||||||||||
Balance
at July 31, 2006
|
1,000
|
$
|
1
|
107,398,360
|
$
|
107,397
|
$
|
-
|
$
|
-
|
$
|
243,097,627
|
$
|
-
|
$
|
(188,495,312
|
)
|
$
|
754,081
|
$
|
55,463,794
|
|
|
|
|
|
|
|
|
Deficit
|
|
|
||||||||||||||||||||||||
SVR
|
|
|
|
Notes
|
Accumulated
|
Accumulated
|
|
|||||||||||||||||||||||||||
Preferred
|
Common
|
Treasury
|
Additional
|
Receivable
-
|
During
the
|
Other
|
Total
|
|||||||||||||||||||||||||||
Stock
|
Stock
|
Stock
|
Paid-In
|
Common
|
Development
|
Comprehensive
|
Stockholders’
|
|||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Stock
|
Stage
|
Income
(Loss)
|
Equity
|
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Balance,
August 1, 2006
|
1,000
|
$
|
1
|
107,398,360
|
$
|
107,397
|
$
|
-
|
$
|
-
|
$
|
243,097,627
|
$
|
-
|
$
|
(188,495,312
|
)
|
$
|
754,081
|
$
|
55,463,794
|
|||||||||||||
Issuance
of common stock as repayment of monthly amortization payments due,
Feb
$4,000,000, Aug 2006, $1.48
|
-
|
-
|
64,718
|
65
|
-
|
-
|
95,718
|
-
|
-
|
-
|
95,783
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Aug 2006,
$1.43
|
-
|
-
|
25,000
|
25
|
-
|
-
|
35,725
|
-
|
-
|
-
|
35,750
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly amortization payments due
Feb
$4,000,000, Sep 2006 $1.53
|
-
|
-
|
64,400
|
64
|
-
|
-
|
98,468
|
-
|
-
|
-
|
98,532
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Oct 2006,
$1.50
|
-
|
-
|
25,000
|
25
|
-
|
-
|
37,475
|
-
|
-
|
-
|
37,500
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly amortization payments due
, Feb
$4,000,000, Oct 2006, $1.65
|
-
|
-
|
64,000
|
64
|
-
|
-
|
105,536
|
-
|
-
|
-
|
105,600
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Oct 2006,
$1.83
|
-
|
-
|
27,262
|
27
|
-
|
-
|
49,862
|
-
|
-
|
-
|
49,889
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Oct 2006,
$1.50
|
-
|
-
|
25,000
|
25
|
-
|
-
|
37,475
|
-
|
-
|
-
|
37,500
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation Oct 2006, $1.83
|
-
|
-
|
100,000
|
100
|
-
|
-
|
182,900
|
-
|
-
|
-
|
183,000
|
|||||||||||||||||||||||
Exercise
of stock warrants for cash, Oct 2006, $1.25
|
-
|
-
|
100,000
|
100
|
-
|
-
|
124,900
|
-
|
-
|
-
|
125,000
|
|||||||||||||||||||||||
Exercise
of stock options for cash, Oct 2006, $1.59
|
-
|
-
|
90,300
|
90
|
-
|
-
|
143,487
|
-
|
-
|
-
|
143,577
|
|||||||||||||||||||||||
Exercise
of stock options for cash, Oct 2006, $1.47
|
-
|
-
|
6,500
|
6
|
-
|
-
|
9,549
|
-
|
-
|
-
|
9,555
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly amortization payments due
Feb
$4,000,000, Nov 2006, $2.02
|
-
|
-
|
63,764
|
64
|
-
|
-
|
128,740
|
-
|
-
|
-
|
128,804
|
|||||||||||||||||||||||
Exercise
of stock options for cash, Nov 2006, $1.59
|
-
|
-
|
15,000
|
15
|
-
|
-
|
23,835
|
-
|
-
|
-
|
23,850
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Nov 2006,
$2.15
|
-
|
-
|
50,000
|
50
|
-
|
-
|
107,450
|
-
|
-
|
-
|
107,500
|
|||||||||||||||||||||||
Issuance
of common stock as repayment of monthly amortization payments due,
Feb
$4,000,000, Dec 2006, $2.08
|
-
|
-
|
63,384
|
63
|
-
|
-
|
131,775
|
-
|
-
|
-
|
131,838
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Dec 2006,
$1.68
|
-
|
-
|
25,000
|
25
|
-
|
-
|
41,975
|
-
|
-
|
-
|
42,000
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Jan 2007,
$1.77
|
-
|
-
|
25,000
|
25
|
-
|
-
|
44,225
|
-
|
-
|
-
|
44,250
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversation of $52,554 of Feb
$4,000,000 debenture, Jan, $1.74
|
-
|
-
|
42,043
|
42
|
-
|
-
|
73,113
|
-
|
-
|
-
|
73,155
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of 52,554 of Feb
$4,000,000
debenture, Jan, $1.77
|
-
|
-
|
42,043
|
42
|
-
|
-
|
74,374
|
-
|
-
|
-
|
74,416
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Feb 2007,
$1.90
|
-
|
-
|
25,000
|
25
|
-
|
-
|
47,475
|
-
|
-
|
-
|
47,500
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Mar 2007,
$1.71
|
-
|
-
|
100,000
|
100
|
-
|
-
|
170,900
|
-
|
-
|
-
|
171,000
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation Mar 2007, $1.71
|
-
|
-
|
9,844
|
10
|
-
|
-
|
16,823
|
-
|
-
|
-
|
16,833
|
|||||||||||||||||||||||
Issuance
of warrants in exchange for the services rendered Mar 2007,
$1.71
|
-
|
-
|
|
|
-
|
-
|
125,000
|
-
|
-
|
-
|
125,000
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation Mar 2007, $1.71
|
-
|
-
|
296,000
|
296
|
-
|
-
|
505,864
|
-
|
-
|
-
|
506,160
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Mar 2007,
$1.65
|
-
|
-
|
13,637
|
13
|
-
|
-
|
22,487
|
-
|
-
|
-
|
22,500
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Mar 2007,
$1.69
|
-
|
-
|
25,000
|
25
|
-
|
-
|
42,225
|
-
|
-
|
-
|
42,250
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of $52,554 of Feb
$4,000,000
debenture, Mar 2007, $1.71
|
-
|
-
|
42,043
|
42
|
-
|
-
|
71,851
|
-
|
-
|
-
|
71,893
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation Mar 2007, $1.70
|
-
|
-
|
4,951
|
5
|
-
|
-
|
8,412
|
-
|
-
|
-
|
8,417
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Apr 2007,
$1.71
|
-
|
-
|
22,728
|
23
|
-
|
-
|
38,842
|
-
|
-
|
-
|
38,865
|
|||||||||||||||||||||||
Preferred
Shares Redemption, April 2007
|
(1,000
|
)
|
(1
|
)
|
-
|
-
|
-
|
-
|
(99
|
)
|
-
|
-
|
-
|
(100
|
)
|
|||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Apr 2007,
$1.65
|
-
|
-
|
13,637
|
14
|
-
|
-
|
22,486
|
-
|
-
|
-
|
22,500
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Apr 2007,
$1.69
|
-
|
-
|
25,000
|
25
|
-
|
-
|
42,225
|
-
|
-
|
-
|
42,250
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation Apr 2007, $1.64
|
-
|
-
|
5,132
|
5
|
-
|
-
|
8,411
|
-
|
-
|
-
|
8,416
|
|||||||||||||||||||||||
Issuance
of common stock in connection with conversion of $52,554 of Feb
$4,000,000
debenture, Apr 2007, $1.61
|
-
|
-
|
42,043
|
42
|
-
|
-
|
67,647
|
-
|
-
|
-
|
67,689
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered May 2007,
$1.60
|
-
|
-
|
22,728
|
23
|
-
|
-
|
36,342
|
-
|
-
|
-
|
36,365
|
|||||||||||||||||||||||
Exercise
of stock options for cash, May 2007, $0.63
|
-
|
-
|
5,000
|
5
|
-
|
-
|
3,145
|
-
|
-
|
-
|
3,150
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered May 2007,
$1.47
|
-
|
-
|
25,000
|
25
|
-
|
-
|
36,725
|
-
|
-
|
-
|
36,750
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered May 2007,
$1.47
|
-
|
-
|
13,637
|
14
|
-
|
-
|
20,033
|
-
|
-
|
-
|
20,047
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation May 2007, $1.45
|
-
|
-
|
5,805
|
6
|
-
|
-
|
8,411
|
-
|
-
|
-
|
8,417
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation May 2007, $1.45
|
-
|
-
|
450,000
|
450
|
-
|
-
|
652,050
|
-
|
-
|
-
|
652,500
|
|||||||||||||||||||||||
Issuance
of warrants in exchange for the services rendered May 2007,
$1.45
|
-
|
-
|
|
|
-
|
-
|
141,400
|
-
|
-
|
-
|
141,400
|
|||||||||||||||||||||||
Cancellation
of common stock, May 2007, $1.45
|
-
|
-
|
(150,000
|
)
|
(150
|
)
|
-
|
-
|
150
|
-
|
-
|
-
|
-
|
|||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Jun 2007
,
$1.40
|
-
|
-
|
22,728
|
23
|
-
|
-
|
31,796
|
-
|
-
|
-
|
31,819
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Jun 2007,
$1.83
|
-
|
-
|
13,637
|
14
|
-
|
-
|
24,942
|
-
|
-
|
-
|
24,956
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for services rendered Jun 2007,
$1.80
|
-
|
-
|
25,000
|
25
|
-
|
-
|
44,975
|
-
|
-
|
-
|
45,000
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation, Jul 2007, $1.78
|
-
|
-
|
4,728
|
5
|
-
|
-
|
8,411
|
-
|
-
|
-
|
8,416
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Jul 2007,
$1.78
|
-
|
-
|
22,728
|
23
|
-
|
-
|
40,433
|
-
|
-
|
-
|
40,456
|
|||||||||||||||||||||||
Exercise
of stock options for cash, Jul 2007, $0.94
|
-
|
-
|
70,000
|
70
|
-
|
-
|
65,730
|
-
|
-
|
-
|
65,800
|
|||||||||||||||||||||||
Exercise
of stock options for cash, Jul 2007, $0.56
|
-
|
-
|
100,000
|
100
|
-
|
-
|
55,900
|
-
|
-
|
-
|
56,000
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Jul 2007,
$1.75
|
-
|
-
|
13,637
|
14
|
-
|
-
|
23,851
|
-
|
-
|
-
|
23,865
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Jul 2007,
$1.68
|
-
|
-
|
25,000
|
25
|
-
|
-
|
41,975
|
-
|
-
|
-
|
42,000
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation April 2007, $1.65
|
-
|
-
|
5,101
|
5
|
-
|
-
|
8,412
|
-
|
-
|
-
|
8,417
|
|||||||||||||||||||||||
Comprehensive
Income (Loss):
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Net
Loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(23,504,958
|
)
|
-
|
(23,504,958
|
)
|
|||||||||||||||||||||
Other
comprehensive income (loss)
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Currency
translation adjustment
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
127,726
|
127,726
|
|||||||||||||||||||||||
Total
Comprehensive Income (Loss)
|
|
|
|
|
|
|
|
(23,504,958
|
)
|
127,726
|
(23,377,232
|
)
|
||||||||||||||||||||||
Balance
at July 31, 2007
|
-
|
-
|
109,616,518
|
109,616
|
-
|
-
|
247,079,439
|
-
|
(212,000,270
|
)
|
881,807
|
36,070,592
|
|
|
|
|
|
|
|
|
Deficit
|
|
|
||||||||||||||||||||||||
SVR
|
|
|
|
Notes
|
Accumulated
|
Accumulated
|
|
|||||||||||||||||||||||||||
Preferred
|
Common
|
Treasury
|
Additional
|
Receivable
-
|
During
the
|
Other
|
Total
|
|||||||||||||||||||||||||||
Stock
|
Stock
|
Stock
|
Paid-In
|
Common
|
Development
|
Comprehensive
|
Stockholders’
|
|||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Stock
|
Stage
|
Income
(Loss)
|
Equity
|
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Balance,
August 1, 2007
|
-
|
$
|
-
|
109,616,518
|
$
|
109,616
|
-
|
$
|
-
|
$
|
247,079,439
|
$
|
-
|
$
|
(212,000,270
|
)
|
$
|
881,807
|
$
|
36,070,592
|
||||||||||||||
Issuance
of common stock in exchange for the services rendered Aug 2007,
$1.57
|
-
|
-
|
22,728
|
23
|
-
|
-
|
35,660
|
-
|
-
|
-
|
35,683
|
|||||||||||||||||||||||
Issuance
of restricted common stock to officers as employee compensation
Aug
2007
|
-
|
-
|
550,000
|
550
|
-
|
-
|
(550
|
)
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||
Stock-based
compensation - officers
|
-
|
-
|
-
|
-
|
-
|
-
|
527,909
|
-
|
-
|
-
|
527,909
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation Aug 2007, $1.51 (Issued
under the
2006 Plan and fully vested)
|
-
|
-
|
100,000
|
100
|
-
|
-
|
150,900
|
-
|
-
|
-
|
151,000
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation Aug 2007, $1.50
|
-
|
-
|
5,611
|
6
|
-
|
-
|
8,411
|
-
|
-
|
-
|
8,417
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Sep 2007,
$1.48
|
-
|
-
|
22,728
|
22
|
-
|
-
|
33,615
|
-
|
-
|
-
|
33,637
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Sep 2007,
$1.61
|
-
|
-
|
8,000
|
8
|
-
|
-
|
12,872
|
-
|
-
|
-
|
12,880
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Sep 2007,
$1.53
|
-
|
-
|
50,000
|
50
|
-
|
-
|
76,450
|
-
|
-
|
-
|
76,500
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation Sep 2007, $1.55
|
-
|
-
|
5,430
|
5
|
-
|
-
|
8,411
|
-
|
-
|
-
|
8,416
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Oct 2007,
$1.50
|
-
|
-
|
22,728
|
23
|
-
|
-
|
34,069
|
-
|
-
|
-
|
34,092
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation Oct 2007, $1.52
|
-
|
-
|
446,000
|
446
|
-
|
-
|
677,474
|
-
|
-
|
-
|
677,920
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Oct 2007,
$1.53
|
-
|
-
|
8,000
|
8
|
-
|
-
|
12,232
|
-
|
-
|
-
|
12,240
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Oct 2007,
$1.50
|
-
|
-
|
37,500
|
38
|
-
|
-
|
56,213
|
-
|
-
|
-
|
56,251
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation Oct 2007, $1.53
|
-
|
-
|
5,501
|
6
|
-
|
-
|
8,411
|
-
|
-
|
-
|
8,417
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Nov 2007,
$1.71
|
-
|
-
|
22,728
|
23
|
-
|
-
|
38,842
|
-
|
-
|
-
|
38,865
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Nov 2007,
$1.75
|
-
|
-
|
8,000
|
8
|
-
|
-
|
13,992
|
-
|
-
|
-
|
14,000
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation Nov 2007, $1.70
|
-
|
-
|
4,951
|
5
|
-
|
-
|
8,412
|
-
|
-
|
-
|
8,417
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Nov 2007,
$1.54
|
-
|
-
|
228,087
|
228
|
-
|
-
|
349,771
|
-
|
-
|
-
|
349,999
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Nov 2007,
$1.53
|
-
|
-
|
98,168
|
98
|
-
|
-
|
149,903
|
-
|
-
|
-
|
150,001
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Dec 2007,
$1.80
|
-
|
-
|
22,728
|
23
|
-
|
-
|
40,888
|
-
|
-
|
-
|
40,911
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Dec 2007,
$1.84
|
-
|
-
|
8,000
|
8
|
-
|
-
|
14,712
|
-
|
-
|
-
|
14,720
|
|||||||||||||||||||||||
Exercise
of stock options for cash, Dec 2007, $1.59
|
-
|
-
|
31,000
|
31
|
-
|
-
|
49,259
|
-
|
-
|
-
|
49,290
|
|||||||||||||||||||||||
Stock-based
compensation - officers
|
-
|
-
|
-
|
-
|
-
|
-
|
67,242
|
-
|
-
|
-
|
67,242
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Dec 2007,
$1.74
|
-
|
-
|
50,000
|
50
|
-
|
-
|
86,950
|
-
|
-
|
-
|
87,000
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation Dec 2007, $7.75
|
-
|
-
|
4,810
|
5
|
-
|
-
|
8,413
|
-
|
-
|
-
|
8,418
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Jan 2008,
$1.61
|
-
|
-
|
22,728
|
23
|
-
|
-
|
36,569
|
-
|
-
|
-
|
36,592
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Jan 2008,
$1.38
|
-
|
-
|
8,000
|
8
|
-
|
-
|
11,032
|
-
|
-
|
-
|
11,040
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Jan 2008,
$1.34
|
-
|
-
|
37,500
|
37
|
-
|
-
|
50,213
|
-
|
-
|
-
|
50,250
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation Oct 2007, $1.36
|
-
|
-
|
6,189
|
6
|
-
|
-
|
8,411
|
-
|
-
|
-
|
8,417
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Feb 2008,
$1.36
|
-
|
-
|
22,728
|
23
|
-
|
-
|
30,887
|
-
|
-
|
-
|
30,910
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Feb 2008,
$1.34
|
-
|
-
|
8,000
|
8
|
-
|
-
|
10,712
|
-
|
-
|
-
|
10,720
|
|||||||||||||||||||||||
Exercise
of stock options for cash, Feb 2008, $1.00
|
-
|
-
|
70,000
|
70
|
-
|
-
|
69,930
|
-
|
-
|
-
|
70,000
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation Feb 2008, $1.32
|
-
|
-
|
6,376
|
6
|
-
|
-
|
8,410
|
-
|
-
|
-
|
8,416
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Mar 2008,
$1.00
|
-
|
-
|
8,000
|
8
|
-
|
-
|
7,992
|
-
|
-
|
-
|
8,000
|
|||||||||||||||||||||||
Stock-based
compensation - officers
|
-
|
-
|
50,000
|
50
|
-
|
-
|
67,242
|
-
|
-
|
-
|
67,292
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Mar 2008,
$0.95
|
-
|
-
|
8,093
|
8
|
-
|
-
|
47,450
|
-
|
-
|
-
|
47,458
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation Mar 2008, $1.04
|
-
|
-
|
200,000
|
200
|
-
|
-
|
8,409
|
-
|
-
|
-
|
8,609
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Mar 2008,
$1.14
|
-
|
-
|
-
|
-
|
-
|
-
|
227,800
|
-
|
-
|
-
|
227,800
|
|||||||||||||||||||||||
Issuance
of warrants in exchange for the services rendered Mar 2008,
$3.75
|
-
|
-
|
-
|
-
|
-
|
-
|
52,500
|
-
|
-
|
-
|
52,500
|
|||||||||||||||||||||||
Issuance
of warrants as employee compensation Mar 2008, $0.94
|
-
|
-
|
-
|
-
|
-
|
-
|
29,500
|
-
|
-
|
-
|
29,500
|
|||||||||||||||||||||||
Issuance
of warrants in conjunction with convertible debenture, Mar 2008,
$1.10
|
-
|
-
|
-
|
-
|
-
|
-
|
5,323,109
|
-
|
-
|
-
|
5,323,109
|
|||||||||||||||||||||||
Issuance
of warrants in conjunction with convertible debentures, Mar 2008,
$1.21
|
-
|
-
|
-
|
-
|
-
|
-
|
5,323,109
|
-
|
-
|
-
|
5,323,109
|
|||||||||||||||||||||||
Repurchase
of common stock Mar 2008, $1.16
|
-
|
-
|
(326,255
|
)
|
(326
|
)
|
-
|
-
|
(378,130
|
)
|
-
|
-
|
-
|
(378,456
|
)
|
|||||||||||||||||||
Option
repricing costs Mar 2008
|
-
|
-
|
-
|
-
|
-
|
-
|
14,500
|
-
|
-
|
-
|
14,500
|
|||||||||||||||||||||||
Value
of Beneficial Conversion Feature on Convertible Debentures, Mar
2008,
$1.21
|
-
|
-
|
-
|
-
|
-
|
-
|
8,768,946
|
-
|
-
|
-
|
8,768,946
|
|||||||||||||||||||||||
Exercise
of stock options for cash, Apr 2008, $1.00
|
-
|
-
|
50,000
|
50
|
-
|
-
|
49,950
|
-
|
-
|
-
|
50,000
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Apr 2008,
$1.19
|
-
|
-
|
8,000
|
8
|
-
|
-
|
9,512
|
-
|
-
|
-
|
9,520
|
|||||||||||||||||||||||
Exercise
of stock options for cash, Apr 2008, $0.89
|
-
|
-
|
250,000
|
250
|
-
|
-
|
222,250
|
-
|
-
|
-
|
222,500
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Apr 2008,
$1.06
|
-
|
-
|
37,500
|
37
|
-
|
-
|
39,713
|
-
|
-
|
-
|
39,750
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation Apr 2008, $1.08
|
-
|
-
|
7,793
|
8
|
-
|
-
|
8,409
|
-
|
-
|
-
|
8,417
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered May 2008,
$1.05
|
-
|
-
|
8,000
|
8
|
-
|
-
|
8,392
|
-
|
-
|
-
|
8,400
|
|||||||||||||||||||||||
Stock-based
compensation - officers stock options, May 2008, $0.96
|
-
|
-
|
-
|
-
|
-
|
-
|
58,078
|
-
|
-
|
-
|
58,078
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation May 2008, $1.00
|
-
|
-
|
8,417
|
8
|
-
|
-
|
8,409
|
-
|
-
|
-
|
8,417
|
|||||||||||||||||||||||
Stock-based
compensation - officers stock
|
-
|
-
|
-
|
-
|
-
|
-
|
67,242
|
-
|
-
|
-
|
67,242
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered May 2008,
$0.97
|
-
|
-
|
50,000
|
50
|
-
|
-
|
48,450
|
-
|
-
|
-
|
48,500
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Jun 2008,
$0.95
|
-
|
-
|
8,000
|
8
|
-
|
-
|
7,592
|
-
|
-
|
-
|
7,600
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation Jun 2008, $0.97
|
-
|
-
|
8,677
|
9
|
-
|
-
|
8,409
|
-
|
-
|
-
|
8,418
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Jul 2008,
$0.79
|
-
|
-
|
8,000
|
8
|
-
|
-
|
6,312
|
-
|
-
|
-
|
6,320
|
|||||||||||||||||||||||
Issuance
of common stock in exchange for the services rendered Jul 2008,
$0.80
|
-
|
-
|
37,500
|
37
|
-
|
-
|
29,963
|
-
|
-
|
-
|
30,000
|
|||||||||||||||||||||||
Issuance
of common stock as employee compensation Jul 2008, $0.83
|
-
|
-
|
10,141
|
10
|
-
|
-
|
8,409
|
-
|
-
|
-
|
8,419
|
|||||||||||||||||||||||
Comprehensive
Income (Loss):
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||
Net
Loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(36,228,991
|
)
|
-
|
(36,228,991
|
)
|
|||||||||||||||||||||
Other
comprehensive income (loss):
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||
Currency
translation adjustment
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
32,688
|
32,688
|
|||||||||||||||||||||||
Total
Comprehensive Income (Loss)
|
|
|
|
|
|
|
|
|
(36,228,991
|
)
|
32,688
|
(36,196,303
|
)
|
|||||||||||||||||||||
Balance
at July 31, 2008
|
-
|
$
|
-
|
111,992,603
|
$
|
111,992
|
-
|
$
|
-
|
$
|
269,849,581
|
$
|
-
|
$
|
(248,229,261
|
)
|
$
|
914,495
|
$
|
22,646,807
|
Cumulative From
|
|||||||||||||
November 2, 1995
|
|||||||||||||
(Date of Inception)
|
|||||||||||||
For the Year Ended July 31,
|
to July 31,
|
||||||||||||
2008
|
2007
|
2006
|
2008
|
||||||||||
Cash
Flows From Operating Activities:
|
|||||||||||||
Net
loss
|
$
|
(36,228,991
|
)
|
$
|
(23,504,958
|
)
|
$
|
(67,967,204
|
)
|
$
|
(245,934,204
|
)
|
|
Adjustments
to reconcile net loss to net cash used in operating
activities:
|
|||||||||||||
Depreciation
and amortization
|
1,084,919
|
1,166,090
|
1,134,676
|
6,966,865
|
|||||||||
Minority
interest share of loss
|
—
|
—
|
—
|
(3,038,185
|
)
|
||||||||
Reduction
of notes receivable - common stock in exchange for services
rendered
|
—
|
—
|
—
|
423,882
|
|||||||||
Write-off
of uncollectible notes receivable - common stock
|
—
|
—
|
—
|
391,103
|
|||||||||
Write-off
of deferred offering costs
|
—
|
—
|
—
|
3,406,196
|
|||||||||
Write-off
of abandoned patents
|
741,690
|
21,721
|
73,699
|
913,196
|
|||||||||
Loss
on disposal of property and equipment
|
—
|
—
|
911
|
911
|
|||||||||
Loss
on extinguishment of debt
|
—
|
237,163
|
12,550,565
|
14,134,069
|
|||||||||
Common
stock issued as employee compensation
|
1,187,685
|
748,076
|
1,545,504
|
3,481,265
|
|||||||||
Issuance
of options and option modifications as employee
compensation
|
72,578
|
—
|
—
|
72,578
|
|||||||||
Common
stock issued for services rendered
|
1,529,882
|
1,695,013
|
515,039
|
8,526,198
|
|||||||||
Amortization
of prepaid services in conjunction with common stock
issuance
|
—
|
—
|
138,375
|
138,375
|
|||||||||
Non-cash
compensation expense
|
—
|
—
|
—
|
45,390
|
|||||||||
Stock
options and warrants issued for services rendered
|
82,000
|
266,400
|
172,450
|
7,354,723
|
|||||||||
Issuance
of warrants as additional exercise right inducement
|
—
|
—
|
21,437,909
|
21,437,909
|
|||||||||
Preferred
stock issued for services rendered
|
—
|
—
|
—
|
100
|
|||||||||
Treasury
stock redeemed for non-performance of services
|
—
|
—
|
—
|
(138,000
|
)
|
||||||||
Amortization
of deferred debt issuance costs and loan origination fees
|
205,056
|
—
|
1,234,772
|
1,687,935
|
|||||||||
Amortization
of discount on convertible debentures
|
3,483,684
|
608,737
|
14,586,879
|
22,414,111
|
|||||||||
Common
stock issued as interest payment on convertible debentures
|
—
|
15,716
|
191,747
|
284,459
|
|||||||||
Interest
on short-term advance
|
—
|
—
|
13,524
|
22,190
|
|||||||||
Founders’
shares transferred for services rendered
|
—
|
—
|
—
|
353,506
|
|||||||||
Fees
in connection with short-term refinancing of long-term
debt
|
—
|
—
|
7,974
|
113,274
|
|||||||||
Changes
in operating assets and liabilities (excluding the effects of
acquisition):
|
|||||||||||||
Accounts
receivable
|
(30,701
|
)
|
(56,680
|
)
|
—
|
(87,381
|
)
|
||||||
Miscellaneous
receivables
|
—
|
—
|
—
|
43,812
|
|||||||||
Inventory
|
(1,345,939
|
)
|
(117,502
|
)
|
—
|
(1,463,441
|
)
|
||||||
Other
current assets
|
53,687
|
(26,068
|
)
|
9,596
|
(75,026
|
)
|
|||||||
Accounts
payable and accrued expenses
|
762,505
|
1,682,196
|
3,780,168
|
12,090,620
|
|||||||||
Deferred
revenue
|
92,481
|
33,031
|
—
|
125,512
|
|||||||||
Other,
net
|
—
|
—
|
—
|
110,317
|
|||||||||
Net
Cash Used in Operating Activities
|
(28,309,464
|
)
|
(17,231,065
|
)
|
(10,573,416
|
)
|
(146,197,741
|
)
|
|||||
Cash
Flows From Investing Activities:
|
|||||||||||||
Purchase
of property and equipment
|
(57,136
|
)
|
(93,704
|
)
|
(149,991
|
)
|
(4,593,547
|
)
|
|||||
Costs
incurred for patents
|
(232,760
|
)
|
(208,606
|
)
|
(114,010
|
)
|
(2,050,362
|
)
|
|||||
Change
in restricted cash
|
—
|
—
|
216,868
|
45,872
|
|||||||||
Proceeds
from maturity of short term investments
|
28,307,895
|
22,795,763
|
8,600,000
|
186,390,704
|
|||||||||
Purchases
of short-term investments
|
(23,148,371
|
)
|
(22,434,848
|
)
|
(22,972,653
|
)
|
(195,242,918
|
)
|
|||||
Cash
received in conjunction with merger
|
—
|
—
|
—
|
82,232
|
|||||||||
Advances
to Antigen Express, Inc.
|
—
|
—
|
—
|
(32,000
|
)
|
||||||||
Increase
in officers’ loans receivable
|
—
|
—
|
—
|
(1,126,157
|
)
|
||||||||
Change
in deposits
|
51,219
|
(196,457
|
)
|
(29,639
|
)
|
(652,071
|
)
|
||||||
Change
in notes receivable - common stock
|
—
|
—
|
—
|
(91,103
|
)
|
||||||||
Change
in due from related parties
|
—
|
—
|
—
|
(2,222,390
|
)
|
||||||||
Other,
net
|
—
|
—
|
—
|
89,683
|
|||||||||
Net
Cash Provided by (Used in) Investing Activities
|
4,920,847
|
(137,852
|
)
|
(14,449,425
|
)
|
(19,402,057
|
)
|
||||||
Cash
Flows From Financing Activities:
|
|||||||||||||
Proceeds
from short-term advance
|
—
|
—
|
—
|
325,179
|
|||||||||
Repayment
of short-term advance
|
—
|
—
|
(347,369
|
)
|
(347,369
|
)
|
|||||||
Proceeds
from issuance of long-term debt
|
—
|
—
|
35,461
|
2,005,609
|
|||||||||
Repayment
of long-term debt
|
(89,475
|
)
|
(73,151
|
)
|
(572,280
|
)
|
(1,941,844
|
)
|
|||||
Change
in due to related parties
|
—
|
—
|
—
|
154,541
|
|||||||||
Proceeds
from exercise of warrants
|
—
|
125,000
|
39,337,065
|
44,015,049
|
|||||||||
Proceeds
from exercise of stock options
|
391,790
|
301,931
|
3,241,755
|
4,945,916
|
|||||||||
Proceeds
from minority interest investment
|
—
|
—
|
—
|
3,038,185
|
|||||||||
Proceeds
from issuance of preferred stock
|
—
|
—
|
—
|
12,015,000
|
|||||||||
Redemption
of SVR preferred stock
|
—
|
(100
|
)
|
—
|
(100
|
)
|
|||||||
Proceeds
from issuance of convertible debentures, net
|
20,450,000
|
—
|
13,955,000
|
40,704,930
|
|||||||||
Payment
of costs associated with convertible debentures
|
(722,750
|
)
|
—
|
—
|
(722,750
|
)
|
|||||||
Repayments
of convertible debentures
|
—
|
(174,399
|
)
|
—
|
(635,757
|
)
|
|||||||
Purchase
of treasury stock
|
—
|
—
|
—
|
(483,869
|
)
|
||||||||
Proceeds
from issuance of common stock, net
|
—
|
—
|
7,000,004
|
80,283,719
|
|||||||||
Purchase
and retirement of common stock
|
(378,456
|
)
|
—
|
—
|
(497,522
|
)
|
|||||||
Net
Cash Provided by Financing Activities
|
19,651,109
|
179,281
|
62,649,636
|
182,858,917
|
|||||||||
Effect
of Exchange Rates on Cash
|
(51,049
|
)
|
7,210
|
(4,832
|
)
|
(21,609
|
)
|
||||||
Net
Increase (Decrease) in Cash and Cash Equivalents
|
(3,788,557
|
)
|
(17,182,426
|
)
|
37,621,963
|
17,237,510
|
|||||||
Cash
and Cash Equivalents, Beginning of Period
|
21,026,067
|
38,208,493
|
586,530
|
—
|
|||||||||
Cash
and Cash Equivalents, End of Period
|
$
|
17,237,510
|
$
|
21,026,067
|
$
|
38,208,493
|
$
|
17,237,510
|
July
31,
|
|||||||
2008
|
2007
|
||||||
Land
|
$
|
222,228
|
$
|
213,312
|
|||
Buildings
and Improvements
|
1,408,524
|
1,352,010
|
|||||
Furniture
and Fixtures
|
105,668
|
101,705
|
|||||
Office
Equipment
|
189,787
|
181,273
|
|||||
Lab
Equipment
|
4,354,027
|
4,221,152
|
|||||
Total
Property and Equipment
|
6,280,234
|
6,069,452
|
|||||
Less
Accumulated Depreciation
|
4,535,260
|
3,932,425
|
|||||
Property
and Equipment, Net
|
$
|
1,744,974
|
$
|
2,137,027
|
July
31,
|
|||||||
2008
|
2007
|
||||||
Assets
Held For Investment
|
$
|
4,672,659
|
$
|
4,485,179
|
|||
Less:
Accumulated Depreciation
|
959,342
|
791,996
|
|||||
Assets
Held For Investment, Net
|
$
|
3,713,317
|
$
|
3,693,183
|
July
31,
|
|||||||
2008
|
2007
|
||||||
Patents
|
$
|
5,844,026
|
$
|
6,580,005
|
|||
Less:
Accumulated Amortization
|
1,889,785
|
1,695,021
|
|||||
Patents,
Net
|
$
|
3,954,241
|
$
|
4,884,984
|
|||
Weighted
Average Life
|
12.8
years
|
13.1
years
|
July
31,
|
|||||||
2008
|
2007
|
||||||
Deferred
Tax Assets:
|
|||||||
Net
operating loss carryforwards
|
$
|
67,575,522
|
$
|
57,628,338
|
|||
Other
timing difference
|
1,545,671
|
2,579,377
|
|||||
Total
Deferred Tax Assets
|
69,121,193
|
60,207,715
|
|||||
Valuation
Allowance
|
(68,133,445
|
)
|
(58,873,007
|
)
|
|||
Deferred
Tax Liabilities
|
|||||||
Intangible
assets
|
(907,327
|
)
|
(1,236,432
|
)
|
|||
Other
timing difference
|
(80,421
|
)
|
(98,276
|
)
|
|||
Total
Deferred Tax Liabilities
|
(987,748
|
)
|
(1,334,708
|
)
|
|||
Net
Deferred Income Taxes
|
$
|
—
|
$
|
—
|
2008
|
2007
|
2006
|
||||||||
Federal
statutory rate
|
(34.0)
|
%
|
(34.0)
|
%
|
(34.0
|
)%
|
||||
Increase
(decrease) in income taxes resulting from:
|
||||||||||
Imputed
interest income on intercompany receivables from foreign
subsidiaries
|
1.0
|
2.0
|
—
|
|||||||
Nondeductible
items
|
1.0
|
—
|
7.0
|
|||||||
Other
timing differences
|
6.0
|
(10.0
|
)
|
6.0
|
||||||
Change
in valuation allowance
|
26.0
|
42.0
|
21.0
|
|||||||
Effective
tax rate
|
—
|
%
|
—
|
%
|
—
|
%
|
July
31,
|
|||||||
2008
|
2007
|
||||||
Accounts
Payable
|
$
|
2,613,789
|
$
|
1,791,080
|
|||
Research
and Development
|
2,048,101
|
1,956,049
|
|||||
Executive
Compensation
|
2,469,026
|
2,252,978
|
|||||
Financial
Services
|
338,794
|
1,156,602
|
|||||
Total
|
$
|
7,469,710
|
$
|
7,156,709
|
Year
|
Amount
|
|||
2009
|
$
|
153,030
|
||
2010
|
122,473
|
|||
2011
|
108,108
|
|||
2012
|
107,257
|
|||
2013
|
2,330
|
|||
Thereafter
|
777
|
|||
Total
Minimum Lease Payments
|
$
|
493,975
|
Amount
|
||||
2009
|
$
|
69,226
|
||
2010
|
45,610
|
|||
2011
|
32,118
|
|||
2012
|
32,680
|
|||
2013
|
15,098
|
|||
—
|
||||
Total
|
$
|
194,732
|
Year
|
Amount
|
|||
2009
|
$
|
335,664
|
||
2010
|
246,358
|
|||
2011
|
215,770
|
|||
2012
|
182,008
|
|||
2013
|
84,535
|
|||
Thereafter
|
21,618
|
|||
Total
|
$
|
1,085,953
|
July
31,
|
|||||||
2008
|
2007
|
||||||
Mortgage
payable - interest at 6.822 percent per annum, monthly principal
and
interest payments of $2,285, due June 2011, secured by real property
located at 98 Stafford Drive, Brampton, Canada
|
$
|
276,602
|
$
|
273,666
|
|||
Mortgage
payable - interest at 6.822 percent per annum, monthly principal
and
interest payments of $3,686, due June 2011, secured by real property
located at 1740 Sismet Road, Mississauga, Canada
|
446,115
|
441,380
|
|||||
Mortgage
payable - interest at 7.6 percent per annum, monthly payments of
principal
and interest of $5,899, due May 2010, secured by first mortgage over
real
property located at 17 Carlaw Avenue and 33 Harbour Square, Toronto,
Canada
|
676,485
|
667,943
|
|||||
Mortgage
payable - interest at 10 percent per annum, monthly payments of principal
and interest of $2,557, due November 2008, secured by real property
located at 13-14, 11 Carlaw Avenue, Toronto, Canada
|
209,530
|
210,371
|
|||||
Mortgage
payable - interest at 8.5 percent per annum, monthly payments of
interest
only of $2,768, principal payment due August 2008, secured by real
property located at 10-11, 11 Carlaw Avenue, Toronto,
Canada
|
390,800
|
375,120
|
|||||
Mortgage
payable - interest at 6.07 percent per annum, monthly interest payments
of
$9,100, principal due March 2009, secured by secondary rights to
real
property located at 1-8, 11 Carlaw Avenue, Toronto, Canada
|
1,187,716
|
1,175,309
|
|||||
Total
Debt
|
3,187,248
|
3,143,789
|
|||||
Less
Current Maturities of Long-Term Debt
|
1,832,684
|
84,503
|
|||||
Total
Long-Term Debt
|
$
|
1,354,564
|
$
|
3,059,286
|
Year
|
Amount
|
|||
2009
|
$
|
1,832,684
|
||
2010
|
681,015
|
|||
2011
|
673,549
|
|||
2012
and thereafter
|
—
|
|||
Total
|
$
|
3,187,248
|
Notes/Debenture
|
||||
$20,650,000
|
||||
Date
Issued
|
3/2008
|
|||
Promissory
Note Amount
|
$
|
(A
|
)
|
|
#
of Promissory Notes
|
6
|
|||
Terms
|
(B
|
)
|
||
Conversion
Price
|
$
|
1.21
|
||
Gross
Proceeds
|
$
|
20,650,000
|
||
Net
Cash Proceeds
|
$
|
20,450,000
|
||
Warrants
Issued to Investors (C)
|
42,665,274
|
|||
Warrant
Exercise Price
|
$
|
1.21
|
||
Existing
Warrants Re-priced (D)
|
12,697,024
|
|||
Re-priced
Warrant Exercise Price (D)
|
1.10
|
|||
Warrant
Fair Value (WFV) (includes value of re-priced warrants)
|
$
|
21,976,130
|
||
Warrant
Relative Fair Value (WRFV)
|
$
|
10,646,218
|
||
Black-Scholes
Model Assumptions
|
(E
|
)
|
||
Beneficial
Conversion Feature (BCF)
|
$
|
8,768,946
|
||
Costs
associated with issuance classified as deferred
|
||||
debt
issuance costs
|
$
|
722,750
|
||
Amortization
of WFV and BCF as
|
||||
Non-cash
Interest Expense
|
$
|
3,483,684
|
||
Principal
and Interest Converted
|
$
|
—
|
||
Shares
Issued Upon Conversion
|
—
|
|||
Principal
and Interest Repayments
|
||||
in
Shares of Common Stock
|
$
|
—
|
||
Shares
Issued for Principal and
|
||||
Interest
Repayments
|
—
|
|||
Principal
and Interest Repayments
|
||||
in
Cash
|
$
|
—
|
(A) |
$7,000,000;
$5,000,000; $3,650,000; (2) $2,000,000;
$1,000,000
|
(B) |
The
notes carry an 8% coupon and mature September 30, 2009, provided,
however,
the maturity date may be extended at the option of the holder. The
notes
carry a 19-month term and amortization in 15 installments commencing
in
the fifth month of the term. The principal and interest payments
are
payable in cash or, at the Company's option, the lower of (i) the
then
applicable conversion price and (ii) the price which shall be computed
as
90% of the arithmetic average of the VWAP of the common stock on
each of
the twenty (20) consecutive trading days immediately preceding the
applicable installment date, subject to certain conditions. Each
note
lists certain “Events of Default”, which include, without limitation, any
default in the payment of principal or interest in respect of the
notes as
when they become due and payable, the Company’s failure to observe or
perform any other covenant, agreement or warranty contained in the
agreements relating to the notes. Upon the occurrence of the “Event of
Default”, the holder may require us to redeem all or any portion of the
notes upon written notice. Other conditions in the notes impede the
Company’s ability to make its monthly installment payments in shares of
its common stock. Two of such conditions - the effectiveness of the
registration statement for at least 30 days prior to installment
notice
and listing maintenance minimum bid price requirement of Nasdaq Stock
Market, were not met as of July 31, 2008, requiring the Company to
procure
waivers from the note holders in respect to these conditions.
|
(C) |
The
warrants issued to investors are comprised of the following: Series
A
warrants 5,257,729; Series A-1 warrants 7,541,857; Series B warrants
17,066,108; Series C warrants 12,799,580.
|
(D) |
The
Company re-priced 12,697,024 existing warrants. The value associated
with
the re-priced warrants amounted to $5,399,160 and was valued using
the
Black-Scholes pricing model. The value of the re-priced warrants
have been
added to the value of the new warrants issued (see (C) above) and
accounted for in accordance with EITF 98-5 and
00-27.
|
(E) |
Black-Scholes
pricing model assumptions used in valuing the warrants were: risk
free
interest (2.70 percent); expected volatility (.8611); life of 1 ½ years, 7
years and 7 ½ years.
|
Number of Shares
|
Warrant Exercise
|
Warrant
|
||||||
To be Purchased
|
Price Per Share
|
Expiration Date
|
||||||
85,034
|
$
|
1.86
|
January
9, 2009
|
|||||
57,143
|
|
$
|
2.20
|
January
9, 2009
|
||||
13,889
|
$
|
2.25
|
January
9, 2009
|
|||||
166,667
|
$
|
1.89
|
February
13, 2009
|
|||||
17,169
|
$
|
2.10
|
February
13, 2009
|
|||||
17,066,117
|
$
|
1.21
|
October
1, 2009
|
|||||
500,000
|
$
|
1.09
|
August
10, 2009
|
|||||
100,000
|
$
|
0.82
|
April
27, 2010
|
|||||
102,232
|
$
|
1.25
|
April
17, 2011
|
|||||
70,000
|
$
|
2.66
|
April
17, 2011
|
|||||
25,000
|
$
|
1.91
|
May
29, 2011
|
|||||
5,000
|
$
|
1.05
|
July
19, 2011
|
|||||
100,000
|
$
|
1.71
|
March
3, 2012
|
|||||
140,000
|
$
|
1.45
|
May
27, 2012
|
|||||
50,000
|
$
|
0.94
|
March
9, 2013
|
|||||
125,000
|
$
|
3.75
|
March
26, 2013
|
|||||
12,697,024
|
$
|
1.10
|
March
31, 2015
|
|||||
5,257,729
|
$
|
1.21
|
March
31, 2015
|
|||||
20,341,437
|
$
|
1.21
|
October
1, 2015
|
|||||
56,919,441
|
Risk-Free
|
|
Expected
|
|
Expected
|
|
Expected
|
|
||||||
|
|
Interest
Rate
|
|
Life
(Years)
|
|
Volatility
|
|
Dividends
|
|||||
July
31, 2008
|
1.96
|
%
|
5.0
|
73.76
|
%
|
-0-
|
|||||||
July
31, 2007 and 2006
|
n/a
|
n/a
|
n/a
|
n/a
|
Weighted Average
|
|||||||
Exercise Price
|
|||||||
Options
|
Per Share
|
||||||
Outstanding
- August 1, 2005
|
11,607,269
|
$
|
1.51
|
||||
Granted
|
—
|
$
|
—
|
||||
Forfeited
or expired
|
(755,000
|
)
|
$
|
5.97
|
|||
Exercised
|
(2,352,672
|
)
|
$
|
1.37
|
|||
Outstanding
- July 31, 2006
|
8,499,597
|
$
|
1.15
|
||||
Granted
|
—
|
$
|
—
|
||||
Forfeited
or expired
|
(250,159
|
)
|
$
|
7.86
|
|||
Exercised
|
(286,800
|
)
|
$
|
1.05
|
|||
Outstanding
- July 31, 2007
|
7,962,638
|
$
|
1.12
|
||||
Granted
|
175,000
|
$
|
0.96
|
||||
Forfeited
or expired
|
(1,490,000
|
)
|
$
|
2.10
|
|||
Exercised
|
(401,000
|
)
|
$
|
0.98
|
|||
Outstanding
- July 31, 2008
|
6,246,638
|
$
|
0.66
|
||||
Exercisable
- July 31, 2008
|
6,159,138
|
$
|
0.66
|
Weighted Average
|
|||||||
Grant Date
|
|||||||
Options
|
Fair Value
|
||||||
Outstanding
- August 1, 2007
|
—
|
$
|
—
|
||||
Granted
|
175,000
|
$
|
0.59
|
||||
Vested
|
(87,500
|
)
|
$
|
0.59
|
|||
Forfeited
|
—
|
$
|
—
|
||||
Outstanding
- July 31, 2008
|
87,500
|
$
|
0.59
|
Options Outstanding
|
|||||||||||||
Weighted
|
|||||||||||||
Number
|
Weighted
|
Average
|
|||||||||||
Outstanding
|
Average
|
Remaining
|
Aggregate
|
||||||||||
Range
of
|
at
|
Exercise
|
Life
|
Intrinsic
|
|||||||||
Exercise
Price
|
July
31, 2008
|
Price
|
(Years)
|
Value
|
|||||||||
$0.001
|
2,239,610
|
$
|
0.001
|
1.68
|
|||||||||
$0.56
- $0.96
|
2,877,528
|
0.78
|
1.60
|
||||||||||
$1.47
- $1.71
|
1,129,500
|
1.68
|
0.29
|
||||||||||
6,246,638
|
1.39
|
$
|
2,061,326
|
Options
Exercisable
|
||||||||||
Number
|
Weighted
|
|||||||||
Outstanding
|
Average
|
Aggregate
|
||||||||
Range
of
|
at
|
Exercise
|
Intrinsic
|
|||||||
Exercise
Price
|
July
31, 2008
|
Price
|
Value
|
|||||||
$0.001
|
2,239,610
|
$
|
0.001
|
|||||||
$0.56
- $0.96
|
2,790,028
|
0.77
|
||||||||
$1.47
- $1.71
|
1,129,500
|
1.68
|
||||||||
6,159,138
|
$
|
2,061,326
|
For
the Year Ended July 31,
|
||||||||||
2008
|
|
2007
|
|
2006
|
||||||
Weighted
Average Grant Date Fair Value of Options Granted
|
$
|
0.59
|
$
|
—
|
$
|
—
|
||||
Aggregate
Intrinsic Value of Options Exercised
|
$
|
103,850
|
$
|
238,179
|
$
|
3,499,814
|
||||
Cash
Received for Exercise of Stock Options
|
$
|
391,790
|
$
|
301,932
|
$
|
3,241,755
|
For
the Years Ended July 31,
|
||||||||||
2008
|
2007
|
2006
|
||||||||
Cash
paid during the year for:
|
||||||||||
Interest
|
$
|
232,440
|
$
|
256,836
|
$
|
273,097
|
||||
Income
taxes
|
$
|
—
|
$
|
—
|
$
|
—
|
Year
Ended July 31, 2008
|
||||
Issuance
of common stock as satisfaction of accrued executive
compensation
|
$
|
471,875
|
||
Deferred
debt issuance costs paid from the proceeds of convertible
notes
|
$
|
200,000
|
||
Value
of warrants issued in conjunction with issuance of convertible debentures
and related beneficial conversion feature
|
$
|
19,415,164
|
||
Year
Ended July 31, 2007
|
||||
Principal
repayment of convertible debentures through the issuance of common
stock
|
$
|
384,616
|
||
Issuance
of common stock in conjunction with convertible debenture
conversion
|
$
|
210,216
|
||
Par
value in connection with voluntary relinquishment and cancellation
of
150,000 shares of common stock
|
$
|
150
|
||
Year
Ended July 31, 2006
|
||||
Value
of common stock issued in conjunction with capitalized services upon
issuance of convertible debentures
|
$
|
619,467
|
||
Value
of warrants issued in conjunction with capitalized services upon
issuance
of convertible debentures
|
$
|
210,300
|
||
Costs
paid from proceeds in conjunction with capitalized services upon
issuance
of convertible debentures
|
$
|
45,000
|
||
Value
of warrants issued in conjunction with issuance of convertible debentures
and related beneficial conversion feature
|
$
|
13,087,156
|
||
Satisfaction
of accounts payable through the issuance of common stock
|
$
|
391,147
|
||
Principal
repayment of convertible debentures through the issuance of common
stock
|
$
|
2,102,689
|
||
Issuance
of common stock in conjunction with convertible debenture
conversion
|
$
|
14,551,466
|
||
Increase
in other current assets for the prepayment of services through the
issuance of common stock
|
$
|
184,500
|
||
Satisfaction
of due from related party through reduction of accrued executive
compensation
|
$
|
415,828
|
||
Repayment
of long-term debt through the issuance of long-term debt upon
refinancing
|
$
|
1,082,443
|
2008
|
2007
|
2006
|
||||||||
Identifiable
Assets
|
||||||||||
Canada
|
$
|
34,529,104
|
$
|
41,899,734
|
$
|
59,583,574
|
||||
United
States
|
3,618,779
|
4,504,670
|
4,521,668
|
|||||||
Total
|
$
|
38,147,883
|
$
|
46,404,404
|
$
|
64,105,242
|
||||
Revenue
|
||||||||||
Canada
|
$
|
6,198
|
$
|
25,242
|
$
|
—
|
||||
United
States
|
121,841
|
157,187
|
175,000
|
|||||||
Total
|
$
|
128,039
|
$
|
182,429
|
$
|
175,000
|
Q1
|
Q2
|
Q3
|
Q4
|
||||||||||
Fiscal
Year July 31, 2008:
|
|||||||||||||
Revenues
|
$
|
44,713
|
$
|
18,627
|
$
|
1,530
|
$
|
60,021
|
|||||
Operating
loss
|
$
|
(7,706,361
|
)
|
$
|
(6,828,022
|
)
|
$
|
(9,852,072
|
)
|
$
|
(9,059,015
|
)
|
|
Net
loss
|
$
|
(7,221,913
|
)
|
$
|
(6,507,174
|
)
|
$
|
(10,174,181
|
)
|
$
|
(12,325,723
|
)
|
|
Net
loss available to common
|
|||||||||||||
stockholders
|
$
|
(7,221,913
|
)
|
$
|
(6,507,174
|
)
|
$
|
(10,174,181
|
)
|
$
|
(12,325,723
|
)
|
|
Net
loss per share
|
$
|
(.07
|
)
|
$
|
(.06
|
)
|
$
|
(.09
|
)
|
$
|
(.11
|
)
|
|
Fiscal
Year July 31, 2007:
|
|||||||||||||
Revenues,
net
|
$
|
139,005
|
$
|
45,421
|
$
|
10,960
|
$
|
(15,188
|
)
|
||||
Operating
loss
|
$
|
(3,980,182
|
)
|
$
|
(5,478,477
|
)
|
$
|
(8,006,072
|
)
|
$
|
(7,411,371
|
)
|
|
Net
loss
|
$
|
(3,658,045
|
)
|
$
|
(5,195,634
|
)
|
$
|
(7,718,355
|
)
|
$
|
(6,932,924
|
)
|
|
Net
loss available to common
|
|||||||||||||
$
|
(3,658,045
|
)
|
$
|
(5,195,634
|
)
|
$
|
(7,718,355
|
)
|
$
|
(6,932,924
|
)
|
||
Net
loss per share
|
$
|
(0.03
|
)
|
$
|
(0.05
|
)
|
$
|
(0.07
|
)
|
$
|
(0.07
|
)
|
(i)
|
pertain
to the maintenance of records that, in reasonable detail, accurately
and
fairly reflect the transactions and dispositions of the assets of
the
Company;
|
(ii)
|
provide
reasonable assurance that transactions are recorded as necessary
to permit
preparation of financial statements in accordance with U.S. generally
accepted accounting principles, and that receipts and expenditures
of the
Company are being made only in accordance with authorizations of
management and directors of the Company; and
|
(iii)
|
provide
reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use or disposition of the Company’s assets that
could have a material effect on the financial statements.
|
Balance at
Beginning
Of Period
|
Additions
Charged
to Expenses
|
Other
Additions
|
Deductions
|
Balance
at End of
Period
|
||||||||||||
Year
Ended July 31, 2006 Valuation Allowance on Deferred Tax
Asset
|
$
|
34,950,200
|
—
|
—
|
14,041,363
|
$
|
48,991,563
|
|||||||||
Year
Ended July 31, 2007 Valuation Allowance on Deferred Tax
Asset
|
$
|
48,991,563
|
—
|
—
|
9,881,444
|
$
|
58,873,007
|
|||||||||
Year
Ended July 31, 2008 Valuation Allowance on Deferred Tax
Asset
|
$
|
58,873,007
|
—
|
—
|
9,260,438
|
$
|
68,133,445
|
GENEREX
BIOTECHNOLOGY CORPORATION
|
|
By:
|
/s/
Anna E. Gluskin
|
|
Name:
Anna E. Gluskin
|
|
Title:
Chief Executive Officer and
President
|
Name
|
|
Capacity in Which Signed
|
|
Date
|
|
|
|
|
|
/s/
Anna E. Gluskin
|
|
President,
Chief Executive Officer and
|
|
October
10, 2008
|
Anna
E. Gluskin
|
Director
(Principal Executive Officer)
|
|||
|
|
|
|
|
/s/
Rose C. Perri
|
|
Chief
Operating Officer, Chief Financial
|
|
October
10, 2008
|
Rose
C. Perri
|
Officer,
Treasurer, Secretary and Director (Principal Financial and Accounting
Officer)
|
|||
|
|
|
|
|
/s/
Brian T. McGee
|
|
Director
|
|
October
10, 2008
|
Brian
T. McGee
|
||||
|
|
|
|
|
/s/
John P. Barratt
|
|
Director
|
|
October
10, 2008
|
John
P. Barratt
|
||||
|
|
|
|
|
/s/
Nola E. Masterson
|
|
Director
|
|
October
10, 2008
|
Nola
E. Masterson
|
||||
|
|
|
|
|
/s/
Slava Jarnitskii
|
|
Controller
|
|
October
10, 2008
|
Slava
Jarnitskii
|
Exhibit
Number
|
Description
of Exhibit(1)
|
|
|
|
|
2
|
|
Agreement
and Plan of Merger among Generex Biotechnology Corporation, Antigen
Express, Inc. and AGEXP Acquisition Inc. (incorporated by reference
to
Exhibit 2.1 to Generex Biotechnology Corporation’s Current Report on Form
8-K filed on August 15, 2003)
|
|
|
|
3(i)
|
|
Restated
Certificate of Incorporation of Generex Biotechnology Corporation
(incorporated by reference to Exhibit 3(II) to Generex Biotechnology
Corporation’s Report on Form 10-Q filed on June 19,
2006)
|
|
|
|
3(ii)
|
|
Amended
and Restated By-Laws of Generex Biotechnology Corporation (incorporated
by
reference to Exhibit 3.2(ii) to Generex Biotechnology Corporation’s Report
on Form 8-K filed December 5, 2007)
|
|
|
|
4.1
|
|
Form
of Common Stock Certificate (incorporated by reference to Exhibit
4.1 to
Generex Biotechnology Corporation’s Registration Statement on Form S-1
(File No. 333-82667) filed on July 12, 1999)
|
4.2.1
|
|
Form
of Securities Purchase Agreement entered into with Cranshire Capital,
L.P.; Gryphon Partners, L.P.; Langley Partners, L.P.; Lakeshore Capital,
Ltd.; LH Financial; Omicron Capital; Photon Fund, Ltd.; Howard Todd
Horberg and Vertical Ventures, LLC dated May 29, 2003 (incorporated
by
reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on
Form 10-Q/A for the quarter ended April 30, 2003 filed on August
13,
2003)
|
|
|
|
4.2.2
|
|
Form
of Registration Rights Agreement entered into with Cranshire Capital,
L.P.; Gryphon Partners, L.P.; Langley Partners, L.P.; Lakeshore Capital,
Ltd.; LH Financial; Omicron Capital; Photon Fund, Ltd.; Howard Todd
Horberg and Vertical Ventures, LLC dated May 29, 2003 (incorporated
by
reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Report on
Form 10-Q/A for the quarter ended April 30, 2003 filed on August
13,
2003)
|
|
|
|
4.2.3
|
|
Form
of Warrant granted to Cranshire Capital, L.P.; Gryphon Partners,
L.P.;
Langley Partners, L.P.; Lakeshore Capital, Ltd.; LH Financial; Omicron
Capital; Photon Fund, Ltd.; Howard Todd Horberg and Vertical Ventures,
LLC
dated May 29, 2003 (incorporated by reference to Exhibit 4.3 to Generex
Biotechnology Corporation’s Report on Form 10-Q/A for the quarter ended
April 30, 2003 filed on August 13, 2003)
|
4.3
|
|
Form
of replacement Warrant issued to warrant holders exercising at reduced
exercise price in May and June 2003 (incorporated by reference to
Exhibit
4.13.7 to Generex Biotechnology Corporation’s Report on Form 10-K for the
period ended July 31, 2003 filed on October 29, 2003)
|
|
|
|
4.4.1
|
|
Securities
Purchase Agreement, dated December 19, 2003, by and among Generex
Biotechnology Corporation and the investors named therein (incorporated
by
reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on
Form 8-K/A filed on March 24, 2004)
|
|
|
|
4.4.2
|
|
Registration
Rights Agreement, dated December 19, 2003, by and among Generex
Biotechnology Corporation and the investors named therein (incorporated
by
reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Report on
Form 8-K/A filed on March 24, 2004)
|
|
|
|
4.4.3
|
|
Form
of Warrant issued in connection with Exhibit 4.4.1 (incorporated
by
reference to Exhibit 4.3 to Generex Biotechnology Corporation’s Report on
Form 8-K/A filed on March 24, 2004)
|
Exhibit
Number
|
Description
of Exhibit(1)
|
|
4.4.4
|
|
Form
of Additional Investment Right issued in connection with Exhibit
4.4.1
(incorporated by reference to Exhibit 4.4 to Generex Biotechnology
Corporation’s Report on Form 8-K/A filed on March 24,
2004)
|
|
|
|
4.5.1
|
|
Securities
Purchase Agreement, dated January 7, 2004, by and between Generex
Biotechnology Corporation and ICN Capital Limited (incorporated by
reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on
Form 8-K filed on March 1, 2004)
|
|
|
|
4.5.2
|
|
Registration
Rights Agreement, dated January 7, 2004, by and between Generex
Biotechnology Corporation and ICN Capital Limited (incorporated by
reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Report on
Form 8-K filed on March 1, 2004)
|
|
|
|
4.5.3
|
|
Warrant
issued in connection with Exhibit 4.5.1 (incorporated by reference
to
Exhibit 4.3 to Generex Biotechnology Corporation’s Report on Form 8-K
filed on March 1, 2004)
|
|
|
|
4.5.4
|
|
Additional
Investment Right issued in connection with Exhibit 4.5.1 (incorporated
by
reference to Exhibit 4.4 to Generex Biotechnology Corporation’s Report on
Form 8-K filed on March 1, 2004)
|
|
|
|
4.6.1
|
|
Securities
Purchase Agreement, dated January 9, 2004, by and between Generex
Biotechnology Corporation and Vertical Ventures, LLC (incorporated
by
reference to Exhibit 4.5 to Generex Biotechnology Corporation’s Report on
Form 8-K filed on March 1, 2004)
|
|
|
|
4.6.2
|
|
Registration
Rights Agreement, dated January 9, 2004, by and between Generex
Biotechnology Corporation and Vertical Ventures, LLC (incorporated
by
reference to Exhibit 4.6 to Generex Biotechnology Corporation’s Report on
Form 8-K filed on March 1, 2004)
|
|
|
|
4.6.3
|
|
Warrant
issued in connection with Exhibit 4.6.1 (incorporated by reference
to
Exhibit 4.7 to Generex Biotechnology Corporation’s Report on Form 8-K
filed on March 1, 2004)
|
|
|
|
4.6.4
|
|
Additional
Investment Right issued in connection with Exhibit 4.6.1 (incorporated
by
reference to Exhibit 4.8 to Generex Biotechnology Corporation’s Report on
Form 8-K filed on March 1, 2004)
|
|
|
|
4.7.1
|
|
Securities
Purchase Agreement, dated February 6, 2004, by and between Generex
Biotechnology Corporation and Alexandra Global Master Fund, Ltd.
(incorporated by reference to Exhibit 4.9 to Generex Biotechnology
Corporation’s Report on Form 8-K filed on March 1,
2004)
|
|
|
|
4.7.2
|
|
Registration
Rights Agreement, dated February 6, 2004, by and between Generex
Biotechnology Corporation and Alexandra Global Master Fund, Ltd.
(incorporated by reference to Exhibit 4.10 to Generex Biotechnology
Corporation’s Report on Form 8-K filed on March 1,
2004)
|
|
|
|
4.7.3
|
|
Warrant
issued in connection with Exhibit 4.7.1 (incorporated by reference
to
Exhibit 4.11 to Generex Biotechnology Corporation’s Report on Form 8-K
filed on March 1, 2004)
|
|
|
|
4.7.4
|
|
Additional
Investment Right issued in connection with Exhibit 4.7.1 (incorporated
by
reference to Exhibit 4.12 to Generex Biotechnology Corporation’s Report on
Form 8-K filed on March 1, 2004)
|
Exhibit
Number
|
Description
of Exhibit(1)
|
|
|
|
|
4.7.5
|
|
Escrow
Agreement, dated February 26, 2004, by and among Generex Biotechnology
Corporation, Eckert Seamans Cherin & Mellott, LLC and Alexandra Global
Master Fund, Ltd. (incorporated by reference to Exhibit 4.13 to Generex
Biotechnology Corporation’s Report on Form 8-K filed on March 1,
2004)
|
|
|
|
4.8.1
|
|
Securities
Purchase Agreement, dated February 11, 2004, by and between Generex
Biotechnology Corporation and Michael Sourlis (incorporated by reference
to Exhibit 4.14 to Generex Biotechnology Corporation’s Report on Form 8-K
filed on March 1, 2004)
|
|
|
|
4.8.2
|
|
Registration
Rights Agreement, dated February 11, 2004, by and between Generex
Biotechnology Corporation and Michael Sourlis (incorporated by reference
to Exhibit 4.15 to Generex Biotechnology Corporation’s Report on Form 8-K
filed on March 1, 2004)
|
|
|
|
4.8.3
|
|
Additional
Investment Right issued in connection with Exhibit 4.8.1 (incorporated
by
reference to Exhibit 4.17 to Generex Biotechnology Corporation’s Report on
Form 8-K filed on March 1, 2004)
|
|
|
|
4.9.1
|
|
Securities
Purchase Agreement, dated February 13, 2004, by and between Generex
Biotechnology Corporation and Zapfe Holdings, Inc. (incorporated
by
reference to Exhibit 4.18 to Generex Biotechnology Corporation’s Report on
Form 8-K filed on March 1, 2004)
|
|
|
|
4.9.2
|
|
Registration
Rights Agreement, dated February 13, 2004, by and between Generex
Biotechnology Corporation and Zapfe Holdings, Inc. (incorporated
by
reference to Exhibit 4.19 to Generex Biotechnology Corporation’s Report on
Form 8-K filed on March 1, 2004)
|
|
|
|
4.9.3
|
|
Warrant
issued in connection with Exhibit 4.9.1 (incorporated by reference
to
Exhibit 4.20 to Generex Biotechnology Corporation’s Report on Form 8-K
filed on March 1, 2004)
|
|
|
|
4.9.4
|
|
Additional
Investment Right issued in connection with Exhibit 4.9.1 (incorporated
by
reference to Exhibit 4.21 Generex Biotechnology Corporation’s Report on
Form 8-K filed on March 1, 2004)
|
|
|
|
4.10.1
|
|
Securities
Purchase Agreement, dated June 23, 2004, by and among Generex
Biotechnology Corporation and the investors named therein (incorporated
by
reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on
Form 8-K filed on July 14, 2004)
|
|
|
|
4.10.2
|
|
Registration
Rights Agreement, dated June 23, 2004, by and among Generex Biotechnology
Corporation and the investors (incorporated by reference to Exhibit
4.2 to
Generex Biotechnology Corporation’s Report on Form 8-K filed on July 14,
2004)
|
|
|
|
4.10.3
|
|
Form
of Warrant issued in connection with Exhibit 4.10.1 (incorporated
by
reference to Exhibit 4.3 to Generex Biotechnology Corporation’s Report on
Form 8-K filed on July 14, 2004)
|
|
|
|
4.10.4
|
|
Form
of Additional Investment Right issued in connection Exhibit 4.10.1
(incorporated by reference to Exhibit 4.4 to Generex Biotechnology
Corporation’s Report on Form 8-K filed on July 14,
2004)
|
|
|
|
4.11.1
|
|
Securities
Purchase Agreement, dated November 10, 2004, by and among Generex
Biotechnology Corporation and the investors named therein (incorporated
by
reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on
Form 8-K filed on November 12,
2004)
|
Exhibit
Number
|
Description
of Exhibit(1)
|
|
|
|
|
4.11.2
|
|
Form
of 6% Secured Convertible Debenture issued in connection with Exhibit
4.11.1 (incorporated by reference to Exhibit 4.2 to Generex Biotechnology
Corporation’s Report on Form 8-K filed on November 12,
2004)
|
|
|
|
4.11.3
|
|
Registration
Rights Agreement, dated November 10, 2004, by and among Generex
Biotechnology Corporation and the investors named therein (incorporated
by
reference to Exhibit 4.3 to Generex Biotechnology Corporation’s Report on
Form 8-K filed on November 12, 2004)
|
|
|
|
4.11.4
|
|
Form
of Voting Agreement entered into in connection with Exhibit 4.11.1
(incorporated by reference to Exhibit 4.7 to Generex Biotechnology
Corporation’s Report on Form 8-K filed on November 12,
2004)
|
|
|
|
4.12
|
|
Warrant
issued to The Aethena Group, LLC on April 28, 2005 (incorporated
by
reference to Exhibit 4.20 to Generex Biotechnology Corporation’s Quarterly
Report on Form 10-Q filed on June 14, 2005)
|
|
|
|
4.13.1
|
|
Amendment
No. 4 to Securities Purchase Agreement and Registration Rights Agreement
entered into by and between Generex Biotechnology Corporation and
the
Purchasers listed on the signature pages thereto on January 19, 2006
(incorporated by reference herein to Exhibit 4.1 to Generex Biotechnology
Corporation’s Report on Form 8-K filed on January 20,
2006)
|
|
|
|
4.13.2
|
|
Form
of Additional AIRs issued in connection with Exhibit 4.13.1 (incorporated
by reference herein to Exhibit 4.4 to Generex Biotechnology Corporation’s
Report on Form 8-K filed on January 20, 2006)
|
|
|
|
4.14
|
|
Form
of Warrant issued by Generex Biotechnology Corporation on January
23, 2006
(incorporated by reference to Exhibit 4.2 to Generex Biotechnology
Corporation’s Report on Form 8-K filed on January 24,
2006)
|
|
|
|
4.15.1
|
|
Agreement
to Amend Warrants between Generex Biotechnology Corporation and Cranshire
Capital L.P. dated February 27, 2006 (incorporated by reference to
Exhibit
4.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on
February 28, 2006).
|
|
|
|
4.15.2
|
|
Agreement
to Amend Warrants between Generex Biotechnology Corporation and Omicron
Master Trust dated February 27, 2006 (incorporated by reference to
Exhibit
4.2 to Generex Biotechnology Corporation’s Report on Form 8-K filed on
February 28, 2006).
|
|
|
|
4.15.3
|
|
Agreement
to Amend Warrants between Generex Biotechnology Corporation and Iroquois
Capital L.P. dated February 27, 2006 (incorporated by reference to
Exhibit
4.3 to Generex Biotechnology Corporation’s Report on Form 8-K filed on
February 28, 2006).
|
|
|
|
4.15.4
|
|
Agreement
to Amend Warrants between Generex Biotechnology Corporation and Smithfield
Fiduciary LLC dated February 27, 2006 (incorporated by reference
to
Exhibit 4.4 to Generex Biotechnology Corporation’s Report on Form 8-K
filed on February 28, 2006).
|
|
|
|
4.15.5
|
|
Form
of Warrant issued by Generex Biotechnology Corporation on February
27,
2006 (incorporated by reference to Exhibit 4.26 to Generex Biotechnology
Corporation’s Report on Form 10-K filed on October 16,
2006)
|
Exhibit
Number
|
Description
of Exhibit(1)
|
|
|
|
|
4.16.1
|
|
Agreement
to Amend Additional Investment Right between Generex Biotechnology
Corporation and Cranshire Capital, L.P. dated February 28, 2006
(incorporated by reference to Exhibit 4.1 to Generex Biotechnology
Corporation’s Report on Form 8-K filed on March 1, 2006).
|
|
|
|
4.16.2
|
|
Agreement
to Amend Additional Investment Right between Generex Biotechnology
Corporation and Omicron Master Trust dated February 28, 2006 (incorporated
by reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Report
on Form 8-K filed on March 1, 2006).
|
|
|
|
4.16.3
|
|
Agreement
to Amend Additional Investment Right between Generex Biotechnology
Corporation and Iroquois Capital LP dated February 28, 2006 (incorporated
by reference to Exhibit 4.3 to Generex Biotechnology Corporation’s Report
on Form 8-K filed on March 1, 2006).
|
|
|
|
4.16.4
|
|
Agreement
to Amend Additional Investment Right between Generex Biotechnology
Corporation and Smithfield Fiduciary LLC dated February 28, 2006
(incorporated by reference to Exhibit 4.4 to Generex Biotechnology
Corporation’s Report on Form 8-K filed on March 1, 2006).
|
|
|
|
4.16.5
|
|
Form
of Additional AIR Debenture issued by Generex Biotechnology Corporation
on
February 28, 2006 (incorporated by reference to Exhibit 4.31 to Generex
Biotechnology Corporation’s Report on Form 10-K filed on October 16,
2006)
|
|
|
|
4.16.6
|
|
Form
of Additional AIR Warrant issued by Generex Biotechnology Corporation
on
February 28, 2006 (incorporated by reference to Exhibit 4.32 to Generex
Biotechnology Corporation’s Report on Form 10-K filed on October 16,
2006)
|
|
|
|
4.17.1
|
|
Form
of Agreement to Amend Warrants between Generex Biotechnology Corporation
and the Investors dated March 6, 2006 (incorporated by reference
to
Exhibit 4.1 to Generex Biotechnology Corporation’s Report on Form 8-K
filed on March 7, 2006).
|
|
|
|
4.17.2
|
|
Form
of Warrant issued by Generex Biotechnology Corporation on March 6,
2006
(incorporated by reference to Exhibit 4.2 to Generex Biotechnology
Corporation’s Report on Form 8-K filed on March 7,
2006)
|
|
|
|
4.18
|
|
Warrant
issued by Generex Biotechnology Corporation on April 17, 2006 to
Zapfe
Holdings, Inc. (incorporated by reference to Exhibit 4.33 to Generex
Biotechnology Corporation’s Report on Form 10-Q filed on June 14,
2006)
|
|
|
|
4.19
|
|
Form
of Warrant issued by Generex Biotechnology Corporation on April 17,
2006
to certain employees (incorporated by reference to Exhibit 4.34 to
Generex
Biotechnology Corporation’s Report on Form 10-Q filed on June 14,
2006).
|
|
|
|
4.20.1
|
|
Securities
Purchase Agreement entered into by and between Generex Biotechnology
Corporation and four Investors on June 1, 2006 (incorporated by reference
to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on Form 8-K
filed on June 2, 2006)
|
|
|
|
4.20.2
|
|
Form
of Warrant issued by Generex Biotechnology Corporation on June 1,
2006
(incorporated by reference to Exhibit 4.2 to Generex Biotechnology
Corporation’s Report on Form 8-K filed on June 2, 2006)
|
|
|
|
4.21.1
|
|
Form
of Amendment to Outstanding Warrants (incorporated by reference to
Exhibit
4.3 to Generex Biotechnology Corporation’s Report on Form 8-K filed on
June 2, 2006)
|
Exhibit
Number
|
Description
of Exhibit(1)
|
|
|
|
|
4.21.2
|
|
Form
of Warrant issued by Generex Biotechnology Corporation on June 1,
2006 in
connection with Exhibit 4.39 (incorporated by reference to Exhibit
4.4 to
Generex Biotechnology Corporation’s Report on Form 8-K filed on June 2,
2006)
|
4.22.1
|
Securities
Purchase Agreement, dated as of March 31, 2008 among the Registrant
and
each of the purchasers named therein (incorporated by reference to
Exhibit
4.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on
April 2, 2008)
|
|
4.22.2
|
Form
of 8% Secured Convertible Note, as amended (incorporated by reference
to
Exhibit 4.2 to Generex Biotechnology Corporation’s Registration Statement
(333-150562) on Form S-3 filed on April 30, 2008)
|
|
4.22.3
|
Form
of Series A Warrant, as amended (incorporated by reference to Exhibit
4.3
to Generex Biotechnology Corporation’s Registration Statement on Form S-3
(333-150562) filed on April 30, 2008)
|
|
4.22.4
|
Form
of Series A-1 Warrant, as amended (incorporated by reference to Exhibit
4.4 to Generex Biotechnology Corporation’s Registration Statement on Form
S-3 (333-150562) filed on April 30, 2008)
|
|
4.22.5
|
Form
of Series B Warrant, as amended (incorporated by reference to Exhibit
4.5
to Generex Biotechnology Corporation’s Registration Statement on Form S-3
(333-150562) filed on April 30, 2008)
|
|
4.22.6
|
Form
of Series C Warrant, as amended (incorporated by reference to Exhibit
4.6
to Generex Biotechnology Corporation’s Registration Statement on Form S-3
(333-150562) filed on April 30, 2008)
|
|
4.22.7
|
Registration
Rights Agreement, dated March 31, 2008, among Registrant and each
of the
purchasers under Securities Purchase Agreement (incorporated by reference
to Exhibit 4.7 to Generex Biotechnology Corporation’s Report on Form 8-K
filed on April 2, 2008)
|
|
4.22.8
|
Security
Agreement (incorporated by reference to Exhibit 4.8 to Generex
Biotechnology Corporation’s Report on Form 8-K filed on April 2,
2008)
|
|
4.22.9
|
Form
of Guaranty (incorporated by reference to Exhibit 4.9 to Generex
Biotechnology Corporation’s Report on Form 8-K filed on April 2,
2008)
|
|
|
|
|
9
|
|
Form
of Voting Agreement entered into in connection with Exhibit 4.11.1
(incorporated by reference to Exhibit 4.7 to Generex Biotechnology
Corporation’s Report on Form 8-K filed on November 12,
2004)
|
10.1
|
|
Stock
Option Agreement by and between Generex Biotechnology Corporation
and
Peter G. Amanatides to purchase 100,000 shares of Common Stock at
the
exercise price of $0.56 per share (incorporated by reference to Exhibit
10.3 to Generex Biotechnology Corporation’s Quarterly Report on Form 10-Q
filed on June 14, 2005)*
|
Exhibit
Number
|
Description
of Exhibit(1)
|
|
|
|
|
10.2
|
|
Stock
Option Agreement by and between Generex Biotechnology Corporation
and John
P. Barratt to purchase 100,000 shares of Common Stock at the exercise
price of $0.56 per share (incorporated by reference to Exhibit 10.4
to
Generex Biotechnology Corporation’s Quarterly Report on Form 10-Q filed on
June 14, 2005)*
|
|
|
|
10.3
|
|
Stock
Option Agreement by and between Generex Biotechnology Corporation
and
Brian T. McGee to purchase 100,000 shares of Common Stock at the
exercise
price of $0.56 per share (incorporated by reference to Exhibit 10.5
to
Generex Biotechnology Corporation’s Quarterly Report on Form 10-Q filed on
June 14, 2005)*
|
|
|
|
10.4
|
|
Stock
Option Agreement by and between Generex Biotechnology Corporation
and John
P. Barratt to purchase 35,714 shares of Common Stock at the exercise
price
of $0.001 per share (incorporated by reference to Exhibit 10.6 to
Generex
Biotechnology Corporation’s Quarterly Report on Form 10-Q filed on June
14, 2005)*
|
|
|
|
10.5
|
|
Stock
Option Agreement by and between Generex Biotechnology Corporation
and
Brian T. McGee to purchase 35,714 shares of Common Stock at the exercise
price of $0.001 per share (incorporated by reference to Exhibit 10.7
to
Generex Biotechnology Corporation’s Quarterly Report on Form 10-Q filed on
June 14, 2005)*
|
|
|
|
10.6
|
|
Stock
Option Agreement by and between Generex Biotechnology Corporation
and
Gerald Bernstein, M.D. to purchase 100,000 shares of Common Stock
at the
exercise price of $0.61 per share (incorporated by reference to Exhibit
10.8 to Generex Biotechnology Corporation’s Quarterly Report on Form 10-Q
filed on June 14, 2005)*
|
|
|
|
10.7
|
|
Stock
Option Agreement by and between Generex Biotechnology Corporation
and Mark
Fletcher to purchase 250,000 shares of Common Stock at the exercise
price
of $0.61 per share (incorporated by reference to Exhibit 10.9 to
Generex
Biotechnology Corporation’s Quarterly Report on Form 10-Q filed on June
14, 2005)*
|
|
|
|
10.8
|
|
Stock
Option Agreement by and between Generex Biotechnology Corporation
and Anna
E. Gluskin to purchase 250,000 shares of Common Stock at the exercise
price of $0.61 per share (incorporated by reference to Exhibit 10.10
to
Generex Biotechnology Corporation’s Quarterly Report on Form 10-Q filed on
June 14, 2005)*
|
|
|
|
10.9
|
|
Stock
Option Agreement by and between Generex Biotechnology Corporation
and Rose
C. Perri to purchase 250,000 shares of Common Stock at the exercise
price
of $0.61 per share (incorporated by reference to Exhibit 10.11 to
Generex
Biotechnology Corporation’s Quarterly Report on Form 10-Q filed on June
14, 2005)*
|
|
|
|
10.10
|
|
Stock
Option Agreement by and between Generex Biotechnology Corporation
and Mark
A. Fletcher to purchase 470,726 shares of Common Stock at the exercise
price of $0.001 per share (incorporated by reference to Exhibit 10.12
to
Generex Biotechnology Corporation’s Quarterly Report on Form 10-Q filed on
June 14, 2005)*
|
|
|
|
10.11
|
|
Stock
Option Agreement by and between Generex Biotechnology Corporation
and Anna
E. Gluskin to purchase 1,120,704 shares of Common Stock at the exercise
price of $0.001 per share (incorporated by reference to Exhibit 10.13
to
Generex Biotechnology Corporation’s Quarterly Report on Form 10-Q filed on
June 14, 2005)*
|
Exhibit
Number
|
Description
of Exhibit(1)
|
|
|
|
|
10.12
|
|
Stock
Option Agreement by and between Generex Biotechnology Corporation
and Rose
C. Perri to purchase 576,752 shares of Common Stock at the exercise
price
of $0.001 per share (incorporated by reference to Exhibit 10.14 to
Generex
Biotechnology Corporation’s Quarterly Report on Form 10-Q filed on June
14, 2005)*
|
|
|
|
10.13
|
|
Employment
Agreement by and between Generex Biotechnology Corporation and Gerald
Bernstein M.D. (incorporated by reference to Exhibit 10.16 to Generex
Biotechnology Corporation’s Quarterly Report on Form 10-Q filed on June
14, 2005)*
|
|
|
|
10.14
|
|
1998
Stock Option Plan (incorporated by reference to Exhibit 4.3 to Generex
Biotechnology Corporation’s Registration Statement on Form S-1 (File No.
333-82667) filed on July 12, 1999)*
|
|
|
|
10.15
|
|
2000
Stock Option Plan (incorporated by reference to Exhibit 4.3.2 to
Generex
Biotechnology Corporation’s Annual Report on Form 10-K filed on October
30, 2000)*
|
|
|
|
10.16
|
|
Amended
2001 Stock Option Plan (incorporated by reference to Exhibit 4.1
to
Generex Biotechnology Corporation’s Quarterly Report on Form 10-Q filed on
December 15, 2003)*
|
|
|
|
10.17
|
|
2006
Stock Plan (incorporated by reference to Annex A to Generex Biotechnology
Corporation’s Proxy Statement for the Annual Meeting of Stockholders held
on May 30, 2006)*
|
10.18
|
|
Stockholders
Agreement among Generex Biotechnology Corporation and the former
holders
of capital stock of Antigen Express, Inc. (incorporated by reference
to
Exhibit 10.4 to Generex Biotechnology Corporation’s Annual Report on Form
10-K filed on October 29, 2003)
|
|
|
|
10.19
|
|
Form
of Warrant issued by Generex Biotechnology Corporation on April 17,
2006
to certain employees (incorporated by reference to Exhibit 4.34 to
Generex
Biotechnology Corporation’s Report on Form 10-Q filed on June 14,
2006)*
|
|
|
|
10.20
|
|
Quotation
for Contract Manufacturing of Oral-lyn™ entered into between Generex
Biotechnology Corporation and Cardinal Health PTS, LLC on June 20,
2006
(subject to confidential treatment) (incorporated by reference to
Exhibit
10.25 to Generex Biotechnology Corporation’s Report on Form 10-K/A filed
on February 14, 2007)
|
|
|
|
10.21
|
|
Quotation
Amendment for Contract Manufacturing of Oral-lyn™ entered into between
Generex Biotechnology Corporation and Cardinal Health PTS, LLC on
August
18, 2006 (subject to confidential treatment) (incorporated by reference
to
Exhibit 10.26 to Generex Biotechnology Corporation’s Report on Form 10-K
filed on October 16, 2006)
|
|
|
|
10.22
|
|
Clinical
Supply Agreement entered into between Generex Biotechnology Corporation
and Cardinal Health PTS, LLC on September 6, 2006 (subject to confidential
treatment) (incorporated by reference to Exhibit 10.27 to Generex
Biotechnology Corporation’s Report on Form 10-K filed on October 16,
2006)
|
10.23
|
Form
of Restricted Stock Agreement for awards to executive officers of
Generex
Biotechnology Corporation under the Generex Biotechnology Corporation
2006
Stock Plan (incorporated by reference to Exhibit 10.1 to Generex
Biotechnology Corporation’s Report on Form 8-K filed on August 23,
2007)*
|
Exhibit
Number
|
Description
of Exhibit(1)
|
|
10.24
|
Summary
of Annual Base Salaries of Executive Officers of Generex Biotechnology
Corporation (incorporated by reference to Exhibit 10.2 to Generex
Biotechnology Corporation’s Report on Form 8-K filed on August 23,
2007)*
|
|
10.25
|
Summary
of Compensation of the Directors of Generex Biotechnology Corporation
(incorporated by reference to Exhibit 10.27 to Generex Biotechnology
Corporation’s Report on Form 10-K filed on October 15,
2007)*
|
|
10.26
|
Summary
of Employment Terms for Anna Gluskin effective as of January 1, 2006
(incorporated by reference to Exhibit 10.28 to Generex Biotechnology
Corporation’s Report on Form 10-K/A filed on November 28,
2007)*
|
|
10.27
|
Summary
of Employment Terms for Rose Perri effective as of January 1, 2006
(incorporated by reference to Exhibit 10.29 to Generex Biotechnology
Corporation’s Report on Form 10-K/A filed on November 28,
2007)*
|
|
10.28
|
Summary
of Employment Terms for Mark A. Fletcher effective as of April 21,
2003
(incorporated by reference to Exhibit 10.30 to Generex Biotechnology
Corporation’s Report on Form 10-K/A filed on November 28,
2007)*
|
|
10.29
|
Employment
Agreement between Generex Biotechnology Corporation and Gerald Bernstein,
M.D., effective as of April 1, 2002 (incorporated by reference to
Exhibit
10.31 to Generex Biotechnology Corporation’s Report on Form 10-K/A filed
on November 28, 2007)*
|
|
10.30
|
Form
of Consent and Waiver Agreement entered into with Cranshire Cranshire
Capital, L.P., Portside Growth and Opportunity Fund and, Smithfield
Fiduciary LLC (incorporated by reference to Exhibit 10.1 to Generex
Biotechnology Corporation’s Report on Form 8-K filed on August 1,
2008)
|
|
10.31
|
Form
of Consent and Waiver Agreement entered into with Rockmore Investment
Master Fund Ltd. (incorporated by reference to Exhibit 10.2 to Generex
Biotechnology Corporation’s Report on Form 8-K filed on August 1,
2008)
|
|
10.32
|
Form
of Consent and Waiver Agreement entered into with the Iroquois Funds
(incorporated by reference to Exhibit 10.3 to Generex Biotechnology
Corporation’s Report on Form 8-K filed on August 1,
2008)
|
|
10.33
|
Summary
of Annual Base Salaries for Executive Officers of Generex Biotechnology
Corporation Effective January 1, 2008*
|
|
10.34
|
Summary
of Compensation of the Directors of Generex Biotechnology Corporation
effective May 27, 2008*
|
|
16
|
Letter
of Concurrence From Danziger Hochman Partners LLP, dated September
18,
2008 (incorporated by reference to Exhibit 16 to Generex Biotechnology
Corporation’s Report on Form 8-K/A filed on September 19, 2008)
|
|
21
|
|
Subsidiaries
of the Registrant
|
|
|
|
23.1
|
|
Consent
of MSCM LLP, independent registered public accounting
firm
|
Exhibit
Number
|
Description
of Exhibit(1)
|
|
23.2
|
Consent
of Danziger Hochman Partners LLP, independent registered public accounting
firm
|
|
|
|
|
31.1
|
|
Certification
of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002
|
|
|
|
31.2
|
|
Certification
of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002
|
|
|
|
32
|
|
Certification
of Chief Executive Officer and Chief Financial Officer pursuant to
Section
906 of the Sarbanes-Oxley Act of
2002
|
*
Management contract or management compensatory plan or arrangement.
|
||
(1)
|
In
the case of incorporation by reference to documents filed by the
Registrant under the Exchange Act, the Registrant’s file number under the
Exchange Act is 000-25169.
|